



(11) **EP 2 305 806 A1**

(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 153(4) EPC

(43) Date of publication:  
**06.04.2011 Bulletin 2011/14**

(51) Int Cl.:  
**C12N 15/09** <sup>(2006.01)</sup> **C12Q 1/25** <sup>(2006.01)</sup>  
**C12Q 1/68** <sup>(2006.01)</sup> **G01N 33/53** <sup>(2006.01)</sup>

(21) Application number: **09762575.0**

(86) International application number:  
**PCT/JP2009/061067**

(22) Date of filing: **11.06.2009**

(87) International publication number:  
**WO 2009/151149 (17.12.2009 Gazette 2009/51)**

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR**  
Designated Extension States:  
**AL BA RS**

- **SATOH, Hideo**  
Ibaraki-shi  
Osaka 567-0826 (JP)
- **TARUI, Hirokazu**  
Toyonaka-shi  
Osaka 561-0802 (JP)

(30) Priority: **11.06.2008 JP 2008152617**

(74) Representative: **Duckworth, Timothy John**  
**J.A. Kemp & Co.**  
**14 South Square**  
**Gray's Inn**  
**London WC1R 5JJ (GB)**

(71) Applicant: **Sumitomo Chemical Company, Limited**  
**Tokyo 104-8260 (JP)**

(72) Inventors:  
• **TOMIGAHARA, Yoshitaka**  
Toyonaka-shi  
Osaka 560-0013 (JP)

(54) **METHOD FOR DETECTING OR QUANTIFYING DNA**

(57) The present invention relates to a method for quantifying or detecting DNA having a target DNA region, and so on.

**EP 2 305 806 A1**

**Description**

TECHNICAL FIELD

5 **[0001]** The present invention relates to a method for quantifying or detecting DNA having a target DNA region, and so on.

BACKGROUND ART

10 **[0002]** Known as a method for quantifying or detecting DNA having a target DNA region contained in a specimen are, for example, a method of detecting DNA having a target DNA region amplified by a chain reaction of DNA synthesis by DNA polymerase (Polymerase Chain Reaction; hereinafter, sometimes referred to as PCR) after extraction of DNA from a specimen, a method of detecting DNA by hybridization of a fluorescent-labeled oligonucleotide with a target DNA region possessed by DNA in a specimen, and so on (see, for example, J. Cataract. Refract. Surg., 2007;33(4):635-641, Environ. Mol. Mutagen., 1991;18(4):259-262).

15

DISCLOSURE OF THE INVENTION

**[0003]** It is an object of the present invention to provide a method for quantifying or detecting DNA having a target DNA region in a simple and convenient manner.

20

**[0004]** Specifically, the present invention provides:

[Invention 1]

**[0005]** A method for quantifying or detecting DNA comprising a target DNA region contained in a specimen comprising:

25

- (1) First step of preparing from a specimen DNA for which the target DNA region is to be detected;
- (2) Second step of treating the DNA prepared in First step with a DNA methylation enzyme,
- (3) Third step of preparing single-stranded methylated DNA from the DNA treated in Second step,
- (4) Fourth step of forming a complex of a single-stranded methylated DNA comprising a methylated target DNA region, a methylated DNA antibody, and a specific oligonucleotide by mixing the single-stranded methylated DNA prepared in Third step, the methylated DNA antibody, and the specific oligonucleotide comprising a nucleotide sequence that does not inhibit binding between one or more methylated bases in the target DNA region in the single-stranded methylated DNA and the methylated DNA antibody, and that is capable of binding with the single-stranded DNA comprising the target DNA region by complementation, and
- (5) Fifth step of quantifying or detecting the DNA comprising the target DNA region in the single-stranded methylated DNA by quantifying or detecting the methylated DNA antibody contained in the complex formed in Fourth step by its identification function (hereinafter, sometimes referred to as the present method);

30

35

[Invention 2]

40

**[0006]** The method according to Invention 1, wherein the complex is formed in a reaction system containing a divalent cation in Fourth step;

[Invention 3]

45

**[0007]** The method according to Invention 2, wherein the divalent cation is a magnesium ion;

[Invention 4]

50

**[0008]** The method according to any one of Inventions 1 to 3, wherein the antibody contained in the complex formed in Fourth step has been bound to a support before starting of Fifth step;

[Invention 5]

55

**[0009]** The method according to any one of Inventions 1 to 3, wherein the specific oligonucleotide contained in the complex formed in Fourth step has been bound to a support before starting of Fifth step;

## EP 2 305 806 A1

[Invention 6]

**[0010]** The method according to any one of Inventions 1 to 5, wherein the DNA methylation enzyme is a cytosine methylation enzyme;

5

[Invention 7]

**[0011]** The method according to any one of Inventions 1 to 6, wherein the DNA methylation enzyme is SssI methylase;

10

[Invention 8]

**[0012]** The method according to any one of Inventions 1 to 7, wherein the methylated DNA antibody is a methylcytosine antibody;

15

[Invention 9]

**[0013]** The method according to any one of Inventions 1 to 8, wherein the specimen is any of the following specimen:

20

- (a) mammalian blood, body fluid, excreta, body secretion, cell lysate, or tissue lysate,
- (b) DNA extracted from one selected from the group consisting of mammalian blood, body fluid, excreta, body secretion, cell lysate, and tissue lysate,
- (c) DNA prepared by using as a template RNA extracted from one selected from the group consisting of mammalian tissue, cell, tissue lysate and cell lysate,
- (e) DNA extracted from cell, fungus or virus, or
- 25 (f) DNA prepared by using as a template RNA extracted from cell, fungus or virus;

[Invention 10]

**[0014]** The method according to any one of Inventions 1 to 9, wherein DNA for which the target DNA region is to be detected is any of the following DNAs (a) to (e):

30

- (a) DNA digested in advance with a restriction enzyme recognition cleavage site for which is not present in the target DNA region,
- (b) DNA purified in advance,
- 35 (c) free DNA in blood,
- (d) DNA derived from microbial genome, or
- (e) DNA generated from RNA by a reverse transcriptase;

[Invention 11]

40

**[0015]** The method according to any one of Inventions 1 to 10, wherein a counter oligonucleotide is added in forming the complex in Fourth step;

[Invention 12]

45

**[0016]** The method according to any one of Inventions 1 to 11, wherein concentration of a sodium salt in a solution used in a DNA extracting operation for preparing DNA from a specimen in First step is 100 mM or more and 1000 mM or less;

50

[Invention 13]

**[0017]** The method according to any one of Inventions 1 to 11, wherein concentration of a sodium salt in a solution used in a DNA extracting operation for preparing DNA from a specimen in First step is 100 mM or more and 200 mM or less;

55

[Invention 14]

**[0018]** A method for selecting a specimen from a cancer patient comprising the step of evaluating that a specimen from a test subject is a specimen from a cancer patient when there is significant difference between a quantification

result or a detection result of DNA quantified or detected by using the specimen from the test subject according to the method of any one of Inventions 1 to 13 and a quantification result or a detection result of DNA quantified or detected by using a specimen from a healthy subject according to the same method, and identifying a specimen from a cancer patient based on a result of the evaluation;

[Invention 15]

**[0019]** The method according to Invention 14, wherein the specimen is mammalian serum; and

[Invention 16]

**[0020]** The method according to Invention 14 or 15, wherein DNA comprising a target DNA region is free DNA comprising the target DNA region in a mammalian serum; and so on.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0021]** Fig. 1 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B1 in Example 1. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution A (10 ng/20  $\mu\text{L}$  TE buffer solution), Solution B (1 ng/20  $\mu\text{L}$  TE buffer solution), Solution C (0.1 ng/20  $\mu\text{L}$  TE buffer solution), and Solution D (0 ng/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

**[0022]** Fig. 2 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B2 in Example 2. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution A (10 ng/20  $\mu\text{L}$  TE buffer solution), Solution B (1 ng/20  $\mu\text{L}$  TE buffer solution), Solution C (0.1 ng/20  $\mu\text{L}$  TE buffer solution), and Solution D (0 ng/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

**[0023]** Fig. 3 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B1 in Example 3. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution MA (10 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MB (1 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MC (0.1 ng each/20  $\mu\text{L}$  TE buffer solution), and Solution MD (0 ng each/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

**[0024]** Fig. 4 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B2 in Example 3. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution MA (10 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MB (1 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MC (0.1 ng each/20  $\mu\text{L}$  TE buffer solution), and Solution MD (0 ng each/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

**[0025]** Fig. 5 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody, 5'-end biotin-labeled oligonucleotide B1 and 5'-end biotin-labeled oligonucleotide B2 in Example 3. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution MA (10 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MB (1 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MC (0.1 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MD (0 ng each/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

**[0026]** Fig. 6 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B1 in Example 4. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution A (1000 ng each/30  $\mu\text{L}$  TE buffer solution), Solution B (500 ng each/30  $\mu\text{L}$  TE buffer solution), Solution C (200 ng each/30  $\mu\text{L}$  TE buffer solution), and Solution D (0 ng each/30  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

**[0027]** Fig. 7 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B3 in Example 5. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution A (1000 ng each/30  $\mu\text{L}$  TE buffer solution), Solution B (500 ng each/30  $\mu\text{L}$  TE buffer solution), Solution C (200 ng each/30  $\mu\text{L}$  TE buffer solution), and Solution D (0 ng each/30  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

**[0028]** Fig. 8 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B3 in Example 6. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution A (500 ng each/20  $\mu\text{L}$  TE buffer solution), Solution B (50 ng each/20  $\mu\text{L}$  TE buffer solution), Solution C (5 ng each/20  $\mu\text{L}$  TE buffer solution), and Solution D (0 ng each/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

**[0029]** Fig. 9 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B4 in Example 7. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm



**[0041]** Fig. 21 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B4 in Example 15. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution A (10 ng/20  $\mu\text{L}$  TE buffer solution), Solution B (1 ng/20  $\mu\text{L}$  TE buffer solution), Solution C (0.1 ng/20  $\mu\text{L}$  TE buffer solution), and Solution D (0 ng/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively

5 in this order from right.  
**[0042]** Fig. 22 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B5 in Example 16. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution A (10 ng/20  $\mu\text{L}$  TE buffer solution), Solution B (1 ng/20  $\mu\text{L}$  TE buffer solution), Solution C (0.1 ng/20  $\mu\text{L}$  TE buffer solution), and Solution D (0 ng/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively

10 in this order from right.  
**[0043]** Fig. 23 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B4 in Example 17. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution A (10 ng/20  $\mu\text{L}$  TE buffer solution), Solution B (1 ng/20  $\mu\text{L}$  TE buffer solution), Solution C (0.1 ng/20  $\mu\text{L}$  TE buffer solution), and Solution D (0 ng/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively

15 in this order from right.  
**[0044]** Fig. 24 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B5 in Example 18. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution A (10 ng/20  $\mu\text{L}$  TE buffer solution), Solution B (1 ng/20  $\mu\text{L}$  TE buffer solution), Solution C (0.1 ng/20  $\mu\text{L}$  TE buffer solution), and Solution D (0 ng/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively

20 in this order from right.  
**[0045]** Fig. 25 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B4 in Example 19. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution MA (10 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MB (1 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MC (0.1 ng each/20  $\mu\text{L}$  TE buffer solution), and Solution MD (0 ng each/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

25  
**[0046]** Fig. 26 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B5 in Example 19. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution MA (10 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MB (1 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MC (0.1 ng each/20  $\mu\text{L}$  TE buffer solution), and Solution MD (0 ng each/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

30  
**[0047]** Fig. 27 is a drawing showing a result obtained by using 0.5  $\mu\text{g}/\text{mL}$  of methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B4 and 5'-end biotin-labeled oligonucleotide B5 in Example 19. Values of DNA amounts measured at excitation 340 nm/fluorescence 612 nm are shown for Solution MA (10 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MB (1 ng each/20  $\mu\text{L}$  TE buffer solution), Solution MC (0.1 ng each/20  $\mu\text{L}$  TE buffer solution), and Solution MD (0 ng each/20  $\mu\text{L}$  TE buffer solution (negative control solution)), respectively in this order from right.

35  
**[0048]** Fig. 28 is a drawing showing a result of an experiment for detecting a target DNA region W by Treatment 1 in Example 20. In Fig. 28, Solution A represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 1 for Serum sample A using biotin-labeled oligonucleotide B6. Solution B represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 1 for Serum sample B using biotin-labeled oligonucleotide B6. Solution C represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 1 for Serum sample C (negative control solution) using biotin-labeled oligonucleotide B6.

40  
**[0049]** Fig. 29 is a drawing showing a result of an experiment for detecting a target DNA region W by Treatment 2 in Example 20. In Fig. 29, Solution A represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 2 for Serum sample A using biotin-labeled oligonucleotide B6. Solution B represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 2 for Serum sample B using biotin-labeled oligonucleotide B6. Solution C represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 2 for Serum sample C (negative control solution) using biotin-labeled oligonucleotide B6.

45  
**[0050]** Fig. 30 is a drawing showing a result of an experiment for detecting a target DNA region W in Example 21. In Fig. 30, Solution A represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 1 for Serum sample A using biotin-labeled oligonucleotide B6. Solution B represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 1 for Serum sample B using biotin-labeled oligonucleotide B6. Solution C represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 1 for Serum sample C (negative control solution) using biotin-labeled oligonucleotide B6.

50  
**[0051]** Fig. 31 is a drawing showing a result of an experiment for detecting a target DNA region W in Example 21. In Fig. 31, Solution A represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 2 for Serum sample A using biotin-labeled oligonucleotide B6. Solution B represents a measurement of

fluorescent intensity of a sample subjected to an operation including Treatment 2 for Serum sample B using biotin-labeled oligonucleotide B6. Solution C represents a measurement of fluorescent intensity of a sample subjected to an operation including Treatment 2 for Serum sample C (negative control solution) using biotin-labeled oligonucleotide B6.

5 **[0052]** Fig. 32 is a drawing showing a result of an experiment for detecting a target DNA region W contained in human serum in Example 22. The drawing shows comparison between a result detected by using methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B6 and a result quantified by real-time PCR. The detection result is plotted on the vertical axis, and the quantification result by real-time PCR is plotted on the horizontal axis. The straight lines in the graph represent regression line (thick line) and standard error range (thin line).

10 **[0053]** Fig. 33 is a drawing showing a result of an experiment for detecting a target DNA region W contained in human serum in Example 22. For serum samples of human beings at age 59 or younger, DNA was detected using methylcytosine antibody and 5'-end biotin-labeled oligonucleotide B6, and plotted separately for cancer patients and healthy subjects, together with respective average values and standard deviations.

#### 15 MODE FOR CARRYING OUT THE INVENTION

**[0054]** Examples of the "specimen" in the present method include (a) mammalian blood, body fluid, excreta, body secretion, cell lysate, or tissue lysate, (b) DNA extracted from one selected from the group consisting of mammalian blood, body fluid, excreta, body secretion, cell lysate and tissue lysate, (c) DNA prepared by using as a template RNA extracted from one selected from the group consisting of mammalian tissue, cell, tissue lysate and cell lysate, (e) DNA extracted from cell, fungus or virus, and (f) DNA prepared by using as a template RNA extracted from cell, fungus or virus. The term "tissue" means broadly including blood and lymph node.

**[0055]** The term "mammal" means animals classified into animal kingdom, Chordata, Chordate subphylum, and Mammalia, and concrete examples include human being, monkey, marmoset, guinea pig, rat, mouse, cattle, sheep, dog, and cat.

25 **[0056]** The term "body fluid" means a liquid existing between cells constituting an individual body, and concretely, plasma and interstitial fluid are recited, and it often functions to maintain homeostasis of an individual body. More concrete examples include lymph, tissue fluid (interinstitutional fluid, intercellular fluid, interstitial fluid), celomic fluid, serous cavity fluid, pleural effusion, ascetic fluid, pericardial fluid, cerebral fluid (spinal fluid), joint fluid (spinal fluid), eye aqueous fluid (aqueous fluid), and cerebrospinal fluid.

30 **[0057]** The term "body secretion" is a secretion from an exocrine gland, and concrete examples include saliva, gastric juice, bile, pancreatic juice, intestinal juice, sweat, tear, runny nose, semen, vaginal lubricant, amniotic fluid, and milk.

**[0058]** When the specimen is blood, body fluid or body secretion of a human being, a sample collected for a clinical test in a regular health check of human may be utilized.

35 **[0059]** Examples of the "cell lysate" include lysates containing intracellular fluids obtained by grinding cells, such as cell strains, primary cultured cells or blood cells, cultured in a plate for cell culture. As a method of grinding cells, a method based on sonication, a method using a surfactant, a method of using an alkaline solution and the like are recited. For lysing cells, a commercially available kit and the like may be used.

40 **[0060]** For example, after culturing cells to be confluent in a 10 cm plate, the culture solution is removed, and 0.6 mL of a RIPA buffer (1x TBS, 1% nonidet P-40, 0.5% sodium deoxysholate, 0.1% SDS, 0.004% sodium azide) is added to the plate. After shaking slowly the plate at 4°C for 15 minutes, cells adhered on the plate are removed by using a scraper or the like, and the liquid on the plate is transferred to a microtube. After adding 10 mg/mL PMSF in an amount of 1/10 volume of the liquid, the tube is left still on ice for 30 to 60 minutes, the solution is centrifuged at 4°C for 10 minutes at 10,000xg, to obtain the supernatant as a cell lysate.

45 **[0061]** As the "tissue lysate", lysates containing intracellular fluids obtained by grinding cells in tissues collected from animals such as mammals can be recited.

**[0062]** Concretely, after measuring the weight of a tissue obtained from an animal, the tissue is cut into small pieces with the use of a razor or the like. When a frozen tissue is used, it is necessary to make a smaller piece. After cutting, an ice-cooled RIPA buffer is added in a rate of 3 mL per 1 g of tissue, and homogenized at 4°C. Here, as the RIPA buffer, a protease inhibitor, a phosphatase inhibitor and the like may be added, and for example, 10 mg/mL PMSF in an amount of 1/10 volume of the RIPA buffer may be added. For homogenization, a sonicator or a pressurized cell grinder is used. In an operation of homogenization, a homogenized liquid is constantly kept at 4°C for preventing heat generation. The homogenized liquid is transferred to a microtube, and centrifuged at 4°C for 10 minutes at 10,000xg, and the supernatant is obtained as a tissue lysate.

50 **[0063]** Examples of the "specimen" in the present method include samples and surface adhered matters collected from foods, rivers, soils or general commercial products, and microorganisms such as fungi, cells, viruses and nucleic acids thereof can be contained.

55 **[0064]** Examples of the DNA used as a specimen include genomic DNA obtained by extraction from the biological sample or the microorganism, and DNA fragment or RNA derived from genomic DNA. For obtaining genomic DNA from

a sample derived from a mammal, for example, a commercially available DNA extraction kit and the like may be used. For obtaining DNA from RNA, a reverse transcriptase such as a commercially available cDNA preparation kit and the like may be used. As the specimen, artificially synthesized DNA may be used.

5 [0065] The term "target DNA region" (hereinafter, sometimes referred to as a target region) in the present method means a DNA region intended to be detected or quantified by the present method in DNA contained in a specimen. The target DNA region is represented by a nucleotide sequence on DNA when the specimen is DNA. When the specimen is RNA, the target DNA region is represented by a nucleotide sequence on DNA prepared from RNA by a reverse transcriptase, and is a complementary nucleotide sequence of a prescribed nucleotide sequence to be detected on RNA. In the present method, when cytosine is methylated and detected or quantified, a target region desirably contains a region abundantly containing cytosine or CpG as will be described later.

[0066] First step is a step of preparing from a specimen DNA for which a target DNA region is to be detected.

10 [0067] Examples of DNA prepared in First step include a DNA sample digested in advance with a restriction enzyme recognition cleavage site for which is not present in the target DNA region possessed by the DNA, a DNA sample purified in advance, free DNA in blood, DNA derived from microbial genome, and DNA prepared from RNA in a specimen by a reverse transcriptase. As DNA prepared in First step, for example, DNA that is designed based on gene information of the specimen and artificially synthesized may be recited.

15 [0068] When blood is used as a specimen, plasma or serum is prepared from blood by a routine method, and the prepared plasma or serum is used as a specimen, and free DNA (containing DNA derived from cancer cells such as gastric cancer cells) contained therein is analyzed, and thus DNA derived from cancer cells such as gastric cancer cells can be analyzed away from DNA derived from hemocytes, and sensitivity of detecting cancer cells such as gastric cancer cells, and tissues containing the same can be improved.

20 [0069] Examples of DNA prepared in First step include DNA derived from microorganisms such as gram-positive bacteria, gram-negative bacteria, fungi, viruses and pathogenic protozoans, and DNA obtained from RNA derived from such microorganisms by a reverse transcriptase. For example, genomic DNA or DNA prepared by a reverse transcriptase from RNA of *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Borrelia burgdorferi* B31, *Rickettsia prowazekii*, *Treponema pallidum*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Helicobacter pylori* J99, *Helicobacter pylori* 26695, *Haemophilus influenzae* Rd, *Mycobacterium tuberculosis* H37Rv, *Pseudomonas aeruginosa*, *Legionella pneumophila*, *Serratia marcescens*, *Escherichia coli*, *Listeria monocytogenes*, *Salmonella enterica*, *Campylobacter jejuni* subsp. *Jejuni*, *Staphylococcus aureus*, *Vibrio parahaemolyticus*, *Bacillus cereus*, *Clostridium botulinum*, *Clostridium perfringens*, *Yersinia enterocolitica*, *Yersinia pseudotuberculosis*, *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Candida albicans*, *Cryptococcus neoformans*, *Aspergillus fumigatus*, *Pneumocystis carinii*, *Coccidioides immitis*, *Cytomegalovirus*, human herpesvirus 5, Epstein-Barr virus, Human Immunodeficiency Virus, Human Papilloma Virus, Enterovirus, Norovirus Influenza Virus, *Toxoplasma gondii*, *Cryptosporidium parvum*, or *Entamoeba histolytica* may be used for detection of a microorganism responsible for an infection in a specimen, or a microorganism responsible for a food poisoning in food.

30 [0070] For preparing genomic DNA, for example, when the specimen is a sample derived from a mammal, a commercially available DNA extraction kit (Genfind v2 Kit (available from BECKMAN COULTER), FastPure DNA Kit (available from TAKARA BIO INC.)) and the like may be used.

35 [0071] When the specimen is a microorganism such as fungus, genomic DNA may be prepared by a general preparation method of yeast genome or the like as described in *Methods in Yeast Genetics* (Cold Spring Harbor Laboratory Press), and when the specimen is a prokaryote such as *Escherichia coli*, a general preparation method of microorganism genome or the like as described in *Molecular Cloning - A Laboratory Manual-* (Cold Spring Harbor Laboratory Press) may be used.

40 [0072] When the specimen is a food sample, DNA may be prepared after separating a microorganism or the like from the food, and genomic DNA of non-microorganism and genome derived from a microorganism contained in the food may be obtained at the same time. When the specimen is a tissue derived from a mammal, and the target DNA region is DNA derived from a virus, RNA may be extracted from the tissue using such as a commercially available RNA extraction kit (ISOGEN(311-02501)(available from NIPPON GENE CO., LTD.), or FastRNA Pro Green Kit (available from Funakoshi Corporation), FastRNA Pro Blue Kit (available from Funakoshi Corporation), FastRNA Pro Red Kit (available from Funakoshi Corporation), and the like), and DNA may be obtained by a reverse transcriptase. When the specimen is a specimen derived from a mammal, viral DNA may be extracted after extracting virus particles, or after extracting virus particles, viral RNA may be extracted using a commercially available kit (QuickGene RNA tissue kit SII, available FUJIFILM Corporation) or the like, and DNA derived from the virus may be obtained by a reverse transcriptase. RNA may be extracted from a tissue infected by a virus, and DNA derived from the virus may be obtained by a reverse transcriptase, or DNA may be obtained from a tissue infected by a virus, and DNA derived from the virus may be obtained. When DNA is obtained from RNA by a reverse transcriptase, a commercially available kit (Transcripser high fidelity cDNA synthesis kit, available from Roche Diagnostics K.K.) and the like may be used.

50 [0073] In "methylated DNA", any of four kinds of bases constituting gene (genomic DNA) is methylated. For example, in a mammal is known a phenomenon that only cytosine in a nucleotide sequence represented by 5'-CG-3' (C represents

cytosine, and G represents guanine. Hereinafter, the nucleotide sequence is occasionally denoted by "CpG") is methylated. A methylation site of cytosine is position 5. In DNA duplication antecedent to cell division, only cytosine in "CpG" in a template chain derived from a parent cell is methylated in nascent double-stranded DNA, and cytosine in "CpG" in a nascent DNA chain is also methylated rapidly by the action of a methyltransferase. In this cytosine methylation is methylated cytosine in CpG in a nascent DNA chain that complementarily binds to CpG containing methylated cytosine in a DNA chain derived from a parent cell. Therefore, the methylation condition of DNA of the parent cell is taken over as it is to new two sets of DNA after DNA duplication. The term "CpG pair" means a double-stranded DNA in which a nucleotide sequence represented by CpG binds to CpG complementary to the sequence.

**[0074]** The term "single-stranded methylated DNA" means single-stranded DNA in which is methylated cytosine at a position 5 in a nucleotide sequence represented by 5'-CG-3' in a nucleotide sequence of the single-stranded DNA.

**[0075]** Examples of the "target DNA region" include promoter regions, untranslated regions or translated regions (coding regions) of useful protein genes such as Lysyl oxidase, HRAS-like suppressor, bA305P22.2.1, Gamma filamin, HAND1, Homologue of RIKEN 2210016F16, FLJ32130, PPARG angiopoietin-related protein, Thrombomodulin, p53-responsive gene 2, Fibrillin 2, Neurofilament 3, disintegrin and metalloproteinase domain 23, G protein-coupled receptor 7, G-protein coupled somatostatin and angiotensin-like peptide receptor, and Solute carrier family 6 neurotransmitter transporter noradrenalin member 2, and preferably include DNA regions containing one or more CpG present in these nucleotide sequences. In the present method, methylated DNA of "target DNA region" may be detected or quantified individually, and, for example, when more methylated DNA of "target DNA region" is detected in one detection system, the quantification accuracy and detection sensitivity are improved correspondingly.

**[0076]** To be more specific, when the useful protein gene is a Lysyl oxidase gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Lysyl oxidase gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 1 (corresponding to a nucleotide sequence represented by base No. 16001 to 18661 in the nucleotide sequence described in Genbank Accession No. AF270645) can be recited. In the nucleotide sequence of SEQ ID NO: 1, ATG codon encoding methionine at amino terminal of Lysyl oxidase protein derived from human is represented in base No. 2031 to 2033, and a nucleotide sequence of the above exon 1 is represented in base No. 1957 to 2661.

**[0077]** To be more specific, when the useful protein gene is a HRAS-like suppressor gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a HRAS-like suppressor gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 2 (corresponding to a nucleotide sequence represented by base No. 172001 to 173953 in the nucleotide sequence described in Genbank Accession No. AC068162) can be recited. In the nucleotide sequence of SEQ ID NO: 2, the nucleotide sequence of exon 1 of a HRAS-like suppressor gene derived from human is represented in base No. 1743 to 1953.

**[0078]** To be more specific, when the useful protein gene is a bA305P22.2.1 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a bA305P22.2.1 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 3 (corresponding to a nucleotide sequence represented by base No. 13001 to 13889 in the nucleotide sequence described in Genbank Accession No. AL121673) can be recited. In the nucleotide sequence of SEQ ID NO: 3, ATG codon encoding methionine at amino terminal of bA305P22.2.1 protein derived from human is represented in base No. 849 to 851, and a nucleotide sequence of the above exon 1 is represented in base No. 663 to 889.

**[0079]** To be more specific, when the useful protein gene is a Gamma filamin gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Gamma filamin gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 4 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 63528 to 64390 in the nucleotide sequence described in Genbank Accession No. AC074373) can be recited. In the nucleotide sequence of SEQ ID NO: 4, ATG codon encoding methionine at amino terminal of Gamma filamin protein derived from human is represented in base No. 572 to 574, and a nucleotide sequence of the above exon 1 is represented in base No. 463 to 863.

**[0080]** To be more specific, when the useful protein gene is a HAND1 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a HAND1 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely,

the nucleotide sequence of SEQ ID NO: 5 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 24303 to 26500 in the nucleotide sequence described in Genbank Accession No. AC026688) can be recited. In the nucleotide sequence of SEQ ID NO: 5, ATG codon encoding methionine at amino terminal of HAND1 protein derived from human is represented in base No. 1656 to 1658, and a nucleotide sequence of the above  
5 exon 1 is represented in base No. 1400 to 2198.

**[0081]** To be more specific, when the useful protein gene is a Homologue of RIKEN 2210016F16 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Homologue of RIKEN 2210016F16 gene derived from human, and a promoter region located 5'  
10 upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 6 (corresponding to a complementary nucleotide sequence to a nucleotide sequence represented by base No. 157056 to 159000 in the nucleotide sequence described in Genbank Accession No. AL354733) can be recited. In the nucleotide sequence of SEQ ID NO: 6, a nucleotide sequence of exon 1 of a Homologue of a RIKEN 2210016F16 gene derived from human is represented in base No. 1392 to 1945.

**[0082]** To be more specific, when the useful protein gene is a FLJ32130 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a FLJ32130 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 7 (corresponding to a complementary nucleotide sequence to a  
20 nucleotide sequence represented by base No. 1 to 2379 in the nucleotide sequence described in Genbank Accession No. AC002310) can be recited. In the nucleotide sequence of SEQ ID NO: 7, ATG codon encoding methionine at amino terminal of FLJ32130 protein derived from human is represented in base No. 2136 to 2138, and a nucleotide sequence assumed to be the above exon 1 is represented in base No. 2136 to 2379.

**[0083]** To be more specific, when the useful protein gene is a PPARG angiopoietin-related protein gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a PPARG angiopoietin-related protein gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 8 can be recited.  
25 In the nucleotide sequence of SEQ ID NO: 8, ATG codon encoding methionine at amino terminal of PPARG angiopoietin-related protein derived from human is represented in base No. 717 to 719, and a nucleotide sequence of the 5' side part of the above exon 1 is represented in base No. 1957 to 2661.

**[0084]** To be more specific, when the useful protein gene is a Thrombomodulin gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of  
35 a Thrombomodulin gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 9 (corresponding to a nucleotide sequence represented by base No. 1 to 6096 in the nucleotide sequence described in Genbank Accession No. AF495471) can be recited. In the nucleotide sequence of SEQ ID NO: 9, ATG codon encoding methionine at amino terminal of Thrombomodulin protein derived from human is represented in base No. 2590 to 2592, and a nucleotide sequence of the above exon 1  
40 is represented in base No. 2048 to 6096.

**[0085]** To be more specific, when the useful protein gene is a p53-responsive gene 2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a p53-responsive gene 2 gene derived from human, and a promoter region located 5' upstream of the same  
45 can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 10 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 113501 to 116000 in the nucleotide sequence described in Genbank Accession No. AC009471) can be recited. In the nucleotide sequence of SEQ ID NO: 10, a nucleotide sequence of exon 1 of a p53-responsive gene 2 gene derived from human is represented in base No. 1558 to 1808.

**[0086]** To be more specific, when the useful protein gene is a Fibrillin2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Fibrillin2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 11 (corresponding to a complementary sequence to a nucleotide  
50 sequence represented by base No. 118801 to 121000 in the nucleotide sequence described in Genbank Accession No. AC113387) can be recited. In the nucleotide sequence of SEQ ID NO: 11, a nucleotide sequence of exon 1 of a Fibrillin2 gene derived from human is represented in base No. 1091 to 1345.

**[0087]** To be more specific, when the useful protein gene is a Neurofilament3 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region,

untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Neurofilament3 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 12 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 28001 to 30000 in the nucleotide sequence described in Genbank Accession No. AF106564) can be recited. In the nucleotide sequence of SEQ ID NO: 12, a nucleotide sequence of exon 1 of a Neurofilament3 gene derived from human is represented in base No. 614 to 1694.

**[0088]** To be more specific, when the useful protein gene is a disintegrin and metalloproteinase domain 23 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a disintegrin and metalloproteinase domain 23 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 13 (corresponding to a nucleotide sequence represented by base No. 21001 to 23300 in the nucleotide sequence described in Genbank Accession No. AC009225) can be recited. In the nucleotide sequence of SEQ ID NO: 13, a nucleotide sequence of exon 1 of a disintegrin and metalloproteinase domain 23 gene derived from human is represented in base No. 1194 to 1630.

**[0089]** To be more specific, when the useful protein gene is a G protein-coupled receptor 7 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a G protein-coupled receptor 7 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 14 (corresponding to a nucleotide sequence represented by base No. 75001 to 78000 in the nucleotide sequence described in Genbank Accession No. AC009800) can be recited. In the nucleotide sequence of SEQ ID NO: 14, a nucleotide sequence of exon 1 of a G protein-coupled receptor 7 gene derived from human is represented in base No. 1666 to 2652.

**[0090]** To be more specific, when the useful protein gene is a G-protein coupled somatostatin and angiotensin-like peptide receptor gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a G-protein coupled somatostatin and angiotensin-like peptide receptor gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 15 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 57001 to 60000 in the nucleotide sequence described in Genbank Accession No. AC008971) can be recited. In the nucleotide sequence of SEQ ID NO: 15, a nucleotide sequence of exon 1 of a G-protein coupled somatostatin and angiotensin-like peptide receptor gene derived from human is represented in base No. 776 to 2632.

**[0091]** To be more specific, when the useful protein gene is a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 16 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 78801 to 81000 in the nucleotide sequence described in Genbank Accession No. AC026802) can be recited. In the nucleotide sequence of SEQ ID NO: 16, a nucleotide sequence of exon 1 of a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene derived from human is represented in base No. 1479 to 1804.

**[0092]** Second step is a step of treating the DNA prepared in First step with a DNA methylation enzyme.

**[0093]** The "DNA methylation enzyme" means an enzyme that methylates a base in DNA, and various kinds DNA methylation enzymes are isolated from mammalian cells, bacteria and the like. DNA methylation enzymes are classified into several kinds such as adenine methylation enzymes, and cytosine methylation enzymes according to the kind of the base of a substrate. A cytosine methylation enzyme is an enzyme that recognizes a specific sequence in a DNA nucleotide sequence, and methylates cytosine near the sequence, and different cytosine methylation enzymes are known according to the recognized nucleotide sequences.

**[0094]** A number of methylation reactions of DNA catalyzed by a DNA methylation enzyme are found from a primitive immune system called a restriction-modification system. The restriction-modification system is a function that digests foreign DNA (in particular, bacteriophage) with a restriction enzyme after regularly methylating the entire genome functioning in bacteria to protect it from being digested by a restriction enzyme (restriction endonuclease) that recognizes a specific sequence, and is a system for protecting a microbial genome from bacteriophage infection. Enzymes functioning in methylation of genome are known to methylate cytosine or adenine, and often known to methylate nitrogen at position 6 (N6) or carbon at position 5 (C5) of a purine residue. Among these enzymes, known as a cytosine methylation enzyme that methylates C5 of cytosine are SssI (M.SssI) methylase, AluI methylase, HhaI methylase, HpaII methylase, MspI

methylase, HaeIII methylase, and so on. These enzymes that methylate position C5 of cytosine recognize different nucleotide sequences, and a cytosine methylation enzyme that recognizes CpG is only SssI.

**[0095]** As a methylation reaction of DNA in human genome, methylation at position 5 (C5) of cytosine in CpG is known as epigenetics (the mechanism generating diversity of gene expression independent of gene sequence), and as such a cytosine methylation enzyme, DNA methyltransferase is known. As a DNA methyltransferase, Dnmt1 methyltransferase is known.

**[0096]** In human cells, since position C5 of cytosine in a CpG sequence is methylated, for methylating genome artificially, the same position of the same cytosine in the same sequence (CpG) with methylation in a human cell can be methylated by using SssI.

**[0097]** For methylating DNA by a cytosine methylation enzyme, concretely, for example, a DNA sample is added with 5  $\mu$ L of an optimum 10 $\times$  buffer (NEBuffer2 (available from NEB Inc.)), 0.5  $\mu$ L of S-adenosyl methionine (3.2 mM, available from NEB Inc.) and 0.5  $\mu$ L of cytosine methylation enzyme SssI(available from NEB Inc.), and then the resultant mixture is added with sterilized ultrapure water to make the liquid amount 50  $\mu$ L, and then incubated at 37°C for 30 minutes.

**[0098]** Third step is a step of preparing single-stranded methylated DNA from the DNA treated with a DNA methylation enzyme in Second step.

**[0099]** For example, when the methylated DNA is double-stranded DNA, the double-stranded DNA is divided into single-stranded DNA. Concretely, DNA that is methylated by a DNA methylation enzyme in Second step is prepared into a solution of 1 ng/ $\mu$ L with Tris-HCl buffer (10 mM), and 10  $\mu$ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu$ L of 100 mM MgCl<sub>2</sub> solution, and 10  $\mu$ L of 1 mg/mL BSA solution are mixed, and the resultant mixture is added with sterilized ultrapure water to make the liquid amount 100  $\mu$ L. Thereafter the mixture is heated at 95°C for 10 minutes, and then rapidly cooled on ice-cooled water for several minutes. For example, when the DNA prepared from a specimen is free DNA contained in blood or the like, the DNA methylated in Second step can be single-stranded DNA. Since such single-stranded DNA sometimes forms a higher order structure, it is advisable to conduct a treatment similar to the case of the double-stranded DNA.

**[0100]** Fourth step is a step of forming a complex of a single-stranded methylated DNA comprising a methylated target DNA region, a methylated DNA antibody, and a specific oligonucleotide by mixing the single-stranded methylated DNA prepared in Third step, the methylated DNA antibody, and the specific oligonucleotide comprising a nucleotide sequence that does not inhibit binding between one or more methylated bases in the target DNA region in the single-stranded methylated DNA and the methylated DNA antibody, and that is capable of binding with the single-stranded DNA by complementation.

**[0101]** "Methylated DNA antibody" is an antibody that binds with a methylated base in DNA as an antigen. Concretely, methylcytosine antibody can be recited, and an antibody having the property of recognizing cytosine whose position 5 is methylated in single-stranded DNA and binding thereto can be recited. Commercially available methylated DNA antibodies may also be used as far as they specifically recognize DNA in a methylation state described in the present specification, and are capable of specifically binding thereto. Such a methylated DNA antibody can be prepared in a conventional method using a methylated base, methylated DNA or the like as an antigen. For concretely preparing a methylcytosine antibody, selection is made according to specific binding to methylcytosine in DNA as an indicator from antibodies prepared using DNA containing 5-methylcytidine, 5-methylcytosine, or 5-methylcytosine as an antigen. Considering the property of the methylated DNA antibody, namely, the fact that one antibody binds to one methylated base (cytosine), improvements in quantification accuracy and detection sensitivity are expected by selecting the region where a number of methylated bases (cytosine), namely CpG, are present, as the target DNA region.

**[0102]** Known as antibodies that can be obtained by immunizing an animal with an antigen are an antibody of IgG fraction (polyclonal antibody), an antibody producing a single clone (monoclonal antibody) and the like that can be obtained by immunizing an animal with an antigen. In the present invention, since an antibody capable of specifically recognizing methylated DNA or methylcytosine is preferred, use of a monoclonal antibody is advisable.

**[0103]** As a method of preparing a monoclonal antibody, a procedure based on a cell fusion method can be recited. For example, in the cell fusion method, a hybridoma is prepared by allowing cell fusion between a spleen cell (B cell) derived from an immunized mouse and a myeloma cell, and an antibody produced by the hybridoma is selected for preparation of a methyl cytosine antibody (monoclonal antibody). When a monoclonal antibody is prepared by a cell fusion method, it is not necessary to purify an antigen, and for example, a mixture of 5-methyl cytidine, 5-methyl cytosine or DNA or the like containing 5-methyl cytosine may be administered as an antigen to an animal used for immunization. As an administration method, 5-methyl cytidine, 5-methyl cytosine or DNA or the like containing 5-methyl cytosine is directly administered to a mouse for production of an antibody. When an antibody is difficult to be produced, an antigen bound to a support may be used for immunization. Also, by thoroughly mixing an adjuvant solution (prepared, for example, by mixing liquid paraffin and Aracel A, and mixing killed tubercle bacilli as an adjuvant) and an antigen and administering the same, or immunizing via liposome incorporating the same, immunity of an antigen can be improved. Also a method involving adding equivalent amounts of a solution containing an antigen and an adjuvant solution, fully emulsifying them, and subcutaneously or intraperitoneally injecting the resultant mixture to a mouse, and a method of adding killed Bordetella

pertussis as an adjuvant after mixing well with alum water are known. A mouse may be boosted intraperitoneally or intravenously after an appropriate term from initial immunization. When the amount of an antigen is small, a solution in which the antigen is suspended may be directly injected into a mouse spleen to effect immunization.

5 [0104] After exenterating a spleen and peeling an adipose tissue off after several days from the final immunization, a spleen cell suspension is prepared. The spleen cell is fused, for example, with an HGPRT-deficient myeloma cell to prepare a hybridoma. As a cell fusion agent, any means capable of efficiently fusing a spleen cell (B cell) and a myeloma cell is applicable, and for example, a method of using a hemagglutinating virus of Japan (HVJ), polyethyleneglycol (PEG) and the like are recited. Cell fusion may be conducted by a method using a high voltage pulse.

10 [0105] After the cell fusion operation, cells are cultured in an HAT medium, a clone of a hybridoma in which a spleen cell and a myeloma cell are fused is selected, and the cell is allowed to grow until screening becomes possible. In a method of detecting an antibody for selecting a hybridoma that produces an intended antibody, or a method of measuring a titer of an antibody, an antigen-antibody reaction system may be used. Concretely, as a method of measuring an antibody against a soluble antigen, a radioisotope immune assay (RIA), an enzyme-linked immunosorbent assay (ELISA) and the like can be recited.

15 [0106] Single-stranded DNA is able to bind with an anti-methylation antibody as far as CpG existing therein is methylated at least at one site. Therefore, the term "methylated" in the present method means DNA in which CpG existing therein is methylated at least at one site, and is not limited to DNA in which every CpG existing therein is methylated.

20 [0107] The term "specific oligonucleotide" is an oligonucleotide comprising a nucleotide sequence capable of binding with single-stranded DNA comprising a target DNA region by complementation, and has a function of binding to a support as will be described later. Here, "nucleotide sequence capable of binding with single-stranded DNA comprising a target DNA region by complementation" is called a specific adhesion sequence.

25 [0108] The term "nucleotide sequence capable of binding with single-stranded DNA comprising a target DNA region by complementation" means a nucleotide sequence capable of complementarily binding with a part of single-stranded DNA comprising a target DNA region, having a nucleotide sequence that is complementary to a part of a nucleotide sequence of single-stranded DNA comprising a target DNA region, or to a part of a nucleotide sequence of the DNA region which is located further 5'-end side from 5'-end of the target DNA region, or to a part of a nucleotide sequence located further 3'-end side from 3'-end of the target DNA region.

30 [0109] The wording "not inhibiting binding between one or more methylated bases in a target DNA region in single-stranded methylated DNA and the methylated DNA antibody" in Fourth step of the present method means that complementary binding between the specific oligonucleotide and the single-stranded DNA does not occur in an occupied space required for the methylated DNA antibody to bind with the methylated single-stranded DNA. It is supposed that for the methylated DNA antibody to bind with the methylated base (cytosine), not only the directly-binding methylated base (cytosine), but also the peripheral space where the methylated base (cytosine) exists would be occupied. Therefore, the specific oligonucleotide should be a nucleotide sequence that fails to complementarily bind with the single-stranded DNA (DNA comprising a target DNA region) in an occupied space required for the methylated DNA antibody to bind on the DNA having a target DNA region. The specific oligonucleotide to be bound with the single-stranded DNA is not necessarily one kind, but two or more kinds may be used unless binding of the methylated DNA antibody is inhibited. By using a plurality of specific oligonucleotides, quantification accuracy and detection sensitivity can be improved.

35 [0110] The wording "forming a complex of a single-stranded methylated DNA comprising a methylated target DNA region, a methylated DNA antibody, and a specific oligonucleotide by mixing the single-stranded methylated DNA, the methylated DNA antibody, and the specific oligonucleotide comprising a nucleotide sequence that does not inhibit binding between one or more methylated bases in the target DNA region in the single-stranded methylated DNA and the methylated DNA antibody, and that is capable of binding with the single-stranded DNA by complementation" in Fourth step means allowing the single-stranded methylated DNA comprising a target DNA region to complementarily bind with the specific oligonucleotide, and further allowing the DNA comprising a target DNA region to bind with the methylated DNA antibody, thereby forming a complex formed of the methylated DNA comprising a target DNA region, the specific oligonucleotide, and the methylated DNA. Here, by immobilizing the specific oligonucleotide to a support, it is possible to immobilize the complex to the support.

40 [0111] In Fourth step, for binding "the single-stranded methylated DNA comprising a target DNA region and the specific oligonucleotide complementarily", for example, the single-stranded methylated DNA comprising a methylated target DNA region may be allowed to complementarily bind with the specific oligonucleotide, and the methylated DNA antibody may be allowed to bind with the methylated DNA comprising a target DNA region after immobilizing the specific oligonucleotide to a support. For "complementarily binding the single-stranded methylated DNA comprising a target DNA region and the specific oligonucleotide", for example, a solution of the DNA comprising a target DNA region and the specific oligonucleotide capable of complementarily binding with the DNA are prepared into solutions of 0.02 $\mu$ M with Tris-HCl buffer (10 mM), and each 10  $\mu$ L of these solutions and a buffer liquid (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu$ L of 100 mM MgCl<sub>2</sub> solution, and 10  $\mu$ L of 1 mg/mL BSA solution are mixed, and further the mixture is added with sterilized ultrapure water to make the liquid amount 100  $\mu$ L. Then the

mixture is heated at 95°C for 10 minutes, and rapidly cooled to 70°C and retained at this temperature for 10 minutes, and cooled to 50°C and retained for 10 minutes, and further retained at 37°C for 10 minutes, and returned to room temperature. In this manner, formation of a conjugate of the DNA comprising a target DNA region and the specific oligonucleotide can be promoted.

5 **[0112]** The wording "complementarily bind" means that double-stranded DNA is formed by base-pairing through a hydrogen bond between bases. For example, it means that respective bases constituting single-stranded DNA of a double strand forming DNA form a double strand by base-pairing between purine and pyrimidine, and more concretely, double-stranded DNA is formed by base-pairing through hydrogen bonds between a plurality of sequential thymine and adenine, and guanine and cytosine. Binding based on complementation may be sometimes expressed by "complementarily binding". "Complementarily binding" may be sometimes expressed by "complementary binding", "binding by complementation", "complementary binding (by base-pairing)", "complementary base-pairing" or "capable of complementarily base-pairing". Nucleotide sequences that are capable of complementarily binding may be sometimes expressed by "having complementation" or "complementary" each other. Binding of inosine contained in an artificially prepared oligonucleotide with cytosine, or adenine, or thymine through hydrogen bonding is also implied in complementary binding. 10 The wording "single-stranded DNA comprising a nucleotide sequence complementary to the target DNA region" means that it is a nucleotide sequence comprising a nucleotide sequence that is necessary for formation of a conjugate (double-strand) with the single-stranded DNA comprising a target DNA region, namely a nucleotide sequence comprising a nucleotide sequence complementary to a part of a nucleotide sequence of the target DNA region, and is also expressed by "complementary nucleotide sequence". The complementary nucleotide sequence may be sometimes expressed by "complementary", "nucleotide sequence capable of binding by complementation" or "complementary sequence". 20

**[0113]** In the present method, when the DNA comprising a target DNA region and the specific oligonucleotide "bind by complementation", it also includes the case where a part of the nucleotide sequence constituting the specific adhesion sequence of the specific oligonucleotide fails to base-pair with the DNA comprising a target DNA region. For example, the cases are also included where among bases constituting the specific adhesion sequence, at least 75%, preferably 80% or more bases base-pair with the DNA comprising a target DNA region, and the oligonucleotide having a homology of at least 75% or more, preferably 80% or more with the DNA comprising a target DNA region is able to bind with the specific adhesion sequence. 25

**[0114]** When the DNA comprising a target DNA region is a repetitive sequence in genome as will be described later, the repetitive sequence is a group of nucleotide sequences having homology, so that there is a possibility that a part of the specific adhesion sequence fails to base-pair with the DNA comprising a target DNA region. In other words, in the present method, when the DNA comprising a target DNA region is a repetitive sequence such as LINE sequence or SINE (Alu) sequence, a specific adhesion sequence capable of binding with a nucleotide sequence having a homology of 80% or more by complementation may be used. 30

**[0115]** As a preferred aspect in forming a conjugate of the single-stranded DNA comprising a target DNA region and the specific oligonucleotide, formation in a reaction system containing a divalent cation can be recited. More preferably, the divalent cation is a magnesium ion. Here, the wording "reaction system containing a divalent cation" means a reaction system containing a divalent cation in an annealing buffer used for binding between the single-stranded DNA comprising a target DNA region and the specific oligonucleotide, and concretely, for example, a system containing a salt composed of a magnesium ion (for example, MgOAc<sub>2</sub>, MgCl<sub>2</sub> and the like) in a concentration of 1 mM to 600 mM can be recited. 35

**[0116]** In Fourth step of the present method, a specific oligonucleotide for two or more kinds of target DNA regions may be mixed to form a complex, or two or more kinds of specific oligonucleotides for one kind of target region may be mixed to form a complex. 40

**[0117]** In the present method, when "a complex is formed", the complex formed of the single-stranded methylated DNA comprising a target DNA region, the specific oligonucleotide and the methylated DNA antibody is bound and immobilized to the support as will be described later. 45

**[0118]** For "forming a complex", concretely, for example, it may be practiced in the following manner using "biotinylated specific oligonucleotide" whose terminal is labeled with biotin as a specific oligonucleotide that is immobilizable to a support. 50

(a) A DNA sample derived from genomic DNA is added with an annealing buffer (for example, 33 mM Tris-Acetate pH 7.9, 66 mM KOAc, 10 mM MgOAc<sub>2</sub>, 0.5 mM Dithiothreitol) and a biotinylated specific oligonucleotide to obtain a mixture. Then the obtained mixture is heated at 95°C, for example, for several minutes to make the double-stranded DNA derived from genomic DNA into single-stranded DNA. Then for forming a conjugate of the single-stranded DNA comprising a target DNA region and the biotinylated specific oligonucleotide, the mixture is cooled rapidly to a temperature lower than the T<sub>m</sub> value of the biotinylated specific oligonucleotide by about 10 to 20°C, and retained at this temperature, for example, for several minutes, and then returned to room temperature. 55

(b) The mixture obtained in the above (a) is added to a support coated with streptavidin, and further retained it at 37°C, for example, for several minutes, to immobilize the conjugate of the single-stranded DNA comprising a target

DNA region and the biotinylated specific oligonucleotide to the support coated with streptavidin. Thereafter, the remaining solution is removed and washed. A washing buffer (for example, 0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)) is added, for example, in an amount of 300  $\mu\text{L}$ /well, and the solution is removed. This washing operation is repeated several times, to leave the conjugate of the biotinylated specific oligonucleotide and the single-stranded DNA comprising a target DNA region that is immobilized to the support, on the well.

(c) An appropriate amount (for example, 100  $\mu\text{L}$ /well of 4  $\mu\text{g}/\text{mL}$  solution) of a methylated DNA antibody is added to a well, and then left still, for example, for three hours at room temperature, to promote formation of a complex of the methylated DNA antibody, the methylated single-stranded DNA comprising a target DNA region from the single-stranded DNA, and the biotinylated specific oligonucleotide (formation of complex). Then the remaining solution is removed and washed. A washing buffer (for example, 0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)) is added, for example, in an amount of 300  $\mu\text{L}$ /well, and the solution is removed. This washing operation is repeated several times, to leave the complex on the well (selection of complex).

**[0119]** As the annealing buffer used in (a), those suited for binding the specific oligonucleotide and the single-stranded DNA comprising a target DNA region may be used without limited to the aforementioned annealing buffer. Use of a buffer in which a divalent ion, preferably a magnesium ion is dissolved in a concentration of 1 to 600 mM improves the binding stability.

**[0120]** The washing operation in (b) and (c) is important for removing the DNA that is not bound to the specific oligonucleotide, the methylated DNA antibody that is not immobilized to the support, or the DNA digested with a later-described restriction enzyme and thus suspended in the solution, from the reaction solution. The washing buffer is not limited to the washing buffer described above, insofar as it is suited for removing the free methylated DNA antibody, single-stranded DNA suspended in the solution and the like, and a DELFIA buffer (available from PerkinElmer, Tris-HCl pH 7.8 with Tween 80), a TE buffer and the like may be used.

**[0121]** In the above (a) to (c), binding between the single-stranded DNA comprising a target DNA region and the biotinylated specific oligonucleotide is executed in a stage previous to immobilization of the biotinylated specific oligonucleotide to the support coated with streptavidin, however, this order may be inverted. For example, by adding a DNA sample derived from genomic DNA to the biotinylated specific oligonucleotide immobilized to the support coated with streptavidin, a mixture is obtained. For making double-stranded DNA comprising a target DNA region possessed by genomic DNA into single strands, the obtained mixture is heated at 95°C, for example, for several minutes, and then for allowing formation of a conjugate with the biotinylated specific oligonucleotide, the mixture is rapidly cooled to a temperature lower than the  $T_m$  value of the biotinylated specific oligonucleotide by about 10 to 20°C, and retained at this temperature, for example, for several minutes. Thereafter, the operation of (c) may be executed, to form and select a complex. In this stage, a conjugate of the unmethylated single-stranded DNA comprising a target DNA region and the specific oligonucleotide fails to form a complex.

**[0122]** The operations of the above (a) to (c) may be conducted using a chromatostrip. In this case, concretely, the operations are conducted in the following manner. A solution in which the conjugate of the single-stranded DNA comprising a target DNA region possessed by genomic DNA and the biotinylated specific oligonucleotide is formed is developed by a chromatostrip partially coated with streptavidin. By this operation, the conjugate of the single-stranded DNA comprising a target DNA region possessed by genomic DNA and the biotinylated specific oligonucleotide is immobilized to the part coated with streptavidin. Then an appropriate amount of the methylated DNA antibody is developed by the chromatostrip as described above. Through these operations, the complex of the methylated single-stranded DNA comprising a target DNA region possessed by genomic DNA, the biotinylated specific oligonucleotide, and the methylated DNA antibody is immobilized to the part coated with streptavidin (formation and selection of complex). Also for these operations, the order of formation of complex may be inverted. For example, after forming a complex made up of a methylated single-stranded DNA comprising a target DNA region, a biotinylated specific oligonucleotide, and a methylated DNA antibody, the complex may be developed by a chromatostrip, and immobilized to the part coated with streptavidin. In these operations, unnecessary components can be removed by developing the solution by a chromatostrip, and a washing operation can be omitted. A washing operation (development of a chromatostrip by a washing buffer (for example, a 0.05% Tween 20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)) may be conducted between these operations without causing any problem.

**[0123]** As the "support", the material and form thereof are not particularly limited as far as a complex can bind thereto. For example, any form suited for use purpose may be employed, including the forms of tube, test plate, filter, disc, bead and the like. As the material, those used as supports for a usual immune measuring method, for example, synthetic resins such as polystyrene, polypropylene, polyacrylamide, polymethylmethacrylate, polysulfone, polyacrylonitrile and nylon, or those obtained by incorporating a reactive functional group such as sulfonic group, amino group or the like to the synthetic resins can be recited. Also, glass, polysaccharides or derivatives thereof (cellulose, nitrocellulose and the

like), silica gel, porous ceramics, metal oxides and the like may be used.

**[0124]** When the complex is immobilized to a support, it suffices that the complex is eventually immobilized to the support in the condition that the complex of the methylated single-stranded DNA comprising a target DNA region, the specific oligonucleotide, and the methylated DNA antibody is formed, and

(1) the specific oligonucleotide may be immobilized in the stage where the single-stranded DNA and the specific oligonucleotide complementarily bind, and then the methylated DNA antibody may be bound to the single-stranded DNA, and

(2) the specific oligonucleotide may be immobilized to the support after the single-stranded DNA, the specific oligonucleotide and the methylated DNA antibody form a complex.

**[0125]** For immobilizing a specific oligonucleotide to a support, concretely a method of immobilizing a biotinylated oligonucleotide obtained by biotinylating 5'-end or 3'-end of the specific oligonucleotide to a support coated with streptavidin (for example, a PCR tube coated with streptavidin, magnetic beads coated with streptavidin, a chromatostrip partially coated with streptavidin and the like) is recited. Also there is a method of letting 5'-end or 3'-end of the specific oligonucleotide covalently bind with a molecule having an active functional group such as an amino group, a thiol group, an aldehyde group or the like, and then letting it covalently bind to a support made of glass, a polysaccharide derivative, silica gel or the synthetic resin or a thermostable plastic whose surface is activated by a silane coupling agent or the like. Covalent binding is achieved, for example, by a spacer formed by serially connecting five triglycerides, a cross linker or the like. Also there is a method of chemically synthesizing from the terminal side of the specific oligonucleotide directly on a support made of glass or silicon.

**[0126]** In the case of "the specific oligonucleotide is immobilized in the stage where the single-stranded DNA and the specific oligonucleotide complementarily bind, and then the methylated DNA antibody is bound to the single-stranded DNA", the methylated DNA antibody and a masking oligonucleotide may be added at the same time.

**[0127]** The "masking oligonucleotide" in the present method is an oligonucleotide capable of complementarily binding with the specific oligonucleotide, and indicates the oligonucleotide added for preventing the methylated DNA antibody from nonspecifically binding with the specific oligonucleotide existing in a single-stranded state by complementarily binding with the specific oligonucleotide in a single-stranded state immobilized to the support without binding with the DNA comprising a target DNA region which is single-stranded DNA in the stage where "the specific oligonucleotide is immobilized to the support in the stage where the single-stranded DNA and the specific oligonucleotide complementarily bind". As the masking oligonucleotide, any oligonucleotide that has a nucleotide sequence complementary to the specific oligonucleotide, and does not generate a part which is to be a single strand as a result of complementary binding with the specific oligonucleotide is employed.

**[0128]** Here, the masking oligonucleotide may be added before formation of a complex by causing the methylated DNA antibody to bind with the conjugate of the DNA comprising a target DNA region and the specific oligonucleotide, or may be added concurrently with the methylated DNA antibody in forming a complex by causing the methylated DNA antibody to bind with the conjugate of the DNA comprising a target DNA region and the specific oligonucleotide.

**[0129]** Fifth step is a step of quantifying or detecting the DNA comprising a target DNA region in the single-stranded methylated DNA by quantifying or detecting the methylated DNA antibody contained in the complex formed in Fourth step based on its identification function.

**[0130]** The term "detection" in Fifth step means that discrimination is possible by the identification function of the methylated DNA antibody, when a total amount of the methylated DNA obtained in First step and the methylated DNA methylated by the DNA methylation enzyme treatment in Second step exceeds a detection limit. When methylated DNA is not detected, it indicates that the methylated DNA obtained in First step and the methylated DNA methylated by the DNA methylation enzyme treatment in Second step is less than a detection limit in the target DNA region in the specimen.

**[0131]** "Quantification" in Fifth step means a quantified detection amount detected by the identification function of the methylated DNA antibody. That is, it means that a value correlated with a total amount of the methylated DNA obtained in First step and the methylated DNA methylated by the DNA methylation enzyme treatment in Second step is obtained. For example, the quantified value of an amount of the methylated DNA antibody as the identification function is a value correlated with an amount of DNA in the target DNA region in the specimen, and for example, when the specimen is 1 mL of serum, it means that a value correlated with a total amount of the methylated DNA obtained in First step and the methylated DNA methylated by the DNA methylation enzyme treatment in Second step of the DNA of the target region contained in 1 mL of serum is acquired.

**[0132]** The term "identification function" in Fifth step may be a function capable of detecting or quantifying a methylated DNA antibody. The identification function may be any function possessed by the methylated DNA antibody, and for example, an identification function based on labeling of the methylated DNA antibody, and an identification function imparted to the methylated DNA antibody by a detection molecule binding to the methylated DNA antibody can be recited. Concretely, fluorescent and chromogenic characteristics of a methylated DNA antibody labeled with europium, gold

colloid, latex bead, radioisotope, fluorescent substance (FITC or the like), horseradish Peroxidase (HRP), alkaline phosphatase, biotin and the like are recited. These labels are fluorescent, chromogenic functions, and such a labeled molecule may be bound to the methylated DNA antibody by the characteristic of the antibody itself (the characteristic of binding with a secondary antibody of the antibody itself). The antibody binding with the methylated DNA antibody (also called secondary antibody) may be labeled with europium, gold colloid, latex bead, radioisotope, fluorescent substance (FITC or the like), horseradish Peroxidase (HRP), alkaline phosphatase, biotin and the like. As to the secondary antibody, when the methylated DNA antibody is not labeled, an antibody that recognizes the methylated DNA antibody as an antigen may be used as a secondary antibody. When the methylated DNA antibody is labeled, an antibody against the label may be used as a secondary antibody. Concretely, for a FITC-labeled methylated DNA antibody, a FITC antibody is applicable as a detection molecule secondary antibody. As a means for quantifying or detecting these functions, for example, measurement by a radiation detector, a spectrophotometer and the like, or visual observation and the like are recited.

**[0133]** In the present method, the support to which the specific oligonucleotide is immobilized may be a microparticle, and a microparticle as same as the support may be bound to the methylated DNA antibody. As the microparticles, latex beads, gold colloids (gold nanoparticles) and the like are recited.

**[0134]** In the present method, when the same kinds of microparticles are bound to the support and the methylated DNA antibody, the microparticle serving as a support, and the microparticle bound to the methylated DNA antibody can be detected as aggregation of microparticles by formation of a complex of the methylated DNA immobilized to the microparticle, the DNA comprising a target DNA region, and the methylated DNA antibody. In this case, when the microparticle is a latex bead, the aggregate can be detected by change in turbidity. When the microparticle is a gold colloid (gold nanoparticle), the aggregate can be detected by change in color tone (pink to purple).

**[0135]** Further, in the present method, aggregation of microparticles can be detected also when a plurality of methylated DNA antibodies to which the microparticles are bound bind at the same time on one DNA comprising a target DNA region. When the microparticle bound to the methylated DNA antibody is a latex bead, an aggregate can be detected by change in turbidity, and when the microparticle bound to the methylated DNA antibody is a gold colloid (gold nanoparticle), an aggregate can be detected by color tone change (from pink to purple). In this case, an equivalent result to that obtained by adding the methylated DNA antibody can be achieved even when the specific oligonucleotide is not added.

**[0136]** That is, it means that by formation of a detection complex as a result of binding of the methylated DNA antibody, the specific oligonucleotide, and the single-stranded methylated DNA comprising a methylated target DNA region, the microparticle which is a support for binding of the specific oligonucleotide, and the microparticle binding to the methylated DNA antibody form an aggregate. When the degree of methylation is detected by aggregation of the microparticles in this manner, an equivalent result to that obtained by adding the specific oligonucleotide can be achieved even when the specific oligonucleotide is not added.

**[0137]** An amount detected by aggregation of microparticles is correlated with a sum of DNA methylated by Second step. When DNA obtained in First step is DNA contained in a cell of a tissue, the degree of methylation of DNA contained in the cell of the tissue differs depending on the tissue, so that the degree of methylation of DNA obtained in Second step includes both the degree of methylation in the cell of the tissue, and the degree of methylation in Second step. That is, an amount detected by an aggregate of microparticles when a DNA methylation enzyme treatment is not executed in Second step is a value correlated with the degree of methylation in the cell of the tissue.

**[0138]** In the present method, one preferred aspect is that "DNA for which a target DNA region is to be detected contained in a specimen" is a DNA sample that is digested in advance with a restriction enzyme recognition cleaving site for which is not present in the target DNA region possessed by the genomic DNA. In forming a conjugate of the single-stranded DNA comprising a target DNA region possessed by genomic DNA and the specific oligonucleotide, the shorter the single-stranded DNA is, the better the operability is and the more easily a complex is formed as far as it contains the target DNA region. To shorten the single-stranded DNA, it is efficient to make it short when it is in original genomic DNA. Therefore, a digestion treatment may be conducted by making a restriction enzyme recognition cleaving site for which is not present in the target DNA region directly act on a DNA sample derived from genomic DNA. As a method of the digestion treatment by the restriction enzyme recognition cleaving site for which is not present in the target DNA region, a generally known restriction enzyme treatment method may be used. When the specimen is a DNA sample purified in advance, the treatment may be executed using an amount of a restriction enzyme generally used, whereas when the specimen is a tissue lysate, a cell lysate or the like, the treatment may be conducted with a large excess of a restriction enzyme, namely using an amount of 500 times or more the DNA amount of a restriction enzyme.

**[0139]** As a method of quantifying or detecting minor substances contained in a biological sample such as blood or urine, immunological measuring methods are generally used. Among such methods, what is called immuno chromatography using chromatography is currently widely used in various situations including, for example, clinical examinations in hospitals, assays in laboratories and the like because of its simple operation and short time required for assay. In recent years, what is called hybrid chromatography has been utilized in which labeled DNA (gene) is developed on a

chromatostrip, and target DNA (gene) is detected by hybridization using a probe capable of capturing the target DNA (gene). Also this method is now coming to be widely used in situations including, for example, clinical examinations in hospitals, assays in laboratories and the like because of its simple operation and short required time for assay. The present method conceptually enables a combined method of the immuno chromatography and the hybrid chromatography. In the present method, since the order of formation of a complex and selection of a complex is not particularly limited, various methods are possible. Concretely, such methods may be executed in the following manner.

**[0140]** Method 1: Methylated DNA (DNA in which a target DNA region has a cytosine methylated by a DNA methylation enzyme) is added with a biotinylated specific oligonucleotide which is a specific oligonucleotide to which biotin is bound as a function of immobilization to a support, to cause formation of a conjugate of the single-stranded methylated DNA comprising a target DNA region and the biotinylated specific oligonucleotide, and then added with a methylated antibody having an identification function, to cause formation of a complex in which the single-stranded DNA comprising a methylated target DNA region, the biotinylated specific oligonucleotide, and the methylated DNA antibody having an identification function are bound. As the obtained sample is dropped (introduced) into an introduction part of a chromatostrip, the complex migrates in a development part by a capillary phenomenon, and is trapped in the part coated in advance with streptavidin. Thereafter, by quantifying or detecting the methylated DNA antibody forming the obtained complex according to its identification function, methylated DNA in the target DNA region can be quantified or detected.

**[0141]** Method 2: Methylated DNA (DNA in which a target DNA region has a cytosine methylated by a DNA methylation enzyme) is added with a biotinylated specific oligonucleotide which is a specific oligonucleotide to which biotin is bound as a function of immobilization to a support, to cause formation of a conjugate of the single-stranded DNA comprising a target DNA region and the biotinylated specific oligonucleotide. As the obtained sample is dropped (introduced) into an introduction part of a chromatostrip, the conjugate migrates in a development part by a capillary phenomenon, and is trapped in the part preliminarily coated with streptavidin. Then, as a methylated antibody having an identification function is dropped (introduced) into an introduction part, it migrates in a development part and binds to methylated cytosine of the conjugate, to form a complex of the single-stranded DNA comprising a methylated target DNA region, the biotinylated specific oligonucleotide, and the methylated DNA antibody having an identification function. By quantifying or detecting the methylated DNA antibody forming the obtained complex according to its identification function, methylated DNA in the target DNA region can be quantified or detected.

**[0142]** Method 3: As a biotinylated specific oligonucleotide is dropped (introduced) into an introduction part of a chromatostrip, the oligonucleotide migrates in a development part by a capillary phenomenon, and is trapped in the part coated in advance with streptavidin. Then, as a single-stranded methylated DNA (single-stranded DNA having methylated cytosine in a target DNA region) is dropped (introduced) into an introduction part, it migrates in a development part, and is trapped by the biotinylated specific oligonucleotide that has been already trapped in the condition that the single-stranded DNA comprising a target DNA region forms a conjugate (the conjugate formed in this stage includes not only a conjugate of the single-stranded DNA comprising a methylated target DNA region and the specific oligonucleotide, but also a conjugate of a single-stranded DNA comprising an unmethylated target DNA region and the specific oligonucleotide). Then, as the methylated antibody having an identification function is dropped (introduced) into an introduction part, it migrates in a development part, and binds to the methylated cytosine of the conjugate, to form a complex of the single-stranded DNA comprising a methylated target DNA region, the biotinylated specific oligonucleotide, and the methylated DNA antibody having an identification function (in this stage, the conjugate of the single-stranded DNA comprising a unmethylated target DNA region and the specific oligonucleotide fails to form a complex). By quantifying or detecting the methylated DNA antibody forming the obtained complex according to its identification function, methylated DNA in the target DNA region can be quantified or detected.

**[0143]** Method 4: As a biotinylated specific oligonucleotide is dropped (introduced) into an introduction part of a chromatostrip, the oligonucleotide migrates in a development part by a capillary phenomenon, and is trapped in the part preliminarily coated with streptavidin. Single-stranded methylated DNA (single-stranded DNA having methylated cytosine in a target DNA region) is added with a methylated DNA antibody having an identification function, to cause formation of a conjugate of the single-stranded DNA having methylated cytosine (in which single-stranded DNA comprising a target DNA region and single-stranded DNA other than the target exist) and the methylated DNA antibody having an identification function (the conjugate formed in this stage includes not only a conjugate of the single-stranded DNA comprising a methylated target DNA region and the methylated antibody, but also a conjugate of methylated single-stranded DNA other than the target DNA region and the methylated antibody). As the obtained conjugate is dropped (introduced) into an introduction part, it migrates in a development part, and the single-stranded DNA comprising a methylated target DNA region binds to the biotinylated specific oligonucleotide that has been already trapped, to form a complex of the single-stranded DNA containing a methylated target DNA region, the biotinylated specific oligonucleotide, and the methylated DNA antibody having an identification function (in this stage, the conjugate of methylated single-stranded DNA other than in the target DNA region and the methylated antibody fails to form a complex). By quantifying or detecting the methylated DNA antibody forming the obtained complex according to its identification function, methylated DNA in the target DNA region can be quantified or detected.

**[0144]** Also a plurality of detection sites may be provided on a single chromatostrip (specific oligonucleotides capable of trapping different target DNA regions are immobilized to a support), and each target DNA region may be sequentially quantified or detected, and by enabling one detection site to trap a plurality of target DNA regions, or by immobilizing a number of the specific oligonucleotides capable of trapping a plurality of target DNA regions on one detection site, it is possible to dramatically improve the detection sensitivity.

**[0145]** In Fourth step of the present invention; a counter oligonucleotide may be added in forming a complex.

**[0146]** The term "counter oligonucleotide" is an oligonucleotide prepared for facilitating binding of a methylated DNA antibody to a methylated base which is a methylated base in double-stranded DNA. Usually, a methylated base is a base methylated in double-stranded DNA, however, the methylated DNA antibody is difficult to bind when DNA is in a double-stranded state. That is, for making the region where the methylated DNA antibody can bind into single-stranded DNA, an oligonucleotide (plus strand) having a nucleotide sequence which is the same as a target sequence (plus strand) is designed, and caused to bind with a nucleotide sequence (minus strand) that pairs with a target region, to make the target region into single-stranded DNA. This makes the methylated DNA antibody easy to bind with a methylated DNA base.

**[0147]** For example, for making a methylcytosine antibody bind with methylcytosine in a target region, a counter oligonucleotide having the same nucleotide sequence as that of the target region is added. In the present method, the counter oligonucleotide has a nucleotide sequence that does not pair with the specific oligonucleotide, and is characterized by not inhibiting binding between the specific oligonucleotide and a DNA fragment comprising a target region. Concretely, the counter oligonucleotide is an oligonucleotide comprising 5 to 100 bases, and preferably an oligonucleotide comprising 10 to 50 bases. The counter oligonucleotide having a nucleotide sequence of a target region is usually used in mixture of several kinds.

**[0148]** By comparing an amount of the methylated DNA measured in Fifth step without conducting methylation of DNA by a DNA methylation enzyme in Second step (total amount of methylated DNA), with an amount of the DNA measured in Fifth step after methylating DNA in Second step by a DNA methylation enzyme (total amount of methylated DNA and unmethylated DNA), it is possible to calculate a rate of methylated DNA in the target DNA region (hereinafter, sometimes referred to as the present methylation rate measuring method).

**[0149]** The present methylation rate measuring method may be used in the following situations.

**[0150]** It is known that DNA methylation abnormality occurs in various diseases (for example, cancer), and it is supposed that the level (degree) of various diseases can be measured by detecting this DNA methylation abnormality. For example, when there is a DNA region where methylation occurs at 100% in genomic DNA contained in a biological specimen derived from disease, and the present method or the present methylation rate measuring method is executed for the DNA region, the amount of methylated DNA that is detected or quantified will be large. On the other hand, when there is a DNA region where methylation does not occur at 100% in genomic DNA contained in a biological specimen derived from disease, and the present method or the present methylation rate measuring method is executed for the DNA region, the amount of methylated DNA that is detected or quantified would be approximately 0. For example, when there is a DNA region where a methylation rate is low in genomic DNA contained in a biological specimen derived from a healthy subject, and a methylation rate is high in genomic DNA contained in a biological specimen derived from a disease subject, and the present method or the present methylation rate measuring method is executed for the DNA region, the amount of methylated DNA would be approximately 0 for the healthy subject. On the other hand, since a value significantly higher than that of the healthy subject is shown in the disease patient, "level (degree) of disease" can be determined based on this difference in value.

**[0151]** "Level of disease" used herein has the same meaning commonly used in this field of art, and concretely means, for example, malignancy of a cell when the biological specimen is the cell, and means, for example, abundance of a disease cell in a tissue when the biological specimen is the tissue. Therefore, the present method or the present methylation rate measuring method makes it possible to diagnose degrees of various diseases by examining the degree (level) of methylation abnormality.

**[0152]** The restriction enzyme, specific oligonucleotide, or methylated DNA antibody that can be used in the present method is useful as a reagent of a detection kit. The present method makes it possible to provide a blood free DNA detection kit and a kit for detecting a microorganism in a sample, which contain the restriction enzyme, specific oligonucleotide, or methylated DNA antibody as a reagent.

**[0153]** The DNA comprising a target DNA region is selected by complementary binding with the specific oligonucleotide. When cytosine in CpG in the target DNA region is methylated, the cytosine is an object detected by binding of the methylcytosine antibody, so that the specific oligonucleotide is advisable not to base-pair with cytosine or CpG in the target DNA region. Therefore, the target DNA region is advisable to have a nucleotide sequence capable of specifically base-pairing with the specific oligonucleotide in the vicinity. When the specific oligonucleotide is caused to bind inside the target region by complementary base-pairing, it is advisable that the nucleotide sequence in the target DNA region which binds with the specific oligonucleotide by complementation does not include CpG.

**[0154]** When the target region is a nucleotide sequence derived from a microorganism, DNA for which a target DNA

region is to be detected may be genomic DNA extracted from a specimen, a DNA fragment, or a nucleotide sequence of DNA that is prepared by a reverse transcriptase from RNA extracted from a specimen. As a nucleotide sequence capable of complementarily binding with a specific oligonucleotide, a region specific to the microorganism may be selected. For example, when the target region in the present invention is a microbial nucleotide sequence, for selectively extracting the target region from the specimen, a nucleotide sequence that is peculiar to the microorganism near the target region may be selected as a nucleotide sequence that specifically binds with the specific oligonucleotide among microbial genomic DNA, or nucleotide sequences of DNA that is prepared by a reverse transcriptase from RNA extracted from the specimen.

**[0155]** Generally, for examining presence or absence of a pathogenic microorganism contained in a biopsy sample or food, presence or absence of such a pathogenic microorganism is examined, or such a pathogenic microorganism is identified by a test based on immunization method for each microbial antigen. However, preparation of an antibody used for such a immunization method is not easy, and for detecting a plurality of pathogenic microorganisms, it is necessary to prepare antibodies against respective antigens of the pathogenic microorganisms. By using the present method, it is possible to realize a simple test for pathogenic microorganisms without conducting such complicated antibody preparation. Further, according to the present method, since nucleotide sequences of different pathogenic microorganisms can be tested at the same time, it is possible to detect several kinds of pathogenic microorganisms contained in one specimen at the same time. Concretely, food poisoning bacteria such as *Listeria monocytogenes*, *Salmonella enterica*, *Campylobacter jejuni* subsp. *jejuni*, *Staphylococcus aureus*, *Vibrio parahaemolyticus*, *Bacillus cereus*, *Clostridium botulinum*, *Yersinia enterocolitica*, *Yersinia pseudotuberculosis* and *Clostridium perfringens* are known, however, a technique of detecting several kinds of these food poisoning bacteria at the same time is not known. However, by using the present method, it is possible to detect nucleotide sequences of several kinds of food poisoning bacteria at the same time. Further, when a nucleotide sequence found plurally in genome such as CRISPR (Clustered regularly interspaced short palindromic repeats) region is selected as a nucleotide sequence to be detected by a specific oligonucleotide, detection at higher sensitivity is realized compared to the case of detecting one gene in one genome. Such a technique is useful also for diagnosis of infection and rapid detection of food poisoning bacteria. Further, the present method may be used for identification of an industrially useful bacterium, or for a simple test of a microbial community in soil, river or lake sediments and the like by detecting genomes of microorganisms in such environments. Of the microorganisms in such environments, inhabitation of, for example, *Methanococcus jannaschii*, *Methanobacterium thermoautotrophicum* deltaH, *Aquifex aeolicus*, *Pyrococcus horikoshii* OT3, *Archaeoglobus fulgidus*, *Thermotoga maritima* MSB8, *Aeropyrum pernix* K1, and *Haloferax mediterranei* can be verified. It is also possible to detect and identify industrially available bacteria such as *Geobacter sulfurreducens* and microorganisms used for fermentation such as *Streptococcus thermophilus*.

**[0156]** For example, applicable as a region where the target region for detecting genome in a microorganism and the specific oligonucleotide complementarily bind is, concretely, a nucleotide sequence not encoding a gene such as a region corresponding to the nucleotide number 271743-272083 of yeast chromosome VII (SEQ ID NO: 38) shown, for example, in Genbank Accession No. NC\_001139, or the nucleotide number 384569-384685 of yeast chromosome VII (SEQ ID NO: 65) shown, for example, in Genbank Accession No. NC\_001139. It is also useful to detect a nucleotide sequence conserved among pathogenic microorganisms in a characteristic gene that is common in various pathogenic microorganisms because a method of detecting a plurality of pathogenic microorganisms at the same time can be provided. Concretely, since mce-family gene (*Micobacterium tuberculosis*), tRNA-Tyrnucleotide sequence on 13th chromosome (*Cryptococcus neoformans*), and chitin synthase activator (*Chs3*) have a nucleotide sequence peculiar to *Aspergillus fumigatus* and genus *Neosartorya*, they can be used for assay of infection by a microorganism, by assaying whether DNA derived from these microorganisms is contained in DNA extracted from a biopsy sample of human expectation or lung.

Further, since *actA* (*Listeria monocytogenes*), *pyrG* (NC 002163, *Campylobacter jejuni* subsp. *jejuni*) and the like are common genes peculiar to food poisoning bacteria, these genes may be used for a microbial assay in food poisoning. *ThrA* has a sequence that is conserved among *Salmonella enterica*, *Yersinia enterocolitica*, and *Escherichia coli*, so that a plurality of microorganisms can be detected by one gene.

**[0157]** Of nucleotide sequences published on a database, a nucleotide sequence peculiar to a microorganism may be retrieved, and a nucleotide sequence peculiar to a microorganism may be searched. For example, a nucleotide sequence on a published database such as PubMed may be obtained through regular procedure, and the obtained nucleotide sequence can be examined whether it is a peculiar nucleotide sequence by Blast search through regular procedure. The peculiar nucleotide sequence means that a nucleotide sequence in a detection object does not include a nucleotide sequence having homology with a nucleotide sequence derived from an organism other than the genomic nucleotide sequence of the microorganism to be detected.

**[0158]** In particular, when the specimen is a human biopsy sample, it is important to design a specific oligonucleotide that would not complementarily bind with human genes. Similarly, when the specimen is food, it is important to design a specific oligonucleotide that would not complementarily bind with a nucleotide sequence derived from an organism

other than the detection object contained in the food.

**[0159]** For detecting free DNA in blood, the target DNA region may be a region correlated with an amount of free DNA, and when it is intended to quantify or detect free DNA, what is called repetitive sequence where the same sequence in genome appears repetitively, several or more times, is preferred, and a simple repetitive sequence (called tandem repetitive sequence, or tandem repeat), and an interspersed repeat sequence are more preferred.

**[0160]** The simple repetitive sequence is **characterized in that** the same sequences neighbor in the same orientation, and a series of nucleotide sequences such as satellite DNA, minisatellite, microsatellite, centromere, telomere, kinetochore, and ribosome group genes are known.

**[0161]** The interspersed repetitive sequence is **characterized in that** the same sequences are interspersed without neighboring each other, and is believed to be DNA derived from retrotransposon. Interspersed repetitive sequences are classified into SINE (Short Interspersed Repetitive Element: short chain interspersed repetitive sequence) and LINE (Long Interspersed Elements: long chain interspersed repetitive sequence) depending on the length of the nucleotide sequence, and as a human nucleotide sequence, Alu sequence and LINE-1 sequence are respectively known as representative repetitive sequences. Also an inactive processed pseudogene that is reverse transcribed from RNA or protein, and a gene sequence amplified by gene duplication are also known.

**[0162]** The term duplicated gene indicates the case where a plurality of genes having high homology exist on one genome, and is, in many cases, a nucleotide sequence that exists in tandem near one gene. It is often the case where a pseudogene is one of duplicated genes.

**[0163]** As concrete examples of the repetitive sequence, such sequences as (A)<sub>n</sub>, (T)<sub>n</sub>, (GA)<sub>n</sub>, (CA)<sub>n</sub>, (TAA)<sub>n</sub>, (GGA)<sub>n</sub>, (CAGC)<sub>n</sub>, (CATA)<sub>n</sub>, (GAAA)<sub>n</sub>, (TATG)<sub>n</sub>, (TTTG)<sub>n</sub>, (TTTA)<sub>n</sub>, (TTTC)<sub>n</sub>, (TAAA)<sub>n</sub>, (TTCA)<sub>n</sub>, (TATAA)<sub>n</sub>, (TCTCC)<sub>n</sub>, (TTTCC)<sub>n</sub>, (TTTAA)<sub>n</sub>, (TTTTTC)<sub>n</sub>, (TTTTA)<sub>n</sub>, (TTTTG)<sub>n</sub>, (CAAAA)<sub>n</sub>, (CACCC)<sub>n</sub>, (TATATG)<sub>n</sub>, (CATATA)<sub>n</sub>, (TCTCTG)<sub>n</sub>, (AGGGGG)<sub>n</sub>, (CCCCCA)<sub>n</sub>, and (TGGGGG)<sub>n</sub> (n means a number of repetition) are known as repetition comprising a relatively short nucleotide sequence, and as a sequence derived from a transcription factor, MER1-Charlie, and Zaphod of hAT group, and MER2-Tigger, Tc-1, and Mariner of Tc-1 group can be recited. As others, concretely, Tigger1, Tigger2a, Tigger5, Charlie4a, Charlie7 and the like are known. These sequences are generally short and simple nucleotide sequences, and are difficult to set the specific adhesion sequence as will be described later, however, these sequences can be used in the present method as far as they have a sequence that can be set into setting objects of the specific adhesion sequence and a detection adhesion sequence as will be described later. Therefore, it is not necessarily excluded as an object of the present method. Further, satellite DNA, minisatellite, microsatellite and the like are repetitive sequences classified into simple repetitive sequences.

**[0164]** Further, as a sequence having multi-copies in gene, ALR6 as a sequence existing in centromere, U2 and U6 as snRNA, as well as the genes such as tRNA and rRNA that are generally known to have multi-copies in genome, and the genes that have plural copies in genome as a result of gene duplication are recited.

**[0165]** It is also known that a retrovirus, a retrotransposon having LTR (Long terminal repeat) in its terminal, an endogenous sequence such as MaLRs (Mammalian apparent LTR-Retrotransposons) considered to be derived from viruses, and LTR derived from a retrovirus exist in multicopy in one genome.

**[0166]** For example, as the LTR derived from a retrovirus, concretely, subfamilies such as LTR1, LTR1B, LTR5, LTR7, LTR8, LTR16A1, LTR16A1, LTR16C, LTR26, LTR26E, MER48, and MLT2CB are known. The LTRs derived from a retrotransposon are classified into classes of ERV, ERVK and ERVL, and concrete examples include subfamilies such as LTR8A, LTR28, MER21B, MER83, MER31B, MER49, MER66B, HERVH, ERVL, LTR16A1, LTR33A, LTR50, LTR52, MLT2A1, MLT2E, MER11C, and MER11C. Further, MaLRs indicate DNA factors including LTRs in both ends likewise a typical retrotransposon, wherein an internal sequence sandwiched between LTRs is not derived from a retrovirus. For example, subfamilies such as MLT1A1, MLT1A2, MLT1B, MLT1C, MLT1D, MLT1F, MLT1G, MLT1H, MLT1J, MLT1K, MLT1I, MLT2CB, MSTA, MSTA-int, MSTB, THE1A, THE1B, THE1B-internal, and THE1 can be recited.

**[0167]** The interspersed repetitive sequences are **characterized in that** the same sequences are interspersed without neighboring each other, and are considered to be derived from a retrotransposon. Further, the interspersed repetitive sequences are classified into SINE (Short Interspersed Repetitive Element: short chain interspersed repetitive sequences) and LINE (Long Interspersed Elements: long-chain interspersed repetitive sequences) according to the length. Most of SINEs are sequences belonging to the Alu family. A common feature is that it has a sequence of 3'-side or a sequence of 5'-side of 7SL RNA, and that it has an AT-Rich region sandwiched between a Left-monomer and a Right-monomer. As subfamilies of the Alu family, Alu, AluJb, AluJo, AluSc, AluSg, AluSp, AluSq, AluSx, AluY, and FAM (Fossil Alu Monomer), FLAM (Free Left Alu Monomer) having a sequence of FAM, and FRAM (Free Right Alu Monomer) can be recited. As SINEs other than the Alu family, MIR, and Ther/MIR3 are known, and MIR and MIR3 are known as respective subfamilies. As subfamilies of the Alu family including other biological species, B1, B2, B4, PB1, PB1D and so on are known. As LINEs, subfamilies of LINE1 to Line23 are reported, and it is known that subfamilies such as LINE-1, LINE2, and LINE3 broadly exist in a genome. As for LINE-1, for example, L1M1, L1M2, L1M3, L1M3d, L1M4, L1M4c, L1MA2, L1MA7, L1MA8, L1MA9, L1MB1, L1MB1, L1MB3, L1MB4, L1MB5, L1MB6, L1MB7, L1MCa, L1MCb, L1MC2, L1MC3, L1MC4, L1MC4a, L1MC5, L1MDa, L1ME, L1MEc, L1MEd, L1MEg, L1ME1, L1ME2, L1ME3, L1ME3A, L1ME3B,

L1ME4a, L1PB3, L1P4, L1PA2, L1PA3, L1PA4, L1PA5, L1PA6, L1PA7, L1PA10, L1PA12, L1PA13, L1PA14, L1PA16, L1PB1, L1PB3, L1PB4, L1PREC2, and HAL1 are known, and as LINE-2, subfamilies such as L2 and L2c are known. For example, if the later-described specific adhesion sequence and the detection adhesion sequence can be set, for a sequence common to the Alu family or subfamilies of Alu, or the LINE-1 family or subfamilies of LINE-1, a plurality of detection objects can be set in one genome, so that sensitivity of genome detection can be improved.

**[0168]** As a target DNA region, concretely, for example, a partial sequence of LINE-1 (the nucleotide sequence of SEQ ID NO: 28, SEQ ID NO: 62, or SEQ ID NO: 63), a partial sequence of Alu (the nucleotide sequence of SEQ ID NO: 64) or nucleotide sequences having homology to these sequences can be recited.

**[0169]** For example, when a repetitive sequence in a certain region needs to be examined, databases such as Rebase (<http://www.girinst.org/rebase/>) and RepeatMasker (<http://www.repeatmasker.org/>) may be used because it is difficult to retrieve a general sequence retrieving database such as PubMed. If a specific adhesion sequence of the present method can be set, the detection sensitivity can be improved. Measuring these repetitive sequences can be treated, for example, as a surrogate marker of a free DNA amount in blood, and can be utilized for identification of an organism species when an organism species-specific repetitive sequence is noted.

**[0170]** In the present method, by measuring a repetitive sequence, a nucleotide sequence existing plurally in one genome can be measured concurrently. For example, a nucleotide sequence having a sequence homology of 80% or higher with the nucleotide sequence of SEQ ID NO: 28 has about 280 copies in a human genome, and a nucleotide sequence having a sequence identity of 80% or higher with the nucleotide sequence of SEQ ID NO: 64 has about 820 copies in a human genome. Therefore, if a specific adhesion sequence can be set in each nucleotide sequence, the detection sensitivity of one genome can be improved to 280 to 820 folds theoretically, compared to the case where a specific adhesion sequence is set for a sequence having just one kind in genome.

**[0171]** A duplicated gene means a gene or a gene fragment that is generated by doubling of a specific gene or gene fragment in genome due to gene duplication. Gene duplication is a phenomenon that a certain region of DNA including a gene is overlapped. As a cause of gene duplication, abnormality of gene recombination, translocation of retrotransposon, duplication of the entire chromosome and the like are recited.

For example, it means that one gene is copied and inserted into genomic DNA, and the copy is inserted to a different chromosome site in some cases, and inserted near the original gene in the other cases. The site where copied genes are aligned as a result of insertion near the original gene is called a tandem repeat, and a group of genes generated by gene duplication is called a gene family.

**[0172]** A pseudogene means a gene having a characteristic nucleotide sequence that is assumable to have encoded a gene product (particularly protein) in a sequence of DNA, but currently losing the function. It is assumed that it is generated as a result of mutation of the original functioning sequence. For example, there is the case where a stop codon arises by mutation and a peptide chain of a protein is shortened, so that the function as a protein is no longer effective, and there is the case where a function of a regulatory sequence required for normal transcription is impaired due to mutation such as single nucleotide substitution. In many pseudogenes, the original normal genes are remained separately, however, those becoming pseudogenes by themselves are also known.

**[0173]** Pseudogenes are classified into three types according to the characteristic of the gene sequence. There are known the case where DNA prepared from mRNA by a reverse transcriptase of retrotransposon is inserted into genome (processed pseudogene), the case where an original gene sequence is duplicated in genome, and a part of the copies loses the function due to mutation or the like to become a pseudogene (duplicated pseudogene or non-processed pseudogene), and the case where gene in genome (in the condition of single gene with no duplicated gene) loses the function to become a pseudogene.

**[0174]** Currently, among the genes known as pseudogenes, transcribed examples, examples having a gene function (whether it is called a pseudogene is not determined) and the like also have been known, so that the term "pseudogene" in the present method means the "processed pseudogene" or "duplicated pseudogene (non-processed pseudogene)" rather than presence or absence of gene function or whether it is transcribed or not.

**[0175]** In First step of the present method, it is preferred to extract DNA from a specimen by a system containing a sodium salt at high concentration. Concretely, as a concentration of sodium salt in a solution (for example, buffer) used in a DNA extraction operation for obtaining DNA from a specimen in First step of the present method, at least 50 mM or more, and preferably 100 mM or more can be recited. More concretely, 50 mM or more and 1000 mM or less, preferably 100 mM or more and 1000 mM or less, more preferably 100 mM or more and 200 mM or less can be recited. Any salts including NaCl, NaCO<sub>3</sub>, Na<sub>2</sub>SO<sub>4</sub> and the like are applied as far as it is a salt containing a sodium ion, and preferably means NaCl.

**[0176]** The present invention is a method of selecting a specimen derived from a cancer patient, and includes the steps of evaluating a specimen derived from a test subject as a specimen derived from a cancer patient when there is a significant difference between a DNA quantification result or detection result quantified or detected using a specimen derived from a test subject by the method according to any one of Inventions 1 to 13, and a DNA quantification result or detection result quantified or detected using a specimen derived from a healthy subject by the method, and identifying

the specimen derived from a cancer patient based on the evaluation result. As a preferred aspect of the present invention, the invention in which the specimen is a serum derived from a mammal, and the invention in which the DNA comprising a target DNA region is free DNA comprising a target DNA region in serum derived from a mammal can be recited. Use of these inventions will make it possible to identify a cancer patient in a simple and convenient manner by a blood test.

**[0177]** Here, the "cancer patient" is a test subject developing a cancer, and as the cancer, solid cancers developing in organs of human and mammals, and non-solid cancers developing in blood of human and mammals such as lung cancer (non-small-cell lung cancer, small-cell lung cancer), esophageal cancer, gastric cancer, duodenal cancer, colon cancer, rectal cancer, hepatic cancer (hepatocarcinoma, cholangiocellular carcinoma), gallbladder cancer, bile duct cancer, pancreatic cancer, colon cancer, anal cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, vulvar cancer, vaginal cancer, prostate cancer, kidney cancer, ureter cancer, bladder cancer, prostate cancer, penile cancer, testicular (testis) cancer, maxillary cancer, tongue cancer, (nasal-, oral-, hypo-) pharyngeal cancer, acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, malignant lymphoma, myelodysplastic syndrome, thyroid cancer, brain tumor, osteosarcoma and skin cancer (basal cell cancer, squamous cell cancer) are included.

**EXAMPLES**

**[0178]** In the following, the present invention will be described in detail by way of examples, however, the present invention is not limited to these examples.

**Example 1**

**[0179]** Using genomic DNA derived from human blood purchased from Clontech as a template, PCR was conducted using an oligonucleotide primer PF1 of SEQ ID NO: 17 and an oligonucleotide primer PR1 of SEQ ID NO: 18 in the following reaction condition, to amplify a DNA fragment X (the region corresponding to the nucleotide numbers 25687390-25687775 shown in Genbank Accession No. NT\_029419) of SEQ ID NO: 19.

<Oligonucleotide primers designed for PCR>

**[0180]**

PF1:5'- CTCAGCACCCAGGCGGCC -3' (SEQ ID NO: 17)  
 PR1:5'- CTGCCAAACTGGAGATCGC -3' (SEQ ID NO: 18)

<DNA fragment>

**[0181]**

X: 5' -  
 CTCAGCACCCAGGCGGCCGCGATCATGAGGCGCGAGCGGCGCGGGCTGTTGCAGAGTCTT  
 GAGCGGGTGGCACACCGCGATGTAGCGGTTCGGCTGTCATGACTACCAGCATGTAGGCCGACG  
 CAAACATGCCGAACACCTGCAGGTGCTTACCACGCGGCACAGCCAGTCGGGGCCGCGGAAG  
 CGGTAGGTGATGTCCCAGCACATTTGCGGCAGCACCTGGAAGAATGCCACGGCCAGGTTCGGC  
 CAGGCTGAGGTGTCGGATGAAGAGGTGCATGCGGGACGTCTTTCGCGGGCGTCCGGTGCAGAG  
 CCAGCAGTACGCTGCTGTTGCCAGCACGGCCACCGCGAAAGTCACCGCCAGCACGGCGATC  
 TCCAGTTTGGCCAG -3' (SEQ ID NO: 19)

**[0182]** Ten (10) ng of genomic DNA as a template, each 3 μL of 5 μM of the above primer solutions, 5 μL of each 2 mM dNTP, and 5 μL of 10×buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25 μL of 5U/μL thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to

## EP 2 305 806 A1

prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 30 seconds at 95°C, 30 seconds at 61°C and 45 seconds at 72°C.

**[0183]** The PCR reaction liquid was subjected to 2% agarose gel electrophoresis to check the amplified DNA, and the DNA was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation), to obtain the DNA fragment X.

5 **[0184]** For the DNA fragment X, the following solutions were prepared respectively in duplicate.

Solution A: DNA fragment X 10ng/20  $\mu\text{L}$  TE buffer solution  
Solution B: DNA fragment X 1ng/20  $\mu\text{L}$  TE buffer solution  
Solution C: DNA fragment X 0.1ng/20  $\mu\text{L}$  TE buffer solution  
10 Solution D: TE buffer solution (negative control solution)

**[0185]** Twenty (20)  $\mu\text{L}$  of each obtained solution, 0.5  $\mu\text{L}$  of SssI methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

15 **[0186]** Synthesized was 5'-end biotin-labeled oligonucleotide B1 having the nucleotide sequence of SEQ ID NO: 20 capable of binding by complementation with a plus strand of the DNA fragment X comprising the target DNA region of SEQ ID NO: 19, and a 0.02  $\mu\text{M}$  TE buffer solution was prepared.

20 <5'-end biotin-labeled oligonucleotide>

**[0187]**

B1:5'- CTGGCCAAACTGGAGAT -3' (SEQ ID NO: 20)

25 **[0188]** In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $\text{MgOAc}_2$ , 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

30 **[0189]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

35 **[0190]** Synthesized was a masking oligonucleotide M1 having the nucleotide sequence of SEQ ID NO: 21 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B1 having the nucleotide sequence of SEQ ID NO: 20, and 0.1  $\mu\text{M}$  TE buffer solution was prepared.

<Masking oligonucleotide>

45 **[0191]**

M1:5'- ATCTCCAGTTTGGCCAG -3' (SEQ ID NO: 21)

50 **[0192]** Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

55 **[0193]** Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

## EP 2 305 806 A1

**[0194]** Each well was added with 150  $\mu$ L of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0195]** The result is shown in Fig. 1. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

**[0196]** In the present experiment, it was revealed that a DNA fragment can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

### Example 2

**[0197]** Using genomic DNA derived from human blood purchased from Clontech as a template, PCR was conducted using an oligonucleotide primer PF2 of SEQ ID NO: 22 and an oligonucleotide primer PR2 of SEQ ID NO: 23 in the following reaction condition, to amplify a DNA fragment Y (the region corresponding to the nucleotide number 76606-76726 shown in Genbank Accession No. ac009800) of SEQ ID NO: 24.

<Oligonucleotide primers designed for PCR>

### **[0198]**

PF2:5'-TGAGCTCCGTAGGGCGTCC -3' (SEQ ID NO: 22)

PR2:5'-GCGCCGGGTCCGGGCC-3' (SEQ ID NO: 23)

<DNA fragment>

### **[0199]**

Y: 5' -

GCGCCGGGTCCGGGCCCGATGCGTTGGCGGGCCAGGGCTCCGAGAACGAGGCGTTGTCCATC

TCAACGAGGGCAGAGGAGCCGGCGACCTGGCGTCCCCAAGGACGCCCTACGGAGCTCA -

3' (SEQ ID NO: 24)

**[0200]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu$ L of 5  $\mu$ M of the above primer solutions, 5  $\mu$ L of each 2 mM dNTP, and 5  $\mu$ L of 10 $\times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25  $\mu$ L of 5U/ $\mu$ L thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 50 cycles each consisting of 30 seconds at 95°C, 30 seconds at 60°C and 45 seconds at 72°C.

**[0201]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment Y was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0202]** For the DNA fragment Y, the following solutions were prepared respectively in duplicate.

Solution A: DNA fragment Y 10ng/20  $\mu$ L TE buffer solution

Solution B: DNA fragment Y 1ng/20  $\mu$ L TE buffer solution

Solution C: DNA fragment Y 0.1ng/20  $\mu$ L TE buffer solution

Solution D: TE buffer solution (negative control solution)

**[0203]** Twenty (20)  $\mu$ L of each obtained solution, 0.5  $\mu$ L of SssI methylase (available from NEB Inc.), 5  $\mu$ L of 10 $\times$ NEBuffer2 (available from NEB Inc.), and 0.5  $\mu$ L of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. The reaction liquid was incubated at 37°C for 30 minutes.

**[0204]** Synthesized was 5'-end biotin-labeled oligonucleotide B2 having the nucleotide sequence of SEQ ID NO: 25

## EP 2 305 806 A1

capable of binding by complementation with a plus strand of the DNA fragment Y comprising the target DNA region of SEQ ID NO: 24, and a 0.02  $\mu$ M TE buffer solution was prepared.

<5'-end biotin-labeled oligonucleotide>

**[0205]**

B2:5'- GACAACGCCTCGTTCTCGG -3' (SEQ ID NO: 25)

**[0206]** Each obtained reaction liquid was subjected to the following treatments.

**[0207]** In a PCR tube, 40  $\mu$ L of the reaction liquid prepared in the above, 10  $\mu$ L of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu$ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu$ L of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu$ L of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu$ L, and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

**[0208]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0209]** Synthesized was masking oligonucleotide M2 having the nucleotide sequence of SEQ ID NO: 26 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B2 having the nucleotide sequence of SEQ ID NO: 25, and 0.1  $\mu$ M TE buffer solution was prepared.

<Masking oligonucleotide>

**[0210]**

M2:5'- CCGAGAACGAGGCGTTGTCT -3' (SEQ ID NO: 26)

**[0211]** Each well was added with 100  $\mu$ L of an methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and added with 1  $\mu$ L of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0212]** Then, each well was added with 100  $\mu$ L of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0213]** Each well was added with 150  $\mu$ L of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0214]** The result is shown in Fig. 2. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

**[0215]** In the present experiment, it was revealed that a DNA fragment can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

Example 3

**[0216]** Using genomic DNA derived from human blood purchased from Clontech as a template, PCR was conducted using the oligonucleotide primer PF1 of SEQ ID NO: 17 and the oligonucleotide primer PR1 of SEQ ID NO: 18 in the following reaction condition, to amplify the DNA fragment X (the region corresponding to the nucleotide number

## EP 2 305 806 A1

25687390-25687775 shown in Genbank Accession No. NT\_029419) of SEQ ID NO: 19.

**[0217]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu\text{L}$  of 5  $\mu\text{M}$  of the above primer solutions, 5  $\mu\text{L}$  of each 2 mM dNTP, and 5  $\mu\text{L}$  of 10 $\times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM  $\text{MgCl}_2$ , 0.01% Gelatin) were mixed with 0.25  $\mu\text{L}$  of 5U/ $\mu\text{L}$  thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 30 seconds at 95°C, 30 seconds at 61°C and 45 seconds at 72°C.

**[0218]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment X was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0219]** Using genomic DNA derived from human blood purchased from Clontech as a template, PCR was conducted using the oligonucleotide primer PF2 of SEQ ID NO: 22 and the oligonucleotide primer PR2 of SEQ ID NO: 23 in the following reaction condition, to amplify the DNA fragment Y (the region corresponding to the nucleotide number 76606-76726 shown in Genbank Accession No. ac009800) of SEQ ID NO: 24.

**[0220]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu\text{L}$  of 5  $\mu\text{M}$  of the above primer solutions, 5  $\mu\text{L}$  of each 2 mM dNTP, and 5  $\mu\text{L}$  of 10 $\times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM  $\text{MgCl}_2$ , 0.01% Gelatin) were mixed with 0.25  $\mu\text{L}$  of 5U/ $\mu\text{L}$  thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 50 cycles each consisting of 30 seconds at 95°C, 30 seconds at 60°C and 45 seconds at 72°C.

**[0221]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment Y was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0222]** For each of the DNA fragment X and the DNA fragment Y, the following solutions were prepared.

Solution A: DNA fragment X or DNA fragment Y 10 ng/10  $\mu\text{L}$  TE buffer solution

Solution B: DNA fragment X or DNA fragment Y 1 ng/10  $\mu\text{L}$  TE buffer solution

Solution C: DNA fragment X or DNA fragment Y 0.1 ng/10  $\mu\text{L}$  TE buffer solution

Solution D: TE buffer solution (negative control solution)

**[0223]** Equivalent amounts of Solution A of the DNA fragment X and Solution A of the DNA fragment Y were mixed, to prepare DNA fragment-mixed Solution MA, equivalent amounts of Solution B of the DNA fragment X and Solution B of the DNA fragment Y were mixed, to prepare DNA fragment-mixed Solution MB, equivalent amounts of Solution C of the DNA fragment X and Solution C of the DNA fragment Y were mixed, to prepare DNA fragment-mixed Solution MC, and equivalent amounts of Solution D of the DNA fragment X and Solution D of the DNA fragment Y were mixed, to prepare DNA fragment-mixed Solution MD. Three sets in duplicate were prepared respectively, for each of DNA fragment-mixed Solutions MA, MB, MC and MD.

**[0224]** Twenty (20)  $\mu\text{L}$  of each obtained solution, 0.5  $\mu\text{L}$  of SssI methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10 $\times$ NEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

**[0225]** Further, prepared were 0.02  $\mu\text{M}$  TE buffer solutions of 5'-end biotin-labeled oligonucleotide B1 having the nucleotide sequence of SEQ ID NO: 20 capable of binding by complementation with a plus strand of the DNA fragment X comprising the target DNA region of SEQ ID NO: 19 and 5'-end biotin-labeled oligonucleotide B2 having the nucleotide sequence of SEQ ID NO: 25 capable of binding by complementation with a plus strand of the DNA fragment Y comprising the target DNA region of SEQ ID NO: 24. Also prepared was a TE buffer solution (0.02  $\mu\text{M}$  for each) mixing equivalent amounts of 5'-end biotin-labeled oligonucleotide B1 having the nucleotide sequence of SEQ ID NO: 20 and 5'-end biotin-labeled oligonucleotide B2 having the nucleotide sequence of SEQ ID NO: 25.

**[0226]** For each reaction liquid of the DNA fragment Solutions MA to MD, the following treatment was conducted using each of the 5'-end biotin-labeled oligonucleotide solutions.

**[0227]** In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $\text{MgOAc}_2$ , 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

**[0228]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to

the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0229]** Synthesized were masking oligonucleotide M1 having the nucleotide sequence of SEQ ID NO: 21 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B1 having the nucleotide sequence of SEQ ID NO: 20 and masking oligonucleotide M2 having the nucleotide sequence of SEQ ID NO: 26 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B2 having the nucleotide sequence of SEQ ID NO: 25, and respective 0.1  $\mu$ M TE buffer solutions were prepared. Prepared was a TE buffer solution (each 0.1  $\mu$ M) mixing equivalent amounts of masking oligonucleotide M1 having the nucleotide sequence of SEQ ID NO: 21 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B1 having the nucleotide sequence of SEQ ID NO: 20 and masking oligonucleotide M2 having the nucleotide sequence of SEQ ID NO: 26 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B2 having the nucleotide sequence of SEQ ID NO: 25.

**[0230]** For respective reaction liquids of the DNA fragment Solutions MA to MD, the following treatment was conducted using each of the masking oligonucleotide solutions. The masking oligonucleotide solutions to be added were: masking oligonucleotide M1 solution for 5'-end biotin-labeled oligonucleotide B1 treatment solution, masking oligonucleotide M2 solution for 5'-end biotin-labeled oligonucleotide B2 treatment solution, and masking oligonucleotide M1 and masking oligonucleotide M2-mixed solution for 5'-end biotin-labeled oligonucleotide B1 and 5'-end biotin-labeled oligonucleotide B2-mixed treatment solution.

**[0231]** Each well was added with 100  $\mu$ L of a methylcytosine antibody [available from Aviva Systems Biology, 0.5 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu$ L of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0232]** Then, each well was added with 100  $\mu$ L of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0233]** Each well was added with 150  $\mu$ L of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0234]** The results are shown in Figs. 3 to 5. It was revealed that the DNA fragment is selected by forming a complex with immobilized 5'-end biotin-labeled oligonucleotide B1 (Fig. 3), immobilized 5'-end biotin-labeled oligonucleotide B2 (Fig. 4), the 5'-end biotin-labeled oligonucleotides which are mixture of the foregoing two kinds (Fig. 5), and the methylcytosine antibody, and is quantified and detected with excellent sensitivity. It was revealed that when two kinds of the 5'-end biotin-labeled oligonucleotides are mixed (Fig. 5), in particular, quantification and detection with better sensitivity can be achieved compared with the case of detection by a single oligonucleotide (Fig. 3 and Fig. 4).

**[0235]** In the present experiment, it was revealed that a DNA fragment can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function. It was also revealed that by using a plurality of immobilized 5'-end biotin-labeled oligonucleotides, more sensitive quantification and detection are realized than the case where one kind of immobilized 5'-end biotin-labeled oligonucleotide is used (that is, not only using one target DNA region but also using a plurality of target DNA regions at the same time).

#### Example 4

**[0236]** Seven (7)  $\mu$ g of genomic DNA derived from human blood purchased from Clontech, 48 U of restriction enzyme AluI, and 40  $\mu$ L of 10x buffer optimum for AluI (100 mM Tris-HCl pH 7.5, 100 mM  $\text{MgCl}_2$ , 10 mM Dithiothreitol, 500 mM NaCl) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 400  $\mu$ L. The reaction liquid was incubated at 37°C for 4 hours. After conducting an enzyme treatment, cleavage was checked by 1.5% agarose gel electrophoresis, and enzyme-treated genomic DNA was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0237]** The following solutions were prepared in duplicate using the obtained enzyme-treated genomic DNA.

- Solution A: Enzyme-treated genomic DNA 1000 ng/30  $\mu$ L TE buffer solution
- Solution B: Enzyme-treated genomic DNA 500 ng/30  $\mu$ L TE buffer solution
- Solution C: Enzyme-treated genomic DNA 200 ng/30  $\mu$ L TE buffer solution
- Solution D: TE buffer solution (negative control solution)

## EP 2 305 806 A1

**[0238]** Thirty (30)  $\mu\text{L}$  of the enzyme-treated genomic DNA solution prepared in the above, 0.5  $\mu\text{L}$  of SssI methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

**[0239]** A 0.02  $\mu\text{M}$  TE buffer solution of 5'-end biotin-labeled oligonucleotide B1 having the nucleotide sequence of SEQ ID NO: 20 capable of binding by complementation with a plus strand of the DNA fragment X' comprising the target DNA region of SEQ ID NO: 27 was prepared.

<DNA fragment comprising target DNA region>

**[0240]**

X' : 5' -

CTCAGCACCCAGGCGGCCGCGATCATGAGGCGCGAGCGGCCGCGGGCTGTTGCAGAGTCTT  
GAGCGGGTGGCACACCGCGATGTAGCGGTCTGGCTGTCATGACTACCAGCATGTAGGCCGACG  
CAAACATGCCGAACACCTGCAGGTGCTTCACCACGCGGCACAGCCAGTCGGGGCCGCGGAAG  
CGGTAGGTGATGTCCCAGCACATTTGCGGCAGCACCTGGAAGAATGCCACGGCCAGGTCGGC  
CAGGCTGAGGTGTCGGATGAAGAGGTGCATGCGGGACGTCTTGCGCGGCGTCCGGTGCAGAG  
CCAGCAGTACGCTGCTGTTGCCAGCACGGCCACCGCGAAAGTCACCGCCAGCACGGCGATC  
TCCAGTTTGGCCAG -3' (SEQ ID NO: 27)

<5'-end biotin-labeled oligonucleotide>

**[0241]**

B1:5'- CTGGCCAAACTGGAGAT -3' (SEQ ID NO: 20)

**[0242]** For respective reaction liquids of enzyme-treated genomic DNA Solutions A to D, the following treatment was conducted.

**[0243]** In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

**[0244]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0245]** Synthesized was masking oligonucleotide M1 having the nucleotide sequence of SEQ ID NO: 21 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B1 having the nucleotide sequence of SEQ ID NO: 20, and 0.1  $\mu\text{M}$  TE buffer solution was prepared.

**[0246]** Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05%

## EP 2 305 806 A1

Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

[0247] Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

[0248] Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

[0249] The result is shown in Fig. 6. It was revealed that in the enzyme-treated human genomic DNA solution, the DNA fragment is selected by forming a complex with immobilized 5'-end biotin-labeled oligonucleotide B1 and the methylcytosine antibody, and thus quantified and detected with excellent sensitivity.

[0250] In the present experiment, it was revealed that genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

### Example 5

[0251] Using genomic DNA derived from human blood purchased from Clontech, the following solutions were prepared respectively in duplicate.

Solution A: Genomic DNA derived from human blood 500 ng/20  $\mu\text{L}$  TE buffer solution

Solution B: Genomic DNA derived from human blood 50 ng/20  $\mu\text{L}$  TE buffer solution

Solution C: Genomic DNA derived from human blood 5 ng/20  $\mu\text{L}$  TE buffer solution

Solution D: TE buffer solution (negative control solution)

[0252] Twenty (20)  $\mu\text{L}$  of each obtained solution, 10 U of restriction enzyme XspI, and 5  $\mu\text{L}$  of 10x buffer optimum for XspI (200 mM Tris-HCl pH 8.5, 100 mM  $\text{MgCl}_2$ , 10 mM Dithiothreitol, 1000 mM KCl) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 1 hour.

[0253] Twenty (20)  $\mu\text{L}$  of the enzyme-treated genomic DNA solution prepared in the above, 0.5  $\mu\text{L}$  of SssI methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

[0254] Prepared was a 0.02  $\mu\text{M}$  TE buffer solution of 5'-end biotin-labeled oligonucleotide B3 having the nucleotide sequence of SEQ ID NO: 29 capable of binding by complementation with a plus strand of DNA fragment Z (region corresponding to the nucleotide number 115-386 as shown in Genbank Accession No. M80340 or the like) comprising the target DNA region of SEQ ID NO: 28.

<DNA fragment>

### [0255]

Z: 5' -

TAGGGAGTGCCAGACAGTGGGCGCAGGCCAGTGTGTGTGCGCACCGTGCGCGAGCCGAAGCA

GGGCGAGGCATTGCCTCACCTGGGAAGCGCAAGGGGTCAGGGAGTTCCTTTCTGAGTCAAA

GAAAGGGGTGACGGTCGCACCTGGAAAATCGGGTCACTCCCACCCGAATATTGCGCTTTTCA

GACCGGCTTAAGAAACGGCGCACACGAGACTATATCCCACACCTGGCTCGGAGGGTCCTAC

CCCCACGGAATCTCGCTGATTGC -3' (SEQ ID NO: 28)

<5'-end biotin-labeled oligonucleotide>

**[0256]**

5 B3:5'- ATAGTCTCGTGGTGCGCCGT-3' (SEQ ID NO: 29)

**[0257]** For respective reaction liquids of enzyme-treated genomic DNA Solutions A to D, the following treatment was conducted.

10 **[0258]** In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $\text{MgOAc}_2$ , 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

15 **[0259]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

20 **[0260]** Synthesized was masking oligonucleotide M3 having the nucleotide sequence of SEQ ID NO: 30 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B3 having the nucleotide sequence of SEQ ID NO: 29, and a 0.1  $\mu\text{M}$  TE buffer solution was prepared.

25 <Masking oligonucleotide>

**[0261]**

30 M3:5'- ACGGCGCACCACGAGACTAT -3' (SEQ ID NO: 30)

**[0262]** Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

35 **[0263]** Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

40 **[0264]** Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

45 **[0265]** The result is shown in Fig. 7, it was revealed that in the enzyme-treated human genomic DNA solution, the DNA fragment is selected by forming a complex with immobilized 5'-end biotin-labeled oligonucleotide B3 and the methylcytosine antibody, and thus quantified and detected with excellent sensitivity.

50 **[0266]** In the present experiment, it was revealed that genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

Example 6

55 **[0267]** Using genomic DNA derived from human blood purchased from Clontech, the following solutions were prepared respectively in duplicate.

Solution A: Genomic DNA derived from human blood 500 ng/20  $\mu\text{L}$  TE buffer solution

## EP 2 305 806 A1

Solution B: Genomic DNA derived from human blood 50 ng/20  $\mu$ L TE buffer solution

Solution C: Genomic DNA derived from human blood 5 ng/20  $\mu$ L TE buffer solution

Solution D: TE buffer solution (negative control solution)

5 **[0268]** Twenty (20)  $\mu$ L of each obtained solution, 10 U of restriction enzyme XspI, and 5  $\mu$ L of 10x buffer optimum for XspI (200 mM Tris-HCl pH 8.5, 100 mM MgCl<sub>2</sub>, 10 mM Dithiothreitol, 1000 mM KCl) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. The reaction liquid was incubated at 37°C for 1 hour.

10 **[0269]** Twenty (20)  $\mu$ L of the enzyme-treated genomic DNA solution prepared in the above, 0.5  $\mu$ L of SssI methylase (available from NEB Inc.), 5  $\mu$ L of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu$ L of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. The reaction liquid was incubated at 37°C for 30 minutes.

15 **[0270]** Prepared was a 0.02  $\mu$ M TE buffer solution of 5'-end biotin-labeled oligonucleotide B3 having the nucleotide sequence of SEQ ID NO: 29 capable of binding by complementation with a plus strand of DNA fragment Z (region corresponding to the nucleotide number 115-386 as shown in Genbank Accession No. M80340 or the like) comprising the target DNA region of SEQ ID NO: 28.

20 **[0271]** Prepared were 0.01  $\mu$ M TE buffer solutions of counter oligonucleotides C1, C2, C3, C4, and C5 having the nucleotide sequences of SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, and SEQ ID NO: 35, respectively capable of binding by complementation with a minus strand (complementary chain) of DNA fragment Z comprising the target DNA region of SEQ ID NO: 28

<DNA fragment>

25 **[0272]**

Z: 5' -

TAGGGAGTGCCAGACAGTGGGCGCAGGCCAGTGTGTGTGCGCACCGTGCGCGAGCCGAAGCA

30 GGGCGAGGCATTGCCTCACCTGGGAAGCGCAAGGGGTGAGGGAGTTCCCTTTCTGAGTCAAA

GAAAGGGGTGACGGTTCGCACCTGGAAAATCGGGTCACTCCCACCCGAATATTGCGCTTTTCA

35 GACCGGCTTAAGAAACGGCGCACCCACGAGACTATATCCCACACCTGGCTCGGAGGGTCTCTAC

GCCCACGGAATCTCGCTGATTGC -3' (SEQ ID NO: 28)

40 <Counter oligonucleotides>

**[0273]**

C1:5'- CAGTGTGTGTGCGCACCGTGCGCGAGCCGA-3' (SEQ ID NO: 31)

45 C2:5'- GCGGAGGCATTGCCTCACCTGGGAAGCGCA-3' (SEQ ID NO: 32)

C3:5'- GGTGACGGTTCGCACCTGGAAAATCGGGTCA-3' (SEQ ID NO: 33)

C4:5'- ACCCGAATATTGCGCTTTTTCAGACCGGCTT-3' (SEQ ID NO: 34)

C5:5'- TCGGAGGGTCTACGCCACGGAATCTCGC-3' (SEQ ID NO: 35)

50 **[0274]** For respective reaction liquids of enzyme-treated genomic DNA Solutions A to D, the following treatment was conducted.

**[0275]** In a PCR tube, 40  $\mu$ L of the reaction liquid prepared in the above, 10  $\mu$ L of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu$ L of the counter oligonucleotide solution, 10  $\mu$ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu$ L of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu$ L of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu$ L, and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50.°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end

biotin-labeled oligonucleotide and the DNA fragment.

**[0276]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0277]** Synthesized was a masking oligonucleotide M3 having the nucleotide sequence of SEQ ID NO: 30 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B3 having the nucleotide sequence of SEQ ID NO: 29, and 0.1  $\mu$ M TE buffer solution was prepared.

**[0278]** Each well was added with 100  $\mu$ L of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu$ L of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0279]** Then, each well was added with 100  $\mu$ L of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0280]** Each well was added with 150  $\mu$ L of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0281]** The result is shown in Fig. 8. It was revealed that in the enzyme-treated human genomic DNA solution, the DNA fragment is selected by forming a complex with immobilized 5'-end biotin-labeled oligonucleotide B3 and the methylcytosine antibody, and thus quantified and detected with excellent sensitivity.

**[0282]** In the present experiment, it was revealed that genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

#### Example 7

**[0283]** Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of  $\text{OD}_{600}$  0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare  $1 \times 10^7$  of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

**[0284]** The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M  $\text{CH}_3\text{COOK}$  was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M  $\text{CH}_3\text{COONa}$  in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40  $\mu$ g/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500  $\mu$ g/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

**[0285]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (S, SEQ ID NO: 38, the region corresponding to the nucleotide number 271743-272083 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF3 and PR3) designed for PCR of SEQ ID NO: 36 and SEQ ID NO: 37 and the following reaction condition.

## EP 2 305 806 A1

<Oligonucleotide primers designed for PCR>

### [0286]

5 PF3: 5'-AGGTGAGCTACGTGTGTTTGG-3' (SEQ ID NO: 36)  
PR3: 5'-AGACATGTGCTCACGTACGGT-3' (SEQ ID NO: 37)

<DNA fragment>

### 10 [0287]

S: 5' -

15 AGGTGAGCTACGTGTGTTTGGGCGTCGTGCACTGGCTCACTTGTACGCGCAGAAATGGCAGC  
TTGTACGATTGGTGACCCGCCTTTTCGACACTGGACCGCTATGGACGTGGCGGCGGTGTGGC  
20 GCGGGCTCAATGACCTGTGGCGCCCGTTTGTGGCGTGCGATAGTCGAGCCGCCTGTCACGTG  
CGCGGCCGCCCTGCTCCGTTTGACGCGATGCATAGCATGCGACCACCCAGTAATCATACTGC  
TGACGCTATTGGTCACGTGGTTATGGCAGCTGCTGTTGACTGCGGTGGCGTCCCGTTTCCAC  
25 ACCGTACGTGAGCACATGTCT-3' (SEQ ID NO: 38)

[0288] As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu$ L of 5  $\mu$ M of the above primer solutions, 5  $\mu$ L of each 2 mM dNTP, and 5  $\mu$ L of 10 $\times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25  $\mu$ L of 5U/ $\mu$ L thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

[0289] After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment S was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

[0290] For the DNA fragment S, the following solutions were prepared respectively in duplicate.

Solution A: 10ng/20  $\mu$ L TE buffer solution

Solution B: 1ng/20  $\mu$ L TE buffer solution

40 Solution C: 0.1ng/20  $\mu$ L TE buffer solution

Solution D: TE buffer solution (negative control solution)

[0291] Twenty (20)  $\mu$ L of each obtained solution, 0.5  $\mu$ L of Sssl methylase (available from NEB Inc.), 5  $\mu$ L of 10 $\times$ NEBuffer2 (available from NEB Inc.), and 0.5  $\mu$ L of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. The reaction liquid was incubated at 37°C for 30 minutes.

[0292] Prepared was 0.02  $\mu$ M TE buffer solution of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 capable of binding by complementation with a plus strand of the DNA fragment S comprising the target DNA region of SEQ ID NO: 38.

50 <5'-end biotin-labeled oligonucleotide>

### [0293]

55 B4:5'- AGACATGTGCTCACGTACGGT -3' (SEQ ID NO: 39)

[0294] Each obtained reaction liquid was subjected to the following treatments.

[0295] In a PCR tube, 40  $\mu$ L of the reaction liquid prepared in the above, 10  $\mu$ L of the 5'-end biotin-labeled oligonu-

## EP 2 305 806 A1

cleotide solution, 10  $\mu$ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu$ L of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu$ L of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu$ L, and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

**[0296]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0297]** Synthesized was a masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39, and 0.1  $\mu$ M TE buffer solution was prepared.

<Masking oligonucleotide>

**[0298]**

M4:5'- ACCGTACGTGAGCACATGTCT -3' (SEQ ID NO: 40)

**[0299]** Each well was added with 100  $\mu$ L of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and added with 1  $\mu$ L of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0300]** Then, each well was added with 100  $\mu$ L of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0301]** Each well was added with 150  $\mu$ L of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0302]** The result is shown in Fig. 9. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

**[0303]** In the present experiment, it was revealed that a DNA fragment can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

Example 8

**[0304]** Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD<sub>600</sub> 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare 1  $\times$  10<sup>7</sup> of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

**[0305]** The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH<sub>3</sub>COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH<sub>3</sub>COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40  $\mu$ g/ml, incubated at 37°C

## EP 2 305 806 A1

for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500  $\mu\text{g}/\text{mL}$  and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

**[0306]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (T, SEQ ID NO: 43, the region corresponding to the nucleotide number 384523-384766 of yeast chromosome VII shown in Genbank Accession No. NC\_0011139) was amplified by conducting PCR using oligonucleotide primers (PF4 and PR4) designed for PCR of SEQ ID NO: 41 and SEQ ID NO: 42 and the following reaction condition.

<Oligonucleotide primers designed for PCR>

### **[0307]**

PF4: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 41)

PR4: 5'-AGTACAGATCTGGCGTTCTCG-3' (SEQ ID NO: 42)

<DNA fragment>

### **[0308]**

T: 5' -

GGACCTGTGTTTGACGGGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCC

GGACGATATCACTCTTGAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACT-3'

(SEQ ID NO: 43)

**[0309]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu\text{L}$  of 5  $\mu\text{M}$  of the above primer solutions, 5  $\mu\text{L}$  of each 2 mM dNTP, and 5  $\mu\text{L}$  of 10 $\times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM  $\text{MgCl}_2$ , 0.01% Gelatin) were mixed with 0.25  $\mu\text{L}$  of 5U/ $\mu\text{L}$  thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

**[0310]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment T was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0311]** For the DNA fragment T, the following solutions were prepared respectively in duplicate.

Solution A: DNA fragment T 10ng/20  $\mu\text{L}$  TE buffer solution

Solution B: DNA fragment T 1ng/20  $\mu\text{L}$  TE buffer solution

Solution C: DNA fragment T 0.1ng/20  $\mu\text{L}$  TE buffer solution

Solution D: TE buffer solution (negative control solution)

**[0312]** Twenty (20)  $\mu\text{L}$  of each obtained solution, 0.5  $\mu\text{L}$  of Sssl methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

**[0313]** Prepared was 0.02  $\mu\text{M}$  TE buffer solution of 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44 capable of binding by complementation with a plus strand of the DNA fragment T comprising the target DNA region of SEQ ID NO: 43.

<5'-end biotin-labeled oligonucleotide>

### **[0314]**

B5:5'- AGTACAGATCTGGCGTTCTCG -3' (SEQ ID NO: 44)

## EP 2 305 806 A1

[0315] Each obtained reaction liquid was subjected to the following treatments.

[0316] In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $\text{MgOAc}_2$ , 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

[0317] The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

[0318] Synthesized was a masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44, and 0.1  $\mu\text{M}$  TE buffer solution was prepared.

<Masking oligonucleotide>

[0319]

M5:5'- CGAGAACGCCAGATCTGTACT -3' (SEQ ID NO: 45)

[0320] Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3. mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

[0321] Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

[0322] Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

[0323] The result is shown in Fig. 10. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

[0324] In the present experiment, it was revealed that a DNA fragment can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

Example 9

[0325] Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of  $\text{OD}_{600}$  0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare  $1 \times 10^7$  of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

[0326] The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M  $\text{CH}_3\text{COOK}$  was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M  $\text{CH}_3\text{COONa}$  in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was

## EP 2 305 806 A1

rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 µg/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500 µg/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

**[0327]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (S, SEQ ID NO: 38, the region corresponding to the nucleotide number 271743-272083 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF3 and PR3) designed for PCR of SEQ ID NO: 36 and SEQ ID NO: 37 and the following reaction condition.

**[0328]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3 µL of 5 µM of the above primer solutions, 5 µL of each 2 mM dNTP, and 5 µL of 10×buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25 µL of 5U/µL thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

**[0329]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment S was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0330]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (T, SEQ ID NO: 43, the region corresponding to the nucleotide number 384523-384766 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF4 and PR4) designed for PCR of SEQ ID NO: 41 and SEQ ID NO: 42 and the following reaction condition.

**[0331]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3 µL of 5 µM of the above primer solutions, 5 µL of each 2 mM dNTP, and 5 µL of 10×buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25 µL of 5U/µL thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

**[0332]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment T was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0333]** For each of the DNA fragment S and the DNA fragment T, the following solutions were prepared.

Solution A: DNA fragment S or DNA fragment T 10 ng/10 µL TE buffer solution

Solution B: DNA fragment S or DNA fragment T 1 ng/10 µL TE buffer solution

Solution C: DNA fragment S or DNA fragment T 0.1 ng/10 µL TE buffer solution

Solution D: TE buffer solution (negative control solution)

**[0334]** Equivalent amounts of Solution A of the DNA fragment S and Solution A of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MA, equivalent amounts of Solution B of the DNA fragment S and Solution B of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MB, equivalent amounts of Solution C of the DNA fragment S and Solution C of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MC, and equivalent amounts of Solution D of the DNA fragment S and Solution D of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MD. Three sets in duplicate were prepared respectively, for each of DNA fragment-mixed Solutions MA, MB, MC and MD.

**[0335]** Twenty (20) µL of each obtained solution, 0.5 µL of SssI methylase (available from NEB Inc.), 5 µL of 10xNEBuffer2 (available from NEB Inc.), and 0.5 µL of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. The reaction liquid was incubated at 37°C for 30 minutes.

**[0336]** Prepared were 0.02 µM TE buffer solutions of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 capable of binding by complementation with the DNA fragment S of SEQ ID NO: 38 and 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44 capable of binding by complementation with the DNA fragment T of SEQ ID NO: 43. Also prepared was a TE buffer solution (0.02 µM for each) of 5'-end biotin-labeled oligonucleotide mixing equivalent amounts of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 and 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44.

**[0337]** For each reaction liquid of the DNA fragment Solutions MA to MD, the following treatment was conducted.

**[0338]** In a PCR tube, 40 µL of the reaction liquid prepared in the above, 10 µL of the 5'-end biotin-labeled oligonu-

## EP 2 305 806 A1

cleotide solution, 10  $\mu$ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu$ L of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu$ L of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu$ L, and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

**[0339]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0340]** Synthesized were masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 and masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44, and respective 0.1  $\mu$ M TE buffer solutions were prepared. Prepared was a TE buffer solution (each 0.1  $\mu$ M) mixing equivalent amounts of masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 and masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45.

**[0341]** Each well was added with 100  $\mu$ L of a methylcytosine antibody [available from Aviva Systems Biology, 0.5 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and added with 1  $\mu$ L of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0342]** Then, each well was added with 100  $\mu$ L of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0343]** Each well was added with 150  $\mu$ L of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0344]** The results are shown in Figs. 11 to 13. It was revealed that the DNA fragment is selected by forming a complex with immobilized 5'-end biotin-labeled oligonucleotide B4 (Fig. 11), immobilized 5'-end biotin-labeled oligonucleotide B5 (Fig. 12), the 5'-end biotin-labeled oligonucleotides which are mixture of the foregoing two kinds (Fig. 13), and the methylcytosine antibody, and is quantified and detected with excellent sensitivity. It was revealed that when two kinds of the 5'-end biotin-labeled oligonucleotides are mixed (Fig. 13), in particular, quantification and detection with better sensitivity can be achieved compared with the case of detection by a single oligonucleotide (Fig. 11 and Fig. 12).

**[0345]** In the present experiment, it was revealed that a DNA fragment can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function. It was also revealed that by using a plurality of immobilized 5'-end biotin-labeled oligonucleotides, more sensitive quantification and detection are realized than the case where one kind of immobilized 5'-end biotin-labeled oligonucleotide is used (that is, not only using one target DNA region but also using a plurality of target DNA regions at the same time).

### Example 10

**[0346]** Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD<sub>600</sub> 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare  $1 \times 10^7$  of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

**[0347]** The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH<sub>3</sub>COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH<sub>3</sub>COONa in a volume ratio of 1/10 and an equal amount

## EP 2 305 806 A1

of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 µg/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500 µg/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

**[0348]** For the obtained yeast genomic DNA, the following solutions were prepared.

Solution A: Yeast genomic DNA 100 ng/20 µL TE buffer solution

Solution B: Yeast genomic DNA 10 ng/20 µL TE buffer solution

Solution C: Yeast genomic DNA 1 ng/20 µL TE buffer solution

Solution D: TE buffer solution (negative control solution)

**[0349]** Twenty (20) µL of each obtained solution, 10 U of restriction enzyme Xspl, and 5 µL of 10x buffer optimum for Xspl (200 mM Tris-HCl pH 8.5, 100 mM MgCl<sub>2</sub>, 10 mM Dithiothreitol, 1000 mM KCl) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. The reaction liquid was incubated at 37°C for 1 hour.

**[0350]** Twenty (20) µL of each obtained solution, 0.5 µL of Sssl methylase (available from NEB Inc.), 5 µL of 10xNEBuffer2 (available from NEB Inc.), and 0.5 µL of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. The reaction liquid was incubated at 37°C for 30 minutes.

**[0351]** Prepared was a 0.02 µM TE buffer solution of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 capable of binding by complementation with a plus strand of DNA fragment S' comprising the target DNA region of SEQ ID NO: 46.

<DNA fragment>

**[0352]**

S' : 5' -

TAGGTGAGCTACGTGTGTTTGGGCGTCGTGCACTGGCTCACTTGTACGCGCAGAAATGGCAG  
CTTGTACGATTGGTGACCCGCCCTTTTCGACACTGGACCGCTATGGACGTGGCGGCGGTGTGG  
CGGCGGCTCAATGACCTGTGGCGCCCGTTTGTGGCGTGCGATAGTCGAGCCGCCTGTCACGT  
GCGCGGCCGCCCTGCTCCGTTTACGCGATGCATAGCATGCGACCACCCAGTAATCATACTG  
CTGACGCTATTGGTCACGTGGTTATGGCAGCTGCTGTTGACTGCGGTGGCGTCCCGTTTCCA  
CACCGTACGTGAGCACATGTCTGGATTGC -3' (SEQ ID NO: 46)

<5'-end biotin-labeled oligonucleotide>

**[0353]**

B4:5'- AGACATGTGCTCACGTACGGT-3' (SEQ ID NO: 39)

**[0354]** For respective reaction liquids of yeast genomic DNA Solutions A to D, the following treatment was conducted.

**[0355]** In a PCR tube, 40 µL of the reaction liquid prepared in the above, 10 µL of the 5'-end biotin-labeled oligonucleotide solution, 10 µL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol),

## EP 2 305 806 A1

10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

5 [0356] The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

10 [0357] Synthesized was masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39, and a 0.1  $\mu\text{M}$  TE buffer solution was prepared.

15 <5'-end biotin-labeled oligonucleotide>

[0358]

20 B4:5'- AGACATGTGCTCACGTACGGT -3' (SEQ ID NO: 39)

<Masking oligonucleotide>

[0359]

25 M4:5'- ACGGCGCACCACGAGACTAT -3' (SEQ ID NO: 40)

30 [0360] Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

35 [0361] Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

40 [0362] Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

[0363] The result is shown in Fig. 14, it was revealed that in the yeast genomic DNA solution, the DNA fragment is selected by forming a complex with immobilized 5'-end biotin-labeled oligonucleotide B4 and the methylcytosine antibody, and thus quantified and detected with excellent sensitivity.

45 [0364] In the present experiment, it was revealed that genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

50 Example 11

[0365] Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of  $\text{OD}_{600}$  0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare  $1 \times 10^7$  of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

55 [0366] The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and

## EP 2 305 806 A1

then incubated at 65°C for 30 minutes. Sequentially, 5 M CH<sub>3</sub>COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH<sub>3</sub>COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 µg/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500 µg/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

**[0367]** For the obtained yeast genomic DNA, the following solutions were prepared.

Solution A: Yeast genomic DNA 100 ng/20 µL TE buffer solution

Solution B: Yeast genomic DNA 10 ng/20 µL TE buffer solution

Solution C: Yeast genomic DNA 1 ng/20 µL TE buffer solution

Solution D: TE buffer solution (negative control solution)

**[0368]** Twenty (20) µL of each obtained solution, 10 U of restriction enzyme Xspl, and 5 µL of 10x buffer optimum for Xspl (200 mM Tris-HCl pH 8.5, 100 mM MgCl<sub>2</sub>, 10 mM Dithiothreitol, 1000 mM KCl) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. The reaction liquid was incubated at 37°C for 1 hour.

**[0369]** Twenty (20) µL of each obtained solution, 0.5 µL of Sssl methylase (available from NEB Inc.), 5 µL of 10xNEBuffer2 (available from NEB Inc.), and 0.5 µL of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. The reaction liquid was incubated at 37°C for 30 minutes.

**[0370]** Prepared was a 0.02 µM TE buffer solution of 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44 capable of binding by complementation with a plus strand of DNA fragment T' comprising the target DNA region of SEQ ID NO: 47.

<DNA fragment>

**[0371]**

T' : 5' -

TAGGAAATACATTCCGAGGGCGCCCGCACAAAGGCCTATTATTAGAGGGACCTGTGTTTGACG  
GGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCCCCGACGATATCACTCTT  
GAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACTGCGATCGCACACGAGGAGACACA  
GCGTCACGTGTTTTGCCATTTTGTACGACAAATGAACCGCCTGGCCACGCCTCTAATC -3'

(SEQ ID NO: 47)

<5'-end biotin-labeled oligonucleotide>

**[0372]**

B5:5'- AGTACAGATCTGGCGTTCTCG-3' (SEQ ID NO: 44)

**[0373]** For respective reaction liquids of yeast genomic DNA Solutions A to D, the following treatment was conducted.

**[0374]** In a PCR tube, 40 µL of the reaction liquid prepared in the above, 10 µL of the 5'-end biotin-labeled oligonucleotide solution, 10 µL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10 µL of a 100 mM MgCl<sub>2</sub> solution and 10 µL of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100 µL, and mixed. Then the PCR tube was heated at 95°C

## EP 2 305 806 A1

for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

5 **[0375]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

10 **[0376]** Synthesized was masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44, and a 0.1  $\mu$ M TE buffer solution was prepared.

15 **[0377]** Each well was added with 100  $\mu$ L of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu$ L of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

20 **[0378]** Then, each well was added with 100  $\mu$ L of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05  $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

25 **[0379]** Each well was added with 150  $\mu$ L of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0380]** The result is shown in Fig. 15, it was revealed that in the yeast genomic DNA solution, the DNA fragment is selected by forming a complex with immobilized 5'-end biotin-labeled oligonucleotide B5 and the methylcytosine antibody, and thus quantified and detected with excellent sensitivity.

30 **[0381]** In the present experiment, it was revealed that genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

### Example 12

35 **[0382]** Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of  $\text{OD}_{600}$  0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare  $1 \times 10^7$  of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

40 **[0383]** The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M  $\text{CH}_3\text{COOK}$  was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M  $\text{CH}_3\text{COONa}$  in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40  $\mu$ g/ml, incubated at 37°C

45 and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500  $\mu$ g/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

50 **[0384]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (S, SEQ ID NO: 38, the region corresponding to the nucleotide number 271743-272083 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF3 and PR3) designed for PCR of SEQ ID NO: 36 and SEQ ID NO: 37 and the following reaction condition.

## EP 2 305 806 A1

**[0385]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu\text{L}$  of 5  $\mu\text{M}$  of the above primer solutions, 5  $\mu\text{L}$  of each 2 mM dNTP, and 5  $\mu\text{L}$  of 10 $\times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM  $\text{MgCl}_2$ , 0.01% Gelatin) were mixed with 0.25  $\mu\text{L}$  of 5U/ $\mu\text{L}$  thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

**[0386]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment S was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0387]** For the DNA fragment S, the following solutions to which genomic DNA derived from human blood purchased from Clontech has been added were prepared respectively in duplicate.

Solution A: DNA fragment S 10ng/20  $\mu\text{L}$  TE buffer solution (containing 5ng/ $\mu\text{L}$  genomic DNA derived from human blood)

Solution B: DNA fragment S 1ng/20  $\mu\text{L}$  TE buffer solution (containing 5ng/ $\mu\text{L}$  genomic DNA derived from human blood)

Solution C: DNA fragment S 0.1ng/20  $\mu\text{L}$  TE buffer solution (containing 5ng/ $\mu\text{L}$  genomic DNA derived from human blood)

Solution D: TE buffer solution (negative control solution)(containing 5ng/ $\mu\text{L}$  genomic DNA derived from human blood)

**[0388]** Twenty (20)  $\mu\text{L}$  of each obtained solution, 0.5  $\mu\text{L}$  of Sssl methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10 $\times$ NEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

**[0389]** Prepared was 0.02  $\mu\text{M}$  TE buffer solution of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 capable of binding by complementation with a plus strand of the DNA fragment S comprising the target DNA region of SEQ ID NO: 38.

**[0390]** Each obtained reaction liquid was subjected to the following treatments.

**[0391]** In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $\text{MgOAc}_2$ , 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

**[0392]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0393]** Synthesized was a masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39, and 0.1  $\mu\text{M}$  TE buffer solution was prepared.

**[0394]** Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0395]** Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0396]** Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0397]** The result is shown in Fig. 16. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

## EP 2 305 806 A1

**[0398]** In the present experiment, it was revealed that a yeast-derived DNA fragment in human genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

### Example 13

**[0399]** Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of  $OD_{600}$  0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare  $1 \times 10^7$  of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

**[0400]** The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M  $CH_3COOK$  was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M  $CH_3COONa$  in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40  $\mu$ g/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500  $\mu$ g/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

**[0401]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (T, SEQ ID NO: 43, the region corresponding to the nucleotide number 384523-384766 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF4 and PR4) designed for PCR of SEQ ID NO: 41 and SEQ ID NO: 42 and the following reaction condition.

**[0402]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu$ L of 5  $\mu$ M of the above primer solutions, 5  $\mu$ L of each 2 mM dNTP, and 5  $\mu$ L of 10 $\times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM  $MgCl_2$ , 0.01% Gelatin) were mixed with 0.25  $\mu$ L of 5U/ $\mu$ L thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

**[0403]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment T was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0404]** For the DNA fragment T, the following solutions to which genomic DNA derived from human blood purchased from Clontech has been added were prepared respectively in duplicate.

Solution A: DNA fragment T 10ng/20  $\mu$ L TE buffer solution (containing 5ng/ $\mu$ L genomic DNA derived from human blood)

Solution B: DNA fragment T 1ng/20  $\mu$ L TE buffer solution (containing 5ng/ $\mu$ L genomic DNA derived from human blood)

Solution C: DNA fragment T 0.1ng/20  $\mu$ L TE buffer solution (containing 5ng/ $\mu$ L genomic DNA derived from human blood)

Solution D: TE buffer solution (negative control solution)(containing 5ng/ $\mu$ L genomic DNA derived from human blood)

**[0405]** Twenty (20)  $\mu$ L of each obtained solution, 0.5  $\mu$ L of SssI methylase (available from NEB Inc.), 5  $\mu$ L of 10 $\times$ NEBuffer2 (available from NEB Inc.), and 0.5  $\mu$ L of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. The reaction liquid was incubated at 37°C for 30 minutes.

**[0406]** Prepared was 0.02  $\mu$ M TE buffer solution of 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44 capable of binding by complementation with a plus strand of the DNA fragment T comprising the target DNA region of SEQ ID NO: 43.

<5'-end biotin-labeled oligonucleotide>

**[0407]**

5 B5:5'- AGTACAGATCTGGCGTTCTCG -3' (SEQ ID NO: 44)

**[0408]** Each obtained reaction liquid was subjected to the following treatments.

**[0409]** In a PCR tube, 40  $\mu$ L of the reaction liquid prepared in the above, 10  $\mu$ L of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu$ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu$ L of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu$ L of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu$ L, and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

**[0410]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0411]** Synthesized was a masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44, and 0.1  $\mu$ M TE buffer solution was prepared.

**[0412]** Each well was added with 100  $\mu$ L of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and added with 1  $\mu$ L of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0413]** Then, each well was added with 100  $\mu$ L of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub> HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0414]** Each well was added with 150  $\mu$ L of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0415]** The result is shown in Fig. 17. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

**[0416]** In the present experiment, it was revealed that a yeast-derived DNA fragment in human genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

#### Example 14

**[0417]** Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD<sub>600</sub> 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare 1  $\times$  10<sup>7</sup> of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

**[0418]** The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH<sub>3</sub>COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH<sub>3</sub>COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl,

## EP 2 305 806 A1

pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 µg/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500 µg/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

**[0419]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (S, SEQ ID NO: 38, the region corresponding to the nucleotide number 271743-272083 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF3 and PR3) designed for PCR of SEQ ID NO: 36 and SEQ ID NO: 37 and the following reaction condition.

**[0420]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3 µL of 5 µM of the above primer solutions, 5 µL of each 2 mM dNTP, and 5 µL of 10×buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25 µL of 5U/µL thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

**[0421]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment S was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0422]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (T, SEQ ID NO: 43, the region corresponding to the nucleotide number 384523-384766 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF4 and PR4) designed for PCR of SEQ ID NO: 41 and SEQ ID NO: 42 and the following reaction condition.

**[0423]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3 µL of 5 µM of the above primer solutions, 5 µL of each 2 mM dNTP, and 5 µL of 10×buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25 µL of 5U/µL thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

**[0424]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment T was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0425]** For each of the DNA fragment S and the DNA fragment T, the following solutions to which genomic DNA derived from human blood purchased from Clontech has been added were prepared.

Solution A: DNA fragment S or DNA fragment T 10 ng/10 µL TE buffer solution (containing 5ng/µL genomic DNA derived from human blood)

Solution B: DNA fragment S or DNA fragment T 1 ng/10 µL TE buffer solution (containing 5ng/µL genomic DNA derived from human blood)

Solution C: DNA fragment S or DNA fragment T 0.1 ng/10 µL TE buffer solution (containing 5ng/µL genomic DNA derived from human blood)

Solution D: TE buffer solution (negative control solution) (containing 5ng/µL genomic DNA derived from human blood)

**[0426]** Equivalent amounts of Solution A of the DNA fragment S and Solution A of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MA, equivalent amounts of Solution B of the DNA fragment S and Solution B of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MB, equivalent amounts of Solution C of the DNA fragment S and Solution C of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MC, and equivalent amounts of Solution D of the DNA fragment S and Solution D of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MD. Three sets in duplicate were prepared respectively, for each of DNA fragment-mixed Solutions MA, MB, MC and MD.

**[0427]** Twenty (20) µL of each obtained solution, 0.5 µL of SssI methylase (available from NEB Inc.), 5 µL of 10xNEBuffer2 (available from NEB Inc.), and 0.5 µL of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. The reaction liquid was incubated at 37°C for 30 minutes.

**[0428]** Prepared were 0.02 µM TE buffer solutions of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 capable of binding by complementation with a plus strand of the DNA fragment S comprising the target DNA region of SEQ ID NO: 38 and 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44 capable of binding by complementation with a plus strand of the DNA fragment T comprising the target DNA region of SEQ ID NO: 43. Also prepared was a TE buffer solution (0.02 µM for each) mixing equivalent amounts of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 and 5'-end biotin-

labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44.

[0429] For each reaction liquid of the DNA fragment Solutions MA to MD, the following treatment was conducted.

[0430] In a PCR tube, 40  $\mu$ L of the reaction liquid prepared in the above, 10  $\mu$ L of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu$ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu$ L of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu$ L of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu$ L, and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

[0431] The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

[0432] Synthesized were masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 and masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44, and respective 0.1  $\mu$ M TE buffer solutions were prepared. Prepared was a TE buffer solution (each 0.1  $\mu$ M) mixing equivalent amounts of masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 and masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45.

[0433] Each well was added with 100  $\mu$ L of a methylcytosine antibody [available from Aviva Systems Biology, 0.5 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O 154 mM NaCl pH7.4) solution], and added with 1  $\mu$ L of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

[0434] Then, each well was added with 100  $\mu$ L of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

[0435] Each well was added with 150  $\mu$ L of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

[0436] The results are shown in Figs. 18 to 20. It was revealed that the DNA fragment is selected by forming a complex with immobilized 5'-end biotin-labeled oligonucleotide B4 (Fig. 18), immobilized 5'-end biotin-labeled oligonucleotide B5 (Fig. 19), the 5'-end biotin-labeled oligonucleotides which are mixture of the foregoing two kinds (Fig. 20), and the methylcytosine antibody, and is quantified and detected with excellent sensitivity. It was revealed that when two kinds of the 5'-end biotin-labeled oligonucleotides are mixed (Fig. 20), in particular, quantification and detection with better sensitivity can be achieved compared with the case of detection by a single oligonucleotide (Fig. 18 and Fig. 19).

[0437] In the present experiment, it was revealed that a yeast-derived DNA fragment in human genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function. It was also revealed that by using a plurality of immobilized 5'-end biotin-labeled oligonucleotides, more sensitive quantification and detection are realized than the case where one kind of immobilized 5'-end biotin-labeled oligonucleotide is used (that is, not only using one target DNA region but also using a plurality of target DNA regions at the same time).

#### Example 15

[0438] Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD<sub>600</sub> 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare 1  $\times$  10<sup>7</sup> of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

[0439] The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was

## EP 2 305 806 A1

suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH<sub>3</sub>COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH<sub>3</sub>COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 µg/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500 µg/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

**[0440]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (S, SEQ ID NO: 38, the region corresponding to the nucleotide number 271743-272083 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF3 and PR3) designed for PCR of SEQ ID NO: 36 and SEQ ID NO: 37 and the following reaction condition.

**[0441]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3 µL of 5 µM of the above primer solutions, 5 µL of each 2 mM dNTP, and 5 µL of 10×buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25 µL of 5U/µL thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

**[0442]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment S was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0443]** For the DNA fragment S, the following solutions were prepared respectively in duplicate.

Solution A: DNA fragment S 10ng/20 µL TE buffer solution

Solution B: DNA fragment S 1ng/20 µL TE buffer solution

Solution C: DNA fragment S 0.1ng/20 µL TE buffer solution

Solution D: TE buffer solution (negative control solution)

**[0444]** Twenty (20) µL of each obtained solution, 0.5 µL of Sssl methylase (available from NEB Inc.), 5 µL of 10xNEBuffer2 (available from NEB Inc.), and 0.5 µL of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 µL. The reaction liquid was incubated at 37°C for 30 minutes.

**[0445]** Prepared was 0.02 µM TE buffer solution of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 capable of binding by complementation with a plus strand of the DNA fragment S comprising the target DNA region of SEQ ID NO: 38.

**[0446]** Synthesized were counter oligonucleotides C6, C7, C8, C9, C10, C11, C12, C13 and C14 having the nucleotide sequences of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55 and SEQ ID NO: 56, respectively capable of binding by complementation with a minus strand of DNA fragment S comprising the target DNA region of SEQ ID NO: 38, and respective 0.01 µM TE buffer solutions were prepared.

<Counter oligonucleotides>

**[0447]**

C6:5'- GCGTCGTGCACTGGCTCACTTGTACGCGCA -3' (SEQ ID NO: 48)

C7:5'- CTTGTACGATTGGTGACCCGCCCTTTTCGAC -3' (SEQ ID NO: 49)

C8:5'- ACTGGACCGCTATGGACGTGGCGGCGGTGT -3' (SEQ ID NO: 50)

C9:5'- GGCGGCGGCTCAATGACCTGTGGCGCCCGT -3' (SEQ ID NO: 51)

C10:5'- TTGTGGCGTGCGATAGTCGAGCCGCCTGTC -3' (SEQ ID NO: 52)

C11:5'- ACGTGCGCGGCCGCCCTGCTCCGTT -3' (SEQ ID NO: 53)

C12:5'- TGACGCGATGCATAGCATGCGACCACCCAG -3' (SEQ ID NO: 54)

C13:5'- ACTGCTGACGCTATTGGTCACGTGGTTATG -3' (SEQ ID NO: 55)

C14:5'- CTGCTGTTGACTGCGGTGGCGTCCCGTTTC -3' (SEQ ID NO: 56)

## EP 2 305 806 A1

[0448] Each obtained reaction liquid was subjected to the following treatments.

[0449] In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of the counter oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

[0450] The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O 154 mM NaCl pH7.4)].

[0451] Synthesized was a masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39, and 0.1  $\mu\text{M}$  TE buffer solution was prepared.

[0452] Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub>SO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

[0453] Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub>PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

[0454] Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

[0455] The result is shown in Fig. 21. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

[0456] In the present experiment, it was revealed that a DNA fragment can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

### Example 16

[0457] Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD<sub>600</sub> 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare  $1 \times 10^7$  of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

[0458] The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH<sub>3</sub>COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH<sub>3</sub>COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40  $\mu\text{g}/\text{ml}$ , incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500  $\mu\text{g}/\text{mL}$  and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

## EP 2 305 806 A1

[0459] From the obtained genomic DNA, a DNA fragment to be used as a test sample (T, SEQ ID NO: 43, the region corresponding to the nucleotide number 384523-384766 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF4 and PR4) designed for PCR of SEQ ID NO: 41 and SEQ ID NO: 42 and the following reaction condition.

[0460] As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu\text{L}$  of 5  $\mu\text{M}$  of the above primer solutions, 5  $\mu\text{L}$  of each 2 mM dNTP, and 5  $\mu\text{L}$  of 10xbuffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM  $\text{MgCl}_2$ , 0.01% Gelatin) were mixed with 0.25  $\mu\text{L}$  of 5U/ $\mu\text{L}$  thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

[0461] After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment T was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

[0462] For the DNA fragment T, the following solutions were prepared respectively in duplicate.

Solution A: DNA fragment T 10ng/20  $\mu\text{L}$  TE buffer solution  
Solution B: DNA fragment T 1ng/20  $\mu\text{L}$  TE buffer solution  
Solution C: DNA fragment T 0.1ng/20  $\mu\text{L}$  TE buffer solution  
Solution D: TE buffer solution (negative control solution)

[0463] Twenty (20)  $\mu\text{L}$  of each obtained solution, 0.5  $\mu\text{L}$  of Sssl methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

[0464] Prepared was 0.02  $\mu\text{M}$  TE buffer solution of 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44 capable of binding by complementation with a plus strand of the DNA fragment T comprising the target DNA region of SEQ ID NO: 43.

[0465] Synthesized were counter oligonucleotides C15, C16, C17 and C18 having the nucleotide sequences of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 and SEQ ID NO: 60, respectively capable of binding by complementation with a minus strand of DNA fragment T comprising the target DNA region of SEQ ID NO: 43, and respective 0.01  $\mu\text{M}$  TE buffer solutions were prepared.

<Counter oligonucleotides>

[0466]

C15:5'- GGACCTGTGTTTGACGGGTAT -3' (SEQ ID NO: 57)  
C16:5'- AACACTAAGTTGCGCAATTTGCTGT -3' (SEQ ID NO: 58)  
C17:5'- ATTGCGAAATCCGCCCGGACGATAT -3' (SEQ ID NO: 59)  
C18:5'- CACTCTTGAGCGCATGTGCCGTTTC -3' (SEQ ID NO: 60)

[0467] Each obtained reaction liquid was subjected to the following treatments.

[0468] In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of the counter oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $\text{MgOAc}_2$ , 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

[0469] The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$  154 mM NaCl pH7.4)].

[0470] Synthesized was a masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44, and 0.1  $\mu\text{M}$  TE buffer solution was prepared.

[0471] Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5

## EP 2 305 806 A1

$\mu\text{g/mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0472]** Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu\text{g/mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

**[0473]** Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0474]** The result is shown in Fig. 22. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

**[0475]** In the present experiment, it was revealed that a DNA fragment can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

### Example 17

**[0476]** Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of  $\text{OD}_{600}$  0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare  $1 \times 10^7$  of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

**[0477]** The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M  $\text{CH}_3\text{COOK}$  was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M  $\text{CH}_3\text{COONa}$  in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40  $\mu\text{g/mL}$ , incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500  $\mu\text{g/mL}$  and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

**[0478]** From the obtained genomic DNA, a DNA fragment to be used as a test sample (S, SEQ ID NO: 38, the region corresponding to the nucleotide number 271743-272083 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF3 and PR3) designed for PCR of SEQ ID NO: 36 and SEQ ID NO: 37 and the following reaction condition.

**[0479]** As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu\text{L}$  of 5  $\mu\text{M}$  of the above primer solutions, 5  $\mu\text{L}$  of each 2 mM dNTP, and 5  $\mu\text{L}$  of 10xbuffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM  $\text{MgCl}_2$ , 0.01% Gelatin) were mixed with 0.25  $\mu\text{L}$  of 5U/ $\mu\text{L}$  thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

**[0480]** After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment S was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

**[0481]** For the DNA fragment S, the following solutions to which genomic DNA derived from human blood purchased from Clontech has been added were prepared respectively in duplicate.

Solution A: DNA fragment S 10ng/20  $\mu\text{L}$  TE buffer solution (containing 5ng/ $\mu\text{L}$  genomic DNA derived from human blood)

Solution B: DNA fragment S 1ng/20  $\mu\text{L}$  TE buffer solution (containing 5ng/ $\mu\text{L}$  genomic DNA derived from human

## EP 2 305 806 A1

blood)

Solution C: DNA fragment S 0.1ng/20  $\mu$ L TE buffer solution (containing 5ng/ $\mu$ L genomic DNA derived from human blood)

Solution D: TE buffer solution (negative control solution)(containing 5ng/ $\mu$ L genomic DNA derived from human blood)

5

**[0482]** Twenty (20)  $\mu$ L of each obtained solution, 0.5  $\mu$ L of SssI methylase (available from NEB Inc.), 5  $\mu$ L of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu$ L of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. The reaction liquid was incubated at 37°C for 30 minutes.

10 **[0483]** Prepared was 0.02  $\mu$ M TE buffer solution of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 capable of binding by complementation with a plus strand of the DNA fragment S comprising the target DNA region of SEQ ID NO: 38.

15 **[0484]** Synthesized were counter oligonucleotides C6, C7, C8, C9, C10, C11, C12, C13, C14 and C19 having the nucleotide sequences of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56 and SEQ ID NO: 61, respectively capable of binding by complementation with a minus strand of DNA fragment S comprising the target DNA region of SEQ ID NO: 38, and respective 0.01  $\mu$ M TE buffer solutions were prepared.

<Counter oligonucleotides>

20

**[0485]**

C6:5'- GCGTCGTGCACTGGCTCACTTGTACGCGCA -3' (SEQ ID NO: 48)

C7:5'- CTTGTACGATTGGTGACCCGCCTTTTCGAC -3' (SEQ ID NO: 49)

25 C8:5'- ACTGGATCGCTATGGACGTGGCGGCGGTGT -3' (SEQ ID NO: 50)

C9:5'- GGCGGCGGCTCAATGACCTGTGGCGCCCGT -3' (SEQ ID NO: 51)

C10:5'- TTGTGGCGTGCGATAGTCGAGCCGCCTGTC -3' (SEQ ID NO: 52)

C11:5'- ACGTGCGCGGCCGCCCTGCTCCGTT -3' (SEQ ID NO: 53)

C12:5'- TGACGCGATGCATAGCATGCGACCACCCAG -3' (SEQ ID NO: 54)

30 C13:5'- ACTGCTGACGCTATTGGTCACGTGGTTATG -3' (SEQ ID NO: 55)

C14:5'- CTGCTGTTGACTGCGGTGGCGTCCCGTTTC -3' (SEQ ID NO: 56)

C19:5'- AGGTGAGCTACGTGTGTTTGG -3' (SEQ ID NO: 61)

**[0486]** Each obtained reaction liquid was subjected to the following treatments.

35 **[0487]** In a PCR tube, 40  $\mu$ L of the reaction liquid prepared in the above, 10  $\mu$ L of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu$ L of the counter oligonucleotide solution, 10  $\mu$ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu$ L of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu$ L of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu$ L, and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

40 **[0488]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

45 **[0489]** Synthesized was a masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39, and 0.1  $\mu$ M TE buffer solution was prepared.

50 **[0490]** Each well was added with 100  $\mu$ L of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and added with 1  $\mu$ L of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu$ L of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

55 **[0491]** Then, each well was added with 100  $\mu$ L of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu$ g/mL 0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well

## EP 2 305 806 A1

was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

[0492] Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

[0493] The result is shown in Fig. 23. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

[0494] In the present experiment, it was revealed that a yeast-derived DNA fragment in human genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

### Example 18

[0495] Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of  $\text{OD}_{600}$  0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare  $1 \times 10^7$  of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

[0496] The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M  $\text{CH}_3\text{COOK}$  was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M  $\text{CH}_3\text{COONa}$  in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40  $\mu\text{g}/\text{ml}$ , incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in concentrations of 500  $\mu\text{g}/\text{mL}$  and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

[0497] From the obtained genomic DNA, a DNA fragment to be used as a test sample (T, SEQ ID NO: 43, the region corresponding to the nucleotide number 384523-384766 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF4 and PR4) designed for PCR of SEQ ID NO: 41 and SEQ ID NO: 42 and the following reaction condition.

[0498] As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3  $\mu\text{L}$  of 5  $\mu\text{M}$  of the above primer solutions, 5  $\mu\text{L}$  of each 2 mM dNTP, and 5  $\mu\text{L}$  of 10 $\times$ buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM  $\text{MgCl}_2$ , 0.01% Gelatin) were mixed with 0.25  $\mu\text{L}$  of 5U/ $\mu\text{L}$  thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

[0499] After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment T was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

[0500] For the DNA fragment T, the following solutions to which genomic DNA derived from human blood purchased from Clontech has been added were prepared respectively in duplicate.

Solution A: DNA fragment T 10ng/20  $\mu\text{L}$  TE buffer solution (containing 5ng/ $\mu\text{L}$  genomic DNA derived from human blood)

Solution B: DNA fragment T 1ng/20  $\mu\text{L}$  TE buffer solution (containing 5ng/ $\mu\text{L}$  genomic DNA derived from human blood)

Solution C: DNA fragment T 0.1ng/20  $\mu\text{L}$  TE buffer solution (containing 5ng/ $\mu\text{L}$  genomic DNA derived from human blood)

Solution D: TE buffer solution (negative control solution) (containing 5ng/ $\mu\text{L}$  genomic DNA derived from human blood)

[0501] Twenty (20)  $\mu\text{L}$  of each obtained solution, 0.5  $\mu\text{L}$  of SssI methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10 $\times$ NEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were

## EP 2 305 806 A1

mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

**[0502]** Prepared was 0.02  $\mu\text{M}$  TE buffer solution of 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44 capable of binding by complementation with a plus strand of the DNA fragment T comprising the target DNA region of SEQ ID NO: 43.

**[0503]** Synthesized were counter oligonucleotides C15, C16, C17 and C18 having the nucleotide sequences of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 and SEQ ID NO: 60, respectively capable of binding by complementation with a minus strand of DNA fragment T comprising the target DNA region of SEQ ID NO: 43, and respective 0.01  $\mu\text{M}$  TE buffer solutions were prepared.

<Counter oligonucleotides>

### **[0504]**

C15:5'- GGACCTGTGTTTGACGGGTAT -3' (SEQ ID NO: 57)

C16:5'- AACACTAAGTTGCGCAATTTGCTGT -3' (SEQ ID NO: 58)

C17:5'- ATTGCGAAATCCGCCCGGACGATAT -3' (SEQ ID NO: 59)

C18:5'- CACTCTTGAGCGCATGTGCCGTTTC -3' (SEQ ID NO: 60)

**[0505]** Each obtained reaction liquid was subjected to the following treatments.

**[0506]** In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of the counter oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc<sub>2</sub>, 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM MgCl<sub>2</sub> solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

**[0507]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0508]** Synthesized was a masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44, and 0.1  $\mu\text{M}$  TE buffer solution was prepared.

<5'-end biotin-labeled oligonucleotide>

### **[0509]**

B5:5'- AGTACAGATCTGGCGTTCTCG -3' (SEQ ID NO: 44)

<Masking oligonucleotide>

### **[0510]**

M5:5'- CGAGAACGCCAGATCTGTACT -3' (SEQ ID NO: 45)

**[0511]** Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

**[0512]** Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>, 3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM KH<sub>2</sub> PO<sub>4</sub>,

## EP 2 305 806 A1

3 mM Na<sub>2</sub>HPO 7H<sub>2</sub>O, 154 mM NaCl pH7.4)].

[0513] Each well was added with 150 μL of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

[0514] The result is shown in Fig. 24. It was revealed that a DNA fragment is selected accurately by the immobilized 5'-end biotin-labeled oligonucleotide, and quantified and detected with excellent sensitivity.

[0515] In the present experiment, it was revealed that an yeast-derived DNA fragment in human genomic DNA can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function.

### Example 19

[0516] Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD<sub>600</sub> 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare 1 × 10<sup>7</sup> of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

[0517] The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH<sub>3</sub>COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH<sub>3</sub>COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 μg/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in concentrations of 500 μg/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)]-chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

[0518] From the obtained genomic DNA, a DNA fragment to be used as a test sample (S, SEQ ID NO: 38, the region corresponding to the nucleotide number 271743-272083 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF3 and PR3) designed for PCR of SEQ ID NO: 36 and SEQ ID NO: 37 and the following reaction condition.

[0519] As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3 μL of 5 μM of the above primer solutions, 5 μL of each 2 mM dNTP, and 5 μL of 10xbuffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25 μL of 5U/μL thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 μL. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

[0520] After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment S was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

[0521] From the obtained genomic DNA, a DNA fragment to be used as a test sample (T, SEQ ID NO: 43, the region corresponding to the nucleotide number 384523-384766 of yeast chromosome VII shown in Genbank Accession No. NC\_001139) was amplified by conducting PCR using oligonucleotide primers (PF4 and PR4) designed for PCR of SEQ ID NO: 41 and SEQ ID NO: 42 and the following reaction condition.

[0522] As a reaction liquid of PCR, 10 ng of genomic DNA as a template, each 3 μL of 5 μM of the above primer solutions, 5 μL of each 2 mM dNTP, and 5 μL of 10xbuffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% Gelatin) were mixed with 0.25 μL of 5U/μL thermostable DNA polymerase (AmpliTaq Gold), and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50 μL. After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 20 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C.

[0523] After conducting PCR, amplification was checked by 2% agarose gel electrophoresis, and the DNA fragment T was purified by Wizard SV Gel/PCR Kit (PROMEGA Corporation).

[0524] For each of the DNA fragment S and the DNA fragment T, the following solutions were prepared.

## EP 2 305 806 A1

Solution A: DNA fragment S or DNA fragment T 10 ng/10  $\mu$ L TE buffer solution  
Solution B: DNA fragment S or DNA fragment T 1 ng/10  $\mu$ L TE buffer solution  
Solution C: DNA fragment S or DNA fragment T 0.1 ng/10  $\mu$ L TE buffer solution  
Solution D: TE buffer solution (negative control solution)

5  
[0525] Equivalent amounts of Solution A of the DNA fragment S and Solution A of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MA, equivalent amounts of Solution B of the DNA fragment S and Solution B of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MB, equivalent amounts of Solution C of the DNA fragment S and Solution C of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MC, and equivalent amounts of Solution D of the DNA fragment S and Solution D of the DNA fragment T were mixed, to prepare DNA fragment-mixed Solution MD. Three sets in duplicate were prepared respectively, for each of DNA fragment-mixed Solutions MA, MB, MC and MD.

10  
[0526] Twenty (20)  $\mu$ L of each obtained solution, 0.5  $\mu$ L of SssI methylase (available from NEB Inc.), 5  $\mu$ L of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu$ L of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. The reaction liquid was incubated at 37°C for 30 minutes.

15  
[0527] Prepared were 0.02  $\mu$ M TE buffer solutions of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 capable of binding by complementation with a plus strand of the DNA fragment S comprising the target DNA region of SEQ ID NO: 38 and 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44 capable of binding by complementation with a plus strand of the DNA fragment T comprising the target DNA region of SEQ ID NO: 43. Also prepared was a TE buffer solution (0.02  $\mu$ M for each) mixing equivalent amounts of 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 and 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44.

20  
[0528] Synthesized were counter oligonucleotides C6, C7, C8, C9, C10, C11, C12, C13, C14 and C19 having the nucleotide sequences of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56 and SEQ ID NO: 61, respectively capable of binding by complementation with a minus strand of DNA fragment S comprising the target DNA region of SEQ ID NO: 38, and respective 0.01  $\mu$ M TE buffer solutions (counter oligonucleotide solution 1) were prepared. Also synthesized were counter oligonucleotides C15, C16, C17 and C18 having the nucleotide sequences of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 and SEQ ID NO: 60, respectively capable of binding by complementation with a minus strand of DNA fragment T comprising the target DNA region of SEQ ID NO: 43, and respective 0.01  $\mu$ M TE buffer solutions (counter oligonucleotide solution 2) were prepared. Also prepared were respective 0.01  $\mu$ M TE buffer solutions (counter oligonucleotide solution 3) of counter oligonucleotides C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18 and C19 having the nucleotide sequences of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60 and SEQ ID NO: 61, respectively.

<Counter oligonucleotides>

40 [0529]

C6:5'- GCGTCGTGCACTGGCTCACTTGTACGCGCA -3' (SEQ ID NO: 48)  
C7:5'- CTTGTACGATTGGTGACCCGCCTTTTCGAC -3' (SEQ ID NO: 49)  
C8:5'- ACTGGACCGCTATGGACGTGGCGGCGGTGT -3' (SEQ ID NO: 50)  
45 C9:5'- GGC GGCGGCTCAATGACCTGTGGCGCCCGT -3' (SEQ ID NO: 51)  
C10:5'- TTGTGGCGTGCGATAGTCGAGCCGCCTGTC -3' (SEQ ID NO: 52)  
C11:5'- ACGTGCGCGGCCGCCCTGCTCCGTT -3' (SEQ ID NO: 53)  
C12:5'- TGACGCGATGCATAGCATGCGACCACCCAG -3' (SEQ ID NO: 54)  
C13:5'- ACTGCTGACGCTATTGGTCACGTGGTTATG -3' (SEQ ID NO: 55)  
50 C14:5'- CTGCTGTTGACTGCGGTGGCGTCCCGTTTC -3' (SEQ ID NO: 56)  
C15:5'- GGACCTGTGTTTGACGGGTAT -3' (SEQ ID NO: 57)  
C16:5'- AACACTAAGTTGCGCAATTTGCTGT -3' (SEQ ID NO: 58)  
C17:5'- ATTGCGAAATCCGCCCGGACGATAT -3' (SEQ ID NO: 59)  
C18:5'- CACTCTTGAGCGCATGTGCCGTTTC -3' (SEQ ID NO: 60)  
55 C19:5'- AGGTGAGCTACGTGTGTTTGG -3' (SEQ ID NO: 61)

[0530] For each reaction liquid of the DNA fragment Solutions MA to MD, the following treatment was conducted using, as a combination of 5'-end biotin-labeled oligonucleotide solution and counter oligonucleotide solution, solution of 5'-

end biotin-labeled oligonucleotide B4 and counter oligonucleotide solution 1, solution of 5'-end biotin-labeled oligonucleotide B5 and counter oligonucleotide solution 2, or mixed solution of 5'-end biotin-labeled oligonucleotide B4 and 5'-end biotin-labeled oligonucleotide B5 and counter oligonucleotide solution 3.

5 **[0531]** In a PCR tube, 40  $\mu\text{L}$  of the reaction liquid prepared in the above, 10  $\mu\text{L}$  of the 5'-end biotin-labeled oligonucleotide solution, 10  $\mu\text{L}$  of counter oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $\text{MgOAc}_2$ , 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution and 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and further the mixture was added with sterilized ultrapure water to make the liquid amount 100  $\mu\text{L}$ , and mixed. Then the PCR tube was heated at 95°C for 10 minutes, cooled rapidly to 70°C, and retained for 10 minutes at this temperature. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained for 10 minutes at 37°C, and then the PCR tube was returned to room temperature, to promote formation of a conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment.

10 **[0532]** The entire obtained mixture was transferred to a well coated with streptavidin, and left still at room temperature for about 30 minutes, to immobilize the conjugate of the 5'-end biotin-labeled oligonucleotide and the DNA fragment to the well. Thereafter, the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

15 **[0533]** Synthesized were a masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B4 having the nucleotide sequence of SEQ ID NO: 39 and a masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45 capable of binding by complementation with 5'-end biotin-labeled oligonucleotide B5 having the nucleotide sequence of SEQ ID NO: 44, and respective 0.1  $\mu\text{M}$  TE buffer solutions were prepared. Also prepared was a TE buffer solution (0.1  $\mu\text{M}$  for each) mixing equivalent amounts of masking oligonucleotide M4 having the nucleotide sequence of SEQ ID NO: 40 and masking oligonucleotide M5 having the nucleotide sequence of SEQ ID NO: 45.

20 **[0534]** The following treatment was conducted using masking oligonucleotide M4 solution for each reaction liquid treated with 5'-end biotin-labeled oligonucleotide B4 solution, masking oligonucleotide M5 solution for each reaction liquid treated with 5'-end biotin-labeled oligonucleotide B5 solution, and mixed solution of masking oligonucleotide M4 and masking oligonucleotide M5 for each reaction liquid treated with mixed solution of 5'-end biotin-labeled oligonucleotide B4 and 5'-end biotin-labeled oligonucleotide B5.

25 **[0535]** Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5 $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and added with 1  $\mu\text{L}$  of the masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

30 **[0536]** Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05 $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and then left still at room temperature for 1 hour. After leaving still, each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4)].

35 **[0537]** Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred at room temperature for 5 minutes, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

40 **[0538]** The results are shown in Figs. 25 to 27. It was revealed that the methylated DNA fragment is selected by forming a complex with immobilized 5'-end biotin-labeled oligonucleotide and the methylcytosine antibody, and is quantified and detected with excellent sensitivity. It was revealed that when two kinds of the 5'-end biotin-labeled oligonucleotides are mixed (Fig. 27), in particular, quantification and detection with better sensitivity can be achieved compared with the case of detection by a single oligonucleotide (Fig. 25 and Fig. 26).

45 **[0539]** In the present experiment, it was revealed that a DNA fragment can be quantified and detected by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and an immobilized 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its identification function. It was also revealed that by using a plurality of immobilized 5'-end biotin-labeled oligonucleotides, more sensitive quantification and detection are realized than the case where one kind of immobilized 5'-end biotin-labeled oligonucleotide is used (that is, not only using one target DNA region but also using a plurality of target DNA regions at the same time).

#### Example 20

55 **[0540]** As a serum sample, mixed liquids of a TE buffer solution of genomic DNA derived from human blood DNA (Human Genomic DNA, #636401, Clontech) and serum collected from rat (Wistar Hannover) were prepared respectively in quadruplicate as follows.

## EP 2 305 806 A1

Serum sample A: Genomic DNA derived from human blood 100 ng/10  $\mu$ L TE buffer solution + rat serum 10  $\mu$ L

Serum sample B: Genomic DNA derived from human blood 10 ng/10  $\mu$ L TE buffer solution + rat serum 10  $\mu$ L

Serum sample C: 0 ng/10  $\mu$ L TE buffer solution + rat serum 10  $\mu$ L (negative control)

5 **[0541]** For Serum samples A to C prepared in the above, Treatment 1 or Treatment 2 was conducted respectively in duplicate.

Treatment 1:

10 **[0542]** Twenty (20)  $\mu$ L of a serum sample and 4  $\mu$ L of a buffer (500 mM Tris-HCl (pH 7.5), 100 mM  $MgCl_2$ , 10 mM DTT, 1000 mM NaCl) were mixed, and the mixture was added with sterilized ultrapure water to make a liquid amount 40  $\mu$ L, and mixed. Then, the PCR tube was retained at 95°C for 10 minutes, retained at 4°C for 10 minutes, and then returned to room temperature. After centrifugation at 9100xg for 10 minutes, the supernatant was collected.

15 Treatment 2:

**[0543]** Twenty (20)  $\mu$ L of a serum sample and 4  $\mu$ L of a buffer (330 mM Tris-Acetate (pH 7.9), 100 mM  $Mg(OAc)_2$ , 5 mM DTT, 660 mM KOAc) were mixed, and the mixture was added with sterilized ultrapure water to make a liquid amount 40  $\mu$ L, and mixed. Then, the PCR tube was retained at 95°C for 10 minutes, retained at 4°C for 10 minutes, and then returned to room temperature. After centrifugation at 9100xg for 10 minutes, the supernatant was collected.

20 **[0544]** Thirty (30)  $\mu$ L of each solution prepared by Treatment 1 or Treatment 2, 2U of restriction enzyme MspI, and 5  $\mu$ L of 10x buffer optimum for MspI (100 mM Tris-HCl pH 7.5, 100 mM  $MgCl_2$ , 10 mM Dithiothreitol, 500 mM NaCl) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. The reaction liquid was incubated at 37°C for 1 hour.

25 **[0545]** Fourty (40)  $\mu$ L of the solution obtained by the above enzyme treatment, 0.5  $\mu$ L of SssI methylase (available from NEB Inc.), 5  $\mu$ L of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu$ L of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu$ L. The reaction liquid was incubated at 37°C for 30 minutes.

30 **[0546]** As a specific oligonucleotide used for obtaining a target DNA region (W, SEQ ID NO: 66, region corresponding to the nucleotide number 178-262 shown in Genbank Accession No. AF458110) designed in Alu region known as human transposon and having the nucleotide sequence of SEQ ID NO: 66, was synthesized 5'-end biotin-labeled oligonucleotide B6 comprising the nucleotide sequence of SEQ ID NO: 67 that binds with a plus strand of the target DNA region W by complementation, and a 0.2 pmol/10  $\mu$ L TE buffer solution was prepared.

35 <Target DNA region>

**[0547]**

40 W: 5' –

45 CGGGCGCGGTGGCTCACGCCTGTAATCCAGCACTTTGGGAGGCCGAGGTGGGCGGATCACG

AGGTCAGGAGATCGAGACCATCC –3' (SEQ ID NO: 66)

<5'-end biotin-labeled oligonucleotide>

50

**[0548]**

B6:5'- GGATGGTCTCGATCTCCTGAC -3' (SEQ ID NO: 67)

55 **[0549]** Fifty (50)  $\mu$ L of the reaction liquid obtained in the above, 10  $\mu$ L of the specific oligonucleotide solution, 10  $\mu$ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $MgOAc_2$ , 5 mM Dithiothreitol), 10  $\mu$ L of a 100 mM  $MgCl_2$  solution, 10  $\mu$ L of a 1 mg/mL BSA solution were added, and the mixture was further added with sterilized ultrapure water to make a liquid amount 100  $\mu$ L, and mixed. Then for forming a double strand between the target DNA region and

## EP 2 305 806 A1

the specific oligonucleotide, the PCR tube was retained at 95°C for 10 minutes, rapidly cooled to 70°C, and retained at this temperature for 10 minutes. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained at 37°C for 10 minutes, and returned to room temperature.

5 [0550] One hundred (100)  $\mu\text{L}$  of the obtained reaction liquid was transferred to a 8-well strip coated with streptavidin (StreptaWell, #11645692001, Roche), and left still for about 30 minutes at room temperature, to immobilize the complex of the target DNA and the specific oligonucleotide to the 8-well strip through a biotin-streptavidin bond. Thereafter, the solution was removed by decantation, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4)].

10 [0551] As a masking oligonucleotide used for masking an immobilized free specific oligonucleotide, was synthesized oligonucleotide M comprising the nucleotide sequence of SEQ ID NO: 68 that binds with the specific oligonucleotide by complementation, and a 0.1 pmol/ $\mu\text{L}$  TE buffer solution was prepared.

<Masking oligonucleotide>

15 [0552]

M:5'- GTCAGGAGATCGAGACCATCC -3' (SEQ ID NO: 68)

20 [0553] Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and further added with 1  $\mu\text{L}$  of a masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4)].

25 [0554] Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05  $\mu\text{g}/\mu\text{L}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution] and left still for 1 hour at room temperature. After leaving still, each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4)].

30 [0555] Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred for 5 minutes at room temperature, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

[0556] The results are shown in Fig. 28 and Fig. 29. In both of Treatment 1 and Treatment 2, fluorescence intensity increased in a concentration dependent manner in Solution A (100 ng) and Solution B (10 ng) of genomic DNA derived from human blood, compared with Solution C (0 ng: control solution).

35 [0557] In this experiment, it was revealed that it is possible to detect and quantify human genomic DNA in serum with excellent sensitivity by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and a 5'-end biotin-labeled oligonucleotide, and detecting the methylcytosine antibody in the complex according to its function. In Treatment 1, human genomic DNA in serum was detected with better sensitivity than in Treatment 2.

40 Example 21

[0558] As a serum sample, mixed liquids of a TE buffer solution of genomic DNA derived from human blood (Human Genomic DNA, #636401, Clontech) and a human serum purchased from Kohjin Bio Co., Ltd (individual human serum) were prepared respectively in quadruplicate as follows.

45 Serum sample A: Genomic DNA derived from human blood 50 ng/10  $\mu\text{L}$  TE buffer solution + human serum 40  $\mu\text{L}$   
Serum sample B: Genomic DNA derived from human blood 5 ng/10  $\mu\text{L}$  TE buffer solution + human serum 40  $\mu\text{L}$   
Serum sample C: 0 ng/10  $\mu\text{L}$  TE buffer solution + human serum 40  $\mu\text{L}$  (negative control solution)

50 [0559] For each of Serum samples A to C prepared in the above, following Treatment 1 or Treatment 2 was conducted respectively in duplicate.

Treatment 1:

55 [0560] Fifty (50)  $\mu\text{L}$  of a serum sample and 20  $\mu\text{L}$  of a buffer (500 mM Tris-HCl (pH 7.5), 100 mM  $\text{MgCl}_2$ , 10 mM DTT, 1000 mM NaCl) were mixed, and the mixture was added with sterilized ultrapure water to make a liquid amount 100  $\mu\text{L}$ , and mixed. Then, the PCR tube was retained at 95°C for 10 minutes, retained at 4°C for 10 minutes, and then returned to room temperature. After centrifugation at 9100xg for 10 minutes, the supernatant was collected.

## EP 2 305 806 A1

### Treatment 2:

**[0561]** Fifty (50)  $\mu\text{L}$  of a serum sample and 10  $\mu\text{L}$  of a buffer (500 mM Tris-HCl (pH 7.5), 100 mM  $\text{MgCl}_2$ , 10 mM DTT, 1000 mM NaCl) were mixed, and the mixture was added with sterilized ultrapure water to make a liquid amount 100  $\mu\text{L}$ , and mixed. Then, the PCR tube was retained at 95°C for 10 minutes, retained at 4°C for 10 minutes, and then returned to room temperature. After centrifugation at 9100xg for 10 minutes, the supernatant was collected.

**[0562]** Twenty (20)  $\mu\text{L}$  of the solution prepared in the above treatment, 2U of restriction enzyme MspI, and 5  $\mu\text{L}$  of a 10x buffer optimum for MspI (100 mM Tris-HCl pH 7.5, 100 mM  $\text{MgCl}_2$ , 10 mM Dithiothreitol, 500 mM NaCl) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 1 hour.

**[0563]** Thirty (30)  $\mu\text{L}$  of the solution obtained by the above enzyme treatment, 0.5  $\mu\text{L}$  of SssI methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

**[0564]** As a specific oligonucleotide used for obtaining a target DNA region (W, SEQ ID NO: 66, region corresponding to the nucleotide number 178-262 shown in Genbank Accession No. AF458110) designed in Alu region known as human transposon and having the nucleotide sequence of SEQ ID NO: 66, was synthesized 5'-end biotin-labeled oligonucleotide B6 comprising the nucleotide sequence of SEQ ID NO: 67 that binds with a plus strand of the target DNA region W by complementation, and a 0.2 pmol/10  $\mu\text{L}$  TE buffer solution was prepared.

**[0565]** Fifty (50)  $\mu\text{L}$  of the reaction liquid obtained in the above, 10  $\mu\text{L}$  of the specific oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $\text{MgOAc}_2$ , 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution, 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and the mixture was further added with sterilized ultrapure water to make a liquid amount 100  $\mu\text{L}$ , and mixed. Then for forming a double strand between the target DNA region and the specific oligonucleotide, the PCR tube was retained at 95°C for 10 minutes, rapidly cooled to 70°C, and retained at this temperature for 10 minutes. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained at 37°C for 10 minutes, and returned to room temperature.

**[0566]** One hundred (100)  $\mu\text{L}$  of the obtained reaction liquid was transferred to a 8-well strip coated with streptavidin (StreptaWell, #11645692001, Roche), and left still for about 30 minutes at room temperature, to immobilize the complex of the target DNA and the specific oligonucleotide to the 8-well strip through a biotin-streptavidin bond. Thereafter, the solution was removed by decantation, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4)].

**[0567]** As a masking oligonucleotide used for masking an immobilized free specific oligonucleotide, was synthesized oligonucleotide M comprising the nucleotide sequence of SEQ ID NO: 68 that binds with the specific oligonucleotide by complementation, and a 0.1 pmol/ $\mu\text{L}$  TE buffer solution was prepared.

**[0568]** Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution], and further added with 1  $\mu\text{L}$  of a masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4)].

**[0569]** Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05  $\mu\text{g}/\mu\text{L}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH7.4) solution] and left still for 1 hour at room temperature. After leaving still, each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4)].

**[0570]** Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred for 5 minutes at room temperature, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm, and an average value of duplicate was calculated for the obtained measurements.

**[0571]** The results are shown in Fig. 30 and Fig. 31. In Treatment 1, fluorescence intensity increased in a concentration dependent manner in Solution A (50 ng) and Solution B (5 ng) of genomic DNA derived from human blood, compared with Solution C (0 ng: control solution) (Fig. 30). On the other hand, in Treatment 2, fluorescence intensity increased in a concentration dependent manner in Solution A (50 ng) of genomic DNA derived from human blood, compared with Solution C (0 ng: control solution), however, increase in fluorescence intensity was not found in Solution B (5 ng) (Fig. 31).

**[0572]** In this experiment, it was revealed that it is possible to detect and quantify human genomic DNA in serum with excellent sensitivity by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and a 5'-end biotin-labeled oligonucleotide, and detecting the methylcytosine antibody in the complex according to its function.

In Treatment 1, human genomic DNA in serum was detected with better sensitivity than in Treatment 2.

## EP 2 305 806 A1

### Example 22

**[0573]** As a serum sample, the following human serums were used. Human serums purchased from Kohjin Bio Co., Ltd (individual human serums)

5 Lot No.:

N51438 (healthy subject)  
N51439 (healthy subject)  
N51441 (healthy subject)

10

Human serums purchased from ProMedDx (individual human serums)

Lot No.:

15

11171268 (healthy subject, age 56, male)  
11171292 (healthy subject, age 62, male)  
11171297 (healthy subject, age 67, male)  
11171314 (healthy subject, age 75, male)  
11171327 (healthy subject, age 70, male)

20

11202510 (healthy subject, age 67, female)  
11202522 (healthy subject, age 64, female)  
11202527 (healthy subject, age 52, female)  
11202615 (healthy subject, age 75, female)  
11202618 (healthy subject, age 78, female)

25

10958886 (healthy subject, age 56, male)  
10958979 (healthy subject, age 39, male)  
10958980 (healthy subject, age 45, male)  
10960268 (healthy subject, age 37, male)  
10960272 (healthy subject, age 50, male)

30

10960276 (healthy subject, age 30, male)  
10960285 (healthy subject, age 39, male)  
11003457 (healthy subject, age 38, male)  
11003479 (healthy subject, age 51, male)  
11003480 (healthy subject, age 48, male)

35

11324997 (healthy subject, age 59, male)  
11325001 (healthy subject, age 61, male)  
10325022 (healthy subject, age 61, male)  
11325032 (healthy subject, age 60, male)  
11325062 (healthy subject, age 69, male)

40

10870623 (breast cancer patient, age 33, female)  
10929521 (breast cancer patient, age 55, female)  
10989644 (breast cancer patient, age 45, female)  
11209430 (breast cancer patient, age 80, female)  
10929514 (breast cancer patient, age 57, female)

45

10843055 (breast cancer patient, age 59, female)  
10984680 (breast cancer patient, age 64, female)  
11209428 (breast cancer patient, age 55, female)  
10840414 (lung cancer patient, age 54, female)  
10929506 (lung cancer patient, age 55, male)

50

11091955 (lung cancer patient, age 76, female)  
11103346 (lung cancer patient, age 66, female)  
11142322 (lung cancer patient, age 62, female)  
11152564 (lung cancer patient, age 67, male)  
11152571 (lung cancer patient, age 67, male)

55

11153198 (lung cancer patient, age 69, female)  
11209435 (lung cancer patient, age 61, male)  
11230621 (lung cancer patient, age 71, female)  
11153192 (lung cancer patient, age 59, male)  
10715942 (lung cancer patient, age 64, male)

## EP 2 305 806 A1

10840422 (lung cancer patient, age 78, female)  
10935547 (prostate cancer patient, age 83, male)  
11000243 (prostate cancer patient, age 78, male)  
11071226 (prostate cancer patient, age 84, male)

5

**[0574]** For each of the above serum samples, the following treatment was conducted respectively in duplicate.

**[0575]** 40  $\mu\text{L}$  of a serum sample and 20  $\mu\text{L}$  of a buffer (500 mM Tris-HCl (pH 7.5), 100 mM  $\text{MgCl}_2$ , 10 mM DTT, 1000 mM NaCl) were mixed, and the mixture was added with sterilized ultrapure water to make a liquid amount 100  $\mu\text{L}$ , and mixed. Then, the reaction was retained at 95°C for 10 minutes, retained at 4°C for 10 minutes, and then returned to room temperature. After centrifugation at 9100xg or 20400xg for 10 minutes, the supernatant was collected.

10

**[0576]** Twenty (20)  $\mu\text{L}$  of the solution prepared in the above treatment, 2U of restriction enzyme MspI, and 5  $\mu\text{L}$  of a 10x buffer optimum for MspI (100 mM Tris-HCl pH 7.5, 100 mM  $\text{MgCl}_2$ , 10 mM Dithiothreitol, 500 mM NaCl) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 1 hour.

15

**[0577]** Thirty (30)  $\mu\text{L}$  of the solution obtained by the above enzyme treatment, 0.5  $\mu\text{L}$  of SssI methylase (available from NEB Inc.), 5  $\mu\text{L}$  of 10xNEBuffer2 (available from NEB Inc.), and 0.5  $\mu\text{L}$  of 3.2 mM S-adenosyl methionine (available from NEB Inc.) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 30 minutes.

20

**[0578]** As a specific oligonucleotide used for obtaining a target DNA region (W, SEQ ID NO: 66, region corresponding to the nucleotide number 178-262 shown in Genbank Accession No. AF458110) designed in Alu region known as human transposon and having the nucleotide sequence of SEQ ID NO: 66, was synthesized 5'-end biotin-labeled oligonucleotide B6 comprising the nucleotide sequence of SEQ ID NO: 67 that binds with a plus strand of the target DNA region W by complementation, and a 0.2 pmol/10  $\mu\text{L}$  TE buffer solution was prepared.

25

**[0579]** Fifty (50)  $\mu\text{L}$  of the reaction liquid obtained in the above, 10  $\mu\text{L}$  of the specific oligonucleotide solution, 10  $\mu\text{L}$  of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM  $\text{MgOAc}_2$ , 5 mM Dithiothreitol), 10  $\mu\text{L}$  of a 100 mM  $\text{MgCl}_2$  solution, 10  $\mu\text{L}$  of a 1 mg/mL BSA solution were added, and the mixture was further added with sterilized ultrapure water to make a liquid amount 100  $\mu\text{L}$ , and mixed. Then for forming a double strand between the target DNA region and the specific oligonucleotide, the PCR tube was retained at 95°C for 10 minutes, rapidly cooled to 70°C, and retained at this temperature for 10 minutes. Then the PCR tube was cooled to 50°C and retained for 10 minutes, and further retained at 37°C for 10 minutes, and returned to room temperature.

30

**[0580]** One hundred (100)  $\mu\text{L}$  of the obtained reaction liquid was transferred to a 8-well strip coated with streptavidin (StreptaWell, #11645692001, Roche), and left still for about 30 minutes at room temperature, to immobilize the complex of the target DNA and the specific oligonucleotide to the 8-well strip through a biotin-streptavidin bond. Thereafter, the solution was removed by decantation, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4)].

35

**[0581]** As a masking oligonucleotide used for masking an immobilized free specific oligonucleotide, was synthesized oligonucleotide M comprising the nucleotide sequence of SEQ ID NO: 68 that binds with the specific oligonucleotide by complementation, and a 0.1 pmol/ $\mu\text{L}$  TE buffer solution was prepared.

40

**[0582]** Each well was added with 100  $\mu\text{L}$  of a methylcytosine antibody [available from Aviva Systems Biology, 0.5  $\mu\text{g}/\text{mL}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4) solution], and further added with 1  $\mu\text{L}$  of a masking oligonucleotide solution, and left still for 1 hour at room temperature. Then the solution was removed by pipetting, and each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4)].

45

**[0583]** Then, each well was added with 100  $\mu\text{L}$  of an Eu-N1-labeled mouse IgG antibody [available from Perkin Elmer, 0.05  $\mu\text{g}/\mu\text{L}$  0.1% BSA-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4) solution] and left still for 1 hour at room temperature. After leaving still, each well was washed three times with 200  $\mu\text{L}$  of a washing buffer [0.05% Tween20-containing phosphate buffer (1 mM  $\text{KH}_2\text{PO}_4$ , 3 mM  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 154 mM NaCl pH 7.4)].

50

**[0584]** Each well was added with 150  $\mu\text{L}$  of Enhancement Solution (available from Perkin Elmer), stirred for 5 minutes at room temperature, and left still for 15 minutes at room temperature. Then fluorescence was measured at excitation 340 nm/fluorescence 612 nm.

**[0585]** DNA in the solution obtained by the above enzyme treatment (MspI treatment) was quantified by real-time PCR.

55

**[0586]** As a standard sample for measuring concentration, a MspI-treated human genomic DNA solution was prepared in the following manner. A 5 ng/ $\mu\text{L}$  TE buffer solution of genomic DNA derived from human blood (Human Genomic DNA, #636401, Clontech) was prepared, and 20  $\mu\text{L}$  of the solution, 2 U of restriction enzyme MspI, and 5  $\mu\text{L}$  of a 10xbuffer optimum for MspI (100 mM Tris-HCl pH 7.5, 100 mM  $\text{MgCl}_2$ , 10 mM Dithiothreitol, 500 mM NaCl) were mixed, and added with sterilized ultrapure water to prepare a reaction liquid having a liquid amount of 50  $\mu\text{L}$ . The reaction liquid was incubated at 37°C for 1 hour. For the obtained reaction liquid,  $10^{-5}$ ,  $10^{-4}$ ,  $10^{-3}$ ,  $10^{-2}$ ,  $10^{-1}$ , 1, 10 ng/5  $\mu\text{L}$  solutions were prepared by dilution with TE buffer.

## EP 2 305 806 A1

**[0587]** For amplifying a target DNA region (W, SEQ ID NO: 66, region corresponding to the nucleotide number 178-262 shown in Genbank Accession No. AF458110) designed in Alu region known as human transposon and quantifying by real-time PCR, a forward primer (F1, SEQ ID NO: 69) and a reverse primer (R1, SEQ ID NO: 70) were designed.

5 <Forward primer>

**[0588]**

F1:5'- GGTGGCTCACGCCTGTAATC -3' ( SEQ ID NO: 69)

10

<Reverse primer>

**[0589]**

15 R1:5'- GGATGGTCTCGATCTCCTGAC -3' (SEQ ID NO: 70)

**[0590]** A reaction liquid of PCR was prepared by mixing 5  $\mu\text{L}$  of the MspI-treated human genomic DNA solution prepared in the above or the standard sample for measuring concentration prepared in the above serving as a template, each 1.5  $\mu\text{L}$  of 5  $\mu\text{M}$  solutions of forward primer F1 and reverse primer R1, 0.1x amount of SYBR® Green I (Lonza), 2.5  $\mu\text{L}$  of each 2 mM dNTP, 2.5  $\mu\text{L}$  of a 10xPCR buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM  $\text{MgCl}_2$ , 0.01% Gelatin), and 0.125  $\mu\text{L}$  of thermostable DNA polymerase (AmpliAq Gold, 5 U/ $\mu\text{L}$ , ABI), and adding sterilized ultrapure water to make the liquid amount 25  $\mu\text{L}$ . Real-time PCR was conducted using Mx3005P (Stratagene). After retaining the reaction liquid at 95°C for 10 minutes, PCR was conducted by 40 cycles each consisting of 30 seconds at 95°C, 30 seconds at 61°C and 45 seconds at 72°C, to amplify the target DNA region. According to a result of the real-time PCR, DNA in a serum sample was quantified.

**[0591]** The results are shown in Fig. 32 and Fig. 33. A measured value by the present method, and a value quantified by the real-time PCR were compared, to reveal that there is a correlation (coefficient of correlation:  $R = 0.74$ ) (Fig. 32). Further, the results quantified for human serum samples aged 59 or younger were compared between cancer patients and healthy subjects, to reveal that serum DNA concentration increases in cancer patients (Fig. 33).

**[0592]** In the present experiment, it was revealed that free DNA in human serum can be detected and quantified with excellent sensitivity by forming and selecting a complex of a methylcytosine antibody, a methylated DNA fragment, and a 5'-end biotin-labeled oligonucleotide, and quantifying and detecting the methylcytosine antibody in the complex according to its function.

35 INDUSTRIAL APPLICABILITY

**[0593]** According to the present invention, it becomes possible to provide a method for quantifying or detecting DNA having a target DNA region in a simple and convenient manner. Further, it becomes possible to provide a method for selecting a specimen derived from a cancer patient by using a specimen derived from a test subject (preferably serum) and comparing a result in the specimen and a result in a specimen derived from a healthy subject, and so on.

Free Text in Sequence Listing

SEQ ID NOs:17 to 70

45

Designed oligonucleotide

**[0594]**

50

55

## SEQUENCE LISTING

<110> Sumitomo Chemical Co., Ltd.

<120> Method for determining or detecting DNA

<130> S21064W001

<150> JP2008-152617

<151> 2008-06-11

<160> 70

<210> 1

<211> 2661

<212> DNA

<213> Homo sapiens

<400> 1

acagacatgt	gccaccatgc	ccagctaatt	ttttgtttgt	ttgtttgttt	gtttgatatt	60
ttagtagaga	tgggtttttg	ccatgttggc	caggctggtc	tcgaactcct	gacctcgaat	120
gataatgatc	cgccgcttgg	cctccaaagt	gctaggatta	cagggtgtgag	ccactgcgcc	180
aggcctgggc	actttcttta	gtagtttgag	gagcaacatt	tttgacagtg	tccttctgct	240
caagattcaa	gatccagat	aaaattaaac	catctagaga	gatggcttga	ttggccaaac	300
ctggatctca	tgaccacttc	ttgaagtggg	taagtctcat	aaatgctcag	tccttccact	360
atgcaactga	gtgggtggg	tgggaagccc	ctcaaaggaa	aatccggttg	ttcttactag	420
aaagaaaagg	aaaatggatg	tgaggcagtc	aaaatcagca	gaggtccacc	acaccaccaa	480
aatgtggtga	ttaaataatg	agagacagag	actaacagag	gtatgtgaat	attgaagtat	540
gtctggacaa	tagcccaatg	atgagaccaa	taaaatggtt	accaaaatct	ggttttgagt	600
agtagtgtaa	aatcagacca	tttagtaacc	atTTTTTgtt	gcaaagtttc	tagcactgcc	660
caaaccctga	gtggtatatg	aataactcgt	ccattatgta	tctctttcca	gtcagcataa	720
tttatcccc	acctatattc	ttttctgacc	actcctactt	ccttctcttt	accaaaatct	780
aaactcctaag	gctgtttcct	cagcaacttc	ttgttttaga	ttggaagata	aattaacag	840
catgctgagt	tttactgact	ttcagtattt	aacagaggtg	atTTAatTTt	TTTTTaaatc	900
caaagtcaaa	cttctttata	agatgaagga	gaaaaatgtc	ttataaaaatg	catatgtgaa	960
gatgccttct	gagtgccttc	tcatgcagac	ttgttctagt	ctTTAatGaa	tcttccctgt	1020
agacactgtg	gagatgaaag	atggttctcc	acttctactc	aaagtacaaa	tcaggccggc	1080
atTTTgaaaa	agagacaggt	ttattcatag	ctgcagcgtt	agctggcctt	gttccctgta	1140
caatttcact	tttggttatt	aaaatattca	ctgtaggaaa	taaatttgta	accatttct	1200
catattacct	acacacagaa	aaacaaaatt	tgatactctg	gggtttatTT	gctgagggcg	1260
cttcccataa	aagcagagaga	gtgtgctggtg	ggaaatgtgt	ctggttaact	cttttatgga	1320
taaactttag	tcacaatcct	ccccgcccc	cctctcacc	ccagcaccct	cccaacctcc	1380
cgacttccc	cctctcaagg	gctggtgacc	taatagcatt	tttcttctg	catattttgg	1440
cgctgcccc	tggcctggct	gccttcgct	gtctgagttt	tttgaaattc	ctgcatgttc	1500
gccccagatt	aagccagtgt	gtctcaggat	gtgtgttccg	ttttgttctt	tcccttaac	1560
gctccctgtg	caactgtct	ggggggagga	gggcagggac	gggagagagg	gaggggcaga	1620
ggcgaggagc	tgtccgcctt	gcacgtttcc	aatcgcatta	cgtgaacaaa	tagctgaggg	1680
gcgccggggc	cagaacggct	tgtgtaactt	tgcaaacgtg	ccagaaagtt	taaatctctc	1740
ctccttctct	cactccagac	actgcccgct	ctccgggact	gccgcgcggc	tccccgttgc	1800
cttccaggac	tgagaaagg	gaaaggggag	ggtgccacgt	ccgagcagcc	gccttgactg	1860
gggaagggtc	tgaatcccac	ccttggcatt	gcttggtgga	gactgagata	cccgtgtctc	1920
gctcgcctcc	ttggttgaag	atttctcctt	ccctcacgtg	atTTGagccc	cgTTTTtatt	1980
ttctgtgagc	cagctcctcc	tcgagcgggg	tcaatctggc	aaaaggagtg	atgcgcttcc	2040
cctggaccgt	gctcctgctc	gggcctttgc	agctctgctc	gctagtgcac	tgccccctc	2100
ccgcccggcg	ccaacagcag	ccccgcgcg	agcccggggc	ggctccgggc	gcctggcgcc	2160
agcagatcca	atgggagaac	aacgggcagg	tgttcagctt	gctgagcctg	ggctcacagt	2220
accagcctca	cgcgcggcg	gacccgggcg	ccgcgctccc	tggtgcagcc	aacgcctccg	2280
cccagcagcc	cgcactccg	atcctgtctga	tccgcgacaa	ccgcaccgcc	gcggcgcgaa	2340
cgcgagcggc	cggctcatct	ggagtaccg	ctggccgccc	caggcccacc	gcccgtcact	2400
ggttccaagc	tggctactcg	acatctagag	cccgcgaacc	tggcgcctcg	cgcgcgagaa	2460
accagacagc	gcccggagaa	gttctctgct	ctagtaacct	gcccggccc	agccgcgtgg	2520
acggcatggt	gggcagcagc	ccttacaacc	tctacaagta	ctctgacgac	aaccttatt	2580
acaactacta	cgatacttat	gaaaggccca	gacctggggg	caggtaccgg	cccggatacg	2640
gcactggcta	cttccagtac	g				2661

<210> 2

<211> 1953

<212> DNA

<213> Homo sapiens

EP 2 305 806 A1

	<400> 2								
	tataaattcc	acgcaggcat	tgaattgaat	ttgttcttaa	ccaaatgcgt	tttatctata	60		
	cctggcagga	atctagaagt	gaaattacaa	gatttatttc	atthtaattc	tattatgaag	120		
	catttaatca	caaataccct	gaaaatgaaa	agataattta	tcattttacc	ttgactgagc	180		
5	aactctcctc	actttcacatt	catgaatcca	taacgcagag	aggagactgg	atgattaagt	240		
	gtttgattag	agaaaacaga	ttaacctagc	aaacataata	aatttggctc	ataagcagga	300		
	tggctttata	aatgctcaca	atacctctcc	tgtataaaat	catgaaccac	ttcctacagt	360		
	gatgactcca	tcgaaatagt	tgagaaacat	aaagcaaatg	catgtttatg	gctttctctt	420		
	tgagacatta	aaagggatatt	gaaaggcata	tctgattcag	cttataactc	tgatatata	480		
	ttaaagaaaca	tgtaagaaaa	tattaatgca	taaaaaaagc	tacaacttct	caagtgttct	540		
10	agtttccact	ttgtcaataa	ttacgttttc	aatgtccttc	tgtggactgt	ttccaaaggt	600		
	gccaatccag	acccaaagtt	tcagatcact	cagattcacc	cttaaccttc	ataacacaac	660		
	ccaatagctt	tacgaaaaaa	gttgcatatt	taggtagtgt	ttatcccatt	atgacaaaat	720		
	acataaaatt	agcgagatat	tttttagcct	tcaaataagt	gggaaaaaat	ccitttagct	780		
	gagattccat	ttacatcaga	ataaaaatct	aagttatgac	taggttgaag	caacgtcctg	840		
	tgacagcctc	cataaagttc	acttagtctt	caagggttcc	ttacttagct	aggttagtat	900		
15	tcctggcctc	tttttttagc	agtgagaaaa	aggatactct	ccctgcccc	gctttattht	960		
	taaactcaca	gccatatacct	ggaggtctct	gctggctatt	tggcgcgtgg	gggaggaggg	1020		
	gggcccgggg	aggggggagg	ggcggggctt	ggaggtctgt	gctggctatc	tgccgtgtgt	1080		
	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	aggtctctgc	tggctatctg	gcgtgtgtgt	1140		
	gtgtgtgtgt	tggtgtgtgt	aagcagttag	gttgttttag	ggccagtcct	tcctccgcca	1200		
	ctttgctgac	tcaaagacc	agaggctttc	ttggggtgca	ggtaccatga	ttccttgggc	1260		
	cctaagggaa	tttttgttag	gctagaagag	tgggtgtact	catgatgggt	gtaccggaac	1320		
20	attcctgggc	tcaacaaaac	cgattatctt	tataaccgcg	gcgccctagc	cagcgcctgg	1380		
	tgccctaaac	gttggctgcg	ggaacgtccg	agacgcgggt	gaggagcccg	ggcggaata	1440		
	actggttgcg	ggcgctttg	accgtaggcg	ctggagcgcg	tgcgttgctg	gcgcgcgcg	1500		
	aggcggctgc	gtcggggcgc	gagaaggtgc	agttccccg	ggggcggcg	ggcggcggg	1560		
	cgaagctggg	ctcggggcca	agcaggtct	agccggagcg	actgtgcccc	gcctcctggg	1620		
	cggagcgggc	ggctccccat	ggtcagagcc	tcgtgcccgc	tcggcagcgc	ccggacgccc	1680		
25	agcccagcgc	gtcggcccc	ggcgtgccc	agctctcaga	gcccgcggag	ggccgcccgg	1740		
	accgtttcag	ctgtggcgcg	ctgggtgctg	cgttggccct	ggaggacggc	cccagtgat	1800		
	ggctggcgcc	tgccctccc	gtgtctccc	ggtacagatg	gagtcgtccc	gcgccgccc	1860		
	gcggcaaggt	cggcagctgc	gaggccaaga	gagaccccag	gacacacaca	gctgcctccc	1920		
	ggtgcgagaa	gaagacccc	gcttgagagt	gag			1953		
30	<210> 3								
	<211> 889								
	<212> DNA								
	<213> Homo sapiens								
	<400> 3								
35	cggccccatg	gctccgtgtc	gtgtccaagg	gatgggctgg	cacctcttgg	accaggctta	60		
	ccaccagggc	ccttctctga	agccccagtc	tgaccggcct	gctgctggga	atccccctct	120		
	gccccacac	taacctctgc	tggggctgag	ccagggcgcg	tcggacagtc	agggcgacct	180		
	agccagggcg	accgttggcc	ccgctcctat	ggggcagcag	ggaccgacgt	ggaccgagtg	240		
	gggcgggcac	ccgagtggta	tgccccgccc	tgccccgcct	gccccccctg	gtggccgtct	300		
	gggggcgaca	agtcctgaga	gaaccagacg	gaagcgcgct	gggactgaca	cgtggacttg	360		
40	ggcgggtgctg	cccgggtggg	tcagcctggg	ctgggaggca	gccccgggac	acagctgtgc	420		
	ccacgccgctc	tgagcacc	aagcccgatg	cagccacccc	cagacgaggc	ccgcagggac	480		
	atggccgggg	acaccagtg	gtccaggtgt	ggcgggggtg	aggggagggg	gggtgggagc	540		
	ggtggagatg	gggccgtggg	gagggagctg	agatactgcc	acgtgggacg	atgctagggtg	600		
	gggagggctg	agctgggcgg	gctcctctgg	ctgtggggcc	ccctgtgttc	cttgtgggag	660		
	gtggaaggaa	gtgagtggcc	tgctcttctt	ccctgccc	agattccagg	accggacctg	720		
45	gcaagtggcc	tatcccagcc	agtgttctct	gggtcttctc	agggcagggt	atgttcccc	780		
	ggccaggggc	attgtcctgg	acagtcagga	ggcatacccc	tcgcccaggtg	gaaccaccct	840		
	gtgtatgcat	gaccctgaca	agcaggcgc	aggacagtca	ggaggccag		889		
	<210> 4								
	<211> 863								
	<212> DNA								
50	<213> Homo sapiens								
	<400> 4								
	gttgttgggt	gtgaatggag	aactgtgggc	cctccccgac	accttccagc	gggacggcaa	60		
	cgggggccca	gggggtgggc	gccatcaacc	ccgtcccacc	gccaggacgg	cgcgggggag	120		
	ggccggcggg	ggcggggcgt	cctgtaaggc	gcgccccca	cccgcggcg	gggaggcatt	180		
55	cctgggaggc	cggcgtctctg	acgtggacc	gggggcccgc	ggcacggcg	gggggcccgc	240		
	gtccgggggc	ttcttaaac	ccccgcccc	gcccagccc	cacttcccga	gcaccgctcc	300		

EP 2 305 806 A1

	gaccctggag	ggagagagag	ccagagagcg	gccgagcgcc	taggaggccc	gccgagcctc	360
	gccgagcccc	gccagccccg	gcgagagaga	agttggagag	gagagcagcg	cagcgagcgc	420
	agtcccgtgg	tcgccccca	acagcgcccc	acagcccccg	atagcccana	ccgcgccctc	480
5	agccccggcc	gcacccccag	cccgcgccag	catgatgaac	aacagcggct	actcagacgc	540
	cgccctcggc	ctgggcgatg	agacagacga	gatgccgtcc	acggagaagg	acctggcggg	600
	ggacgcgccc	tggagaaga	tccagcagaa	cacattcacg	cgctgggtgca	atgagcacct	660
	caagtgcgtg	ggcaagcgcc	tgaccgacct	gcagcgcgac	ctcagcgagc	ggctccggct	720
	catcgcgctg	ctcgaaggtg	tcagccagaa	gcgcatgtac	cgcaagttcc	atccgcgccc	780
	caacttccgc	caaatgaagc	tggagaacgt	gtccgtggcc	ctcgagttcc	tcgagcgcg	840
	gcacatcaag	ctcgtgtcca	tag				863
10	<210>	5					
	<211>	2198					
	<212>	DNA					
	<213>	Homo sapiens					
15	<400>	5					
	aagagaggca	cactccctct	accacaccga	gggagggggc	gttgagctga	gaaaggttga	60
	gagaatgagg	gaccaggtga	ggtggacatc	ggccaagaaa	ggaaccacag	cgggaggtaa	120
	gaccgagagt	ccccagcttg	aagcgtcacc	actccgggat	tcccagattc	caacgcgagc	180
	ctggggaaag	cccacagtgg	agagagtccg	gctggcaggg	aatggcccta	ccccgggggt	240
	gaaatctcgg	agggctcgtc	agccgagtcg	cgctctcgcg	ctgatgctg	agagatgccg	300
	gacgtcgcgt	ttgcctgtgc	gagcctcgcg	gatgctgtgc	agtcttggtc	ccctctgcgt	360
20	gtgtctaact	ccgaatgctg	gtgtctcgag	gtgtgagctt	cggggcccgt	gtctttaaag	420
	aaccaaagat	tcttaaggag	tgatgatctg	ggtagagcgg	cccgcgtag	ccgcgctccc	480
	aggtctcggg	gagagtcctg	cggacagacc	agaggagacc	tgctggccag	atgccccggg	540
	cccaaggcgg	acgccagact	gtctctgcgc	cagccgggct	ggccttcgga	atggatcagg	600
	caccggggag	gcccggagtg	atctcagacc	ctcaagccgg	gaacaaacc	gtcgatgcc	660
	gtgggcctgg	agtcgcctc	ctccttccc	ccccaccct	accctgcct	ccgaaaggct	720
25	tcttcgctgg	tcagtagctg	cgctcccgtc	tgcttgaggc	tggttcagaa	ttggcgggct	780
	ggtaacgacc	ccgtgcacaa	gcggctccca	gtctctccag	aaagggccga	tgactaaggg	840
	gtgggggtgg	ggggggaggg	ctggaagggt	ttagggaaaga	acgttagcgg	cctatcctgt	900
	cttcagcagc	gcccctcctc	cttctagctc	ttagcccgag	cagagcagtt	ggagctcggg	960
	actgggaact	gctggaattc	ctatttagac	ttctagacag	tctagaaaca	agaacctttc	1020
	tttccctggg	cctcagtttc	cttgtctgta	aaatcaaaa	gcgggctcta	ggtgtaggcc	1080
30	ttcttttcgc	ttgggtgatt	tggtatcctt	tccttggatc	cgtaggggag	gggtggcagc	1140
	aacagtccag	ggcgttggcc	gtcctgtgcc	tcaagtacgt	agtccccgtg	cccgccctct	1200
	caacaccccc	agcagcccgc	ccccctaagc	ccgcagagca	gggagctgag	tgggaggggc	1260
	agaggcgggg	ccggttccca	gtcccctgct	gcggactaga	gtggcgcggg	ctgagcgtaa	1320
	aacctgggat	agccactccc	ccttttcctt	atccccgcc	ccctgccatt	ggctcccggg	1380
	agaggttgac	atcaaagccg	cggtcttata	taagccagat	ccgcagggga	gtccgcagaa	1440
35	gggttaaaca	ggtctttggg	cttcggcgac	ctcggccgcg	gcagaaaccg	gtaagaagac	1500
	agtagggctg	cgctctcatt	ttcagccttg	cccggactct	cccaaagccg	gcgccagta	1560
	gtggctccag	agcccacagg	tggtccccgg	cagtctctgg	ggcgcagtaa	gcccgttaa	1620
	tagggctggc	ggcgcaggcc	agtagccgct	ccaacatgaa	cctcgtgggc	agctacgcac	1680
	accatcacca	ccatcaccac	ccgcaccctg	cgcccccatt	gctccacgaa	cccttctct	1740
	tcggtccggc	ctcgcgctgt	catcaggaaa	ggccctactt	ccagagctgg	ccagctgacc	1800
	cggtgacgc	tgcccgggac	ttccctgcgg	gcgggcccgc	gcccgcggcc	gctgcagccg	1860
40	ccaccgccta	tggtcctgac	gccaggcctg	ggcagagccc	ggggcgctg	gaggcgcttg	1920
	gcgcccgctc	tgccggcgcg	aaaggctcag	gacccaagaa	ggagcggaga	cgactgaga	1980
	gcattaacag	cgatttcgcg	gagttgcgcg	agtgcatccc	caacgtgccg	gccgacacca	2040
	agctctccaa	gatcaagact	ctgcgcctag	ccaccagcta	catcgcctac	ctgatggacg	2100
	tgctggccaa	ggatgcacag	tctggcgatc	ccgaggcctt	caaggctgaa	ctcaagaagg	2160
	cggatggcgg	ccgtgagagc	aagcggaaaa	gggagctg			2198
45	<210>	6					
	<211>	1945					
	<212>	DNA					
	<213>	Homo sapiens					
50	<400>	6					
	ctggatgaca	gagtgagact	ccgtctcaaa	aaaaaagctc	catttggggag	gccgaggagg	60
	gtggattacc	tgaggtcagg	agtttgagac	cagcctggcc	cacatagggg	aacccatct	120
	ctactaaaaa	tacaaaaatt	agtcagggtg	ggtggctgac	acctataatc	ccagctactt	180
	gggaagctga	ggcagggaga	atcacttgaa	ccggggaggt	ggaggttgca	gtgagctgag	240
	atcatgccac	tgactccag	cctgggcgac	agggtgagat	tctgtctcaa	acaaacaaat	300
	ttaaaagctc	cgaatcctcc	aaaaatacca	agattttctt	gtcggtaact	agagatgggt	360
55	actgatgatt	atTTTTaata	ggtgattttc	aaagatgtga	acgttatcca	tgagattta	420
	agtctccaaa	agggaaaaaa	atgcatacct	ttatactaaa	acttcatcac	cagtcaaat	480

EP 2 305 806 A1

	tggatcatca	ctaaattggc	ttctacacct	ctctccta	ataaggtact	tgtgtaagtt	540
	tgcagttgtg	agacacttat	ttcctcattt	ttaatgtctt	ctcagtaggg	ccactgatat	600
	agtactattt	tgactgacca	gaatggttgg	cactggtgat	tggctcataa	agtgcctctg	660
5	atttaggggg	ctcaattatc	aaagggttaa	atcctagccc	aaaccattgc	tgtgatgggg	720
	gttaatcaat	gaaccactca	gcttcacttg	caaaagcggg	atcacaatag	ccgctttcgt	780
	catgaccag	cctaggtgag	atttagtact	taagtacact	gccaggcaca	caaggttaat	840
	ttaacaattt	aacacatttg	tttctcctc	catttctcca	aaccttccaa	ctaactctaa	900
	cgttcgttcg	gccaaatggg	ccaggaattc	acttaaacaa	aaacaaaaaa	caaaacaaac	960
	aaaaaaaaac	tccctggggc	ttggggaagg	aggcaccgcc	gccatgtctg	cagtctgggg	1020
	gtggctcagt	cctcagcacc	cagatctacg	gccataatgc	tcttcgaggc	caaggagccc	1080
10	ggatgcgggg	cgttgccgaa	ggcgtcttgc	tcaggctcgc	ggaaaggaga	gggggtgggag	1140
	cggggtgggg	gcatcgcgac	ccagggcaag	gcggcgagtc	gccgtcttcg	agtcccacct	1200
	gtccgaagcg	gggtgagaaa	aggcaaaaac	tggcaaagcc	atgcacctcc	caggggtgggc	1260
	aactcacggc	cggtgaacgc	cggaccctta	gcagtttcca	gacctttgga	accggaagcg	1320
	gagcctgaga	gcgcgcccga	gagggcgtga	acgggaccgc	tttcccggaa	gtgcttgccg	1380
	cctctgcca	gcgagctgcc	ccggggctct	tctggtttcc	taatcagggc	aacgcccgcg	1440
15	gagagaacct	ttaccttggc	tgcactaagt	tctcggtgcc	actccttggc	agggcggggac	1500
	cttgttttag	ccctgtgatc	gcgcggttcg	tagtagcgca	aggcgcagag	tggaccttga	1560
	cccgcctagg	gcggaagag	tttgcccgc	cgggtcccaa	agggcagaat	ggacgggctc	1620
	ctaaatcca	gggaatcctc	taaattcatt	gcagaaaaca	gtcgggatgt	gtttattgac	1680
	agcggaggcg	tacggagggt	ggcagagctg	ctgctggcca	aggcggcggg	gccagagctg	1740
	cgcggtggag	ggtggaaaag	ccttcatgag	ctgaaccca	gggcggccga	cgaggccgcg	1800
	gtcaactggg	tgttcgtgac	agacagcctc	aacttctcct	tttggtcgga	gcaggagcag	1860
20	cacaagtgtg	tggtgaggtg	cagagggaaa	acatacagtg	ggtactggtc	cctgtgccc	1920
	gccgtcaaca	gagccctcga	cgaag				1945
	<210>	7					
	<211>	2379					
	<212>	DNA					
25	<213>	Homo sapiens					
	<400>	7					
	aagcttgtgg	tttacttggg	cctctgcctc	atctttcttc	ttttgcgctt	cagcctgcgc	60
	attcgccttc	tccactaggc	tctcatgggtg	cagaggtttc	caagaagatg	gtgtgaaggc	120
	cgagatcatt	tggttatatt	ataaaataga	atgcaaattc	acacaagttt	ttgtttttta	180
30	ttttatttatt	tttttagaga	tgagggtcttg	ctatgtttgtt	tagtctggtc	tcgaaactcct	240
	ggcctcgtga	tcctcccacc	ttgacctccc	aaagtgtctgg	gattacaggc	ctgaggcctg	300
	agccactaca	cccaactgaa	ttcacattttt	tttttttctt	ttctgagacg	gagctctcact	360
	ctgtcaccca	gtatggagtg	cagtggcgcg	actgcggctc	actgcaagct	ccgtctctcg	420
	ggttcaagtg	attctcatgc	ctcagcccc	caagtagctg	gaattacagg	gggtgactac	480
	cacacctggc	taatttttct	gttttagtag	agatgggggtt	tcacctggtt	gcctggctctc	540
35	aaactcctga	ctttaagtg	tccacacacc	tcagcctccc	aaagtgtctgg	gattacaggt	600
	gtgagcctcc	acaccgggcc	gaattcacat	gaattttaaa	gtgatgtctt	caaagtgggt	660
	tcactgtggg	gatgggcagc	ttttgttat	acatctagaa	cgttcctctt	ctgtttctat	720
	gaatactcgg	ttggaagggg	ctgaaaaacg	gtcttaagag	attatctgat	tcgtttccca	780
	gttttattac	tcacatatca	gctgtaattt	gagcacgttt	tctgattgag	acaagactca	840
	gatggtatta	aacttacta	caacacatcc	gggcacggtg	gctcacgcct	gtaatcccag	900
	cactttggga	ggccgaggcg	ggcggatcac	gaggtcagga	gatcgagacc	atcctggcta	960
40	acacggtgaa	gccctgtctc	tactaaaaat	acaaaaaatt	aggcgggcat	ggtggcgggc	1020
	gcctgtagtc	ccagctactc	gggaggctga	ggcaggagaa	tggcgtgaac	ccgggaggcg	1080
	gagcttgacg	tgagccgaga	tcgcgccact	gcactccagc	ctgggcgaca	gagcaagact	1140
	ccatctcaaa	aaaaaaaaaaa	aaaaaaaaaaa	actacaacac	tataaattca	tatctattat	1200
	aatagtactt	tgtgcagggc	cctaccctaa	gtccttaacc	gaaccggaa	gcgagaagat	1260
	gacttttgtt	tgtttttaga	gatgggcgcc	tggctctgtc	gccagcctgg	agtgtggggg	1320
45	cgcgatctcg	actcacagca	gcctccacct	cccagattca	ggcgatcttc	ctgcctcagc	1380
	ccctcgagga	gctgggacca	ccggcgcgct	ccatcgcgcc	cggctaggag	ctgactttga	1440
	atccgggctc	tgcgcctggc	cttctgcctc	tctataaggg	aagacatctg	tgacctcggg	1500
	gcaaagggtca	aattagatcc	tggttaggat	cctgttcccg	ctgcccctcg	ggctggcact	1560
	gccaggagta	ctcagagctc	aaagctggga	tctgcagctc	cttaccacct	cagtgcacgc	1620
	cgctaaaggc	tttgcgcttc	acctttactc	acctcgaagc	cctggacatc	cgcatctgcc	1680
	ctaagacttc	tcacctcagt	agcagaagga	agtcgcctca	gctggccaca	gcctctctcc	1740
50	taggagaccg	tccgggaaaa	gcgagtcagg	gtagaccctg	aggcccctca	gctccggcta	1800
	ttttcagatc	tgctgctcct	tcaccctcag	cctttcaaac	aggccactcc	aaaaaaaaagc	1860
	ccaatcacag	ccttctctct	tctcctggcc	ttccggcact	gtccaatcaa	cgtacgcat	1920
	ctatcggtta	gtgggtgtgc	ggggccacc	ttcccgtgg	tttccctcgt	ggtgtgtaaa	1980
	ggcagagtag	aaaggcgagg	ggtgttgacg	ccaggaaggt	tccatcttgg	ttaagggcag	2040
	gagtccttta	cggactgtgc	tgaggaaaga	caggaaagcg	ccagcatctc	caccttcccc	2100
55	ggaagcctcc	ctttgccagg	cagaaaggg	ttcccatggg	gccgcccctg	gcgcccgcgc	2160
	cggcccacgt	accgggggag	gccgggcccc	ggaggacgag	ggaaagcagg	ccgggcgccc	2220

EP 2 305 806 A1

	tgagcttcgc	ggacgtggcc	gtgtactttc	ctccccgagga	gtgggaatgc	ctgcggccag	2280
	cgcagagggc	cctgtaccgg	gacgtgatgc	gggagacctt	cggccacctg	ggcgcgctgg	2340
	gtgaggccgg	gccctccggc	cgggaccccc	agtccgctgc			2379
5	<210>	8					
	<211>	933					
	<212>	DNA					
	<213>	Homo sapiens					
	<400>	8					
10	gagacgtact	ctggctctgt	cgcccaggct	ggagcgcgaat	ggcgccatct	cggcgcactg	60
	caacctccac	ctccccgggt	caagcgcattc	tactgcctca	gcctccccgag	tagctggggac	120
	tacaggcgcg	cactaccaag	cccgggcta	ttcttttga	tttttagtag	agactgggtt	180
	tcacgatggt	ggccgggctg	gtctggaagt	cttgacctca	agcgtgcgcc	ctctccgcca	240
	ctgggtaagg	ggggggcgcg	aatagggggc	ttgcaatttc	acactagagg	cgggcgccgt	300
	gggggaaaga	agagtcacgt	ctcccacggt	tcgtagagga	aggcctgcct	gagcctggag	360
	cggggcgggg	agagccacag	tttggcatcc	ccaggggcatc	ccccagcccg	cagactacca	420
15	ggcctccaga	ggacaggacc	ccacccccgg	ccacaggccc	tgccccagc	actccccgca	480
	ccccgcctcc	aagactcctc	cgccccactcc	gcacccaact	tataaaaacc	gtcctcggggc	540
	gcggcgggga	gaagccgagc	tgagcggatc	ctcacacgac	tgtgatccga	ttctttccag	600
	cggcttctgc	aaccaagcgg	gtcttaccct	cggctctccg	cgtctccagt	cctcgcacct	660
	ggaaccccaa	cgtccccgag	agtccccgaa	tccccgctcc	caggctacct	aagaggatga	720
	gcggtgctcc	gacggccggg	gcagccctga	tgctctgcgc	cgccaccgcc	gtgctactga	780
20	gcgctcaggg	cggacccgtg	cagtccaagt	gcggcgctt	tgcgtcctgg	gacgagatga	840
	atgtcctggc	gcacggactc	ctgcggctcg	gccaggggct	gcgcgaacac	gcggagcgca	900
	cccgcagcca	gctgagcgcg	ctggagcggc	gcc			933
	<210>	9					
	<211>	6096					
	<212>	DNA					
	<213>	Homo sapiens					
	<400>	9					
30	atctgcacct	cctcatatag	ggttgatcca	agtttcacag	acatcactga	gttcttagtg	60
	gactcagcta	ttggggctgt	tctcacactt	ttttttctt	tgcaagaatc	agcaatgggt	120
	gcaagtggac	ctgtgtagga	cgccagtgga	aacattgtgt	tggtgaatca	gctagaatcc	180
	atccaagaac	tcagccagcc	tggtgtgggg	tgagatctga	tccttgaatg	tcctcagtg	240
	gcttttaggg	ctggcaggtt	cagaagggcc	ctctcatcac	ccccccaggg	cctcattcct	300
	tgtttaacac	tttgctatca	cagtcttgaa	tccttgaat	tgaacaatgg	acccacatt	360
	ttcactttgc	actggtttct	gattctgtaa	ccgatcctgt	ccccctctct	tgtctcattc	420
	actctgggaa	ttgtccccac	attctgagac	ctttcagcag	tgccccaacg	aggttcctgc	480
35	ccttatctga	agctccacc	tcacccccat	gcgggcaccg	caggcagccc	tgcttttgcg	540
	tcccgcgtag	gcaggctgtg	caccggagtc	agcaccctct	gattcagcct	aggcagccac	600
	agcttgactg	ctcccccgcg	acaagcccta	ctgtgctatc	tgccgctctt	cccttctctt	660
	tcccaggggg	tccgcgtcag	gggagggcga	gctgtgtgca	ttccgggagc	ttcagacccc	720
	cgtgtccagg	agctccttcg	tttcttgggt	gctggggcgg	ccttcccagc	gaagagtca	780
	actcagcggg	acgtttggag	gctctctgcc	ccaagggcgt	ggggagtgtg	cgccgggaca	840
	gtcgtgcttg	cctttttcac	tttcagagtg	tccacgcccc	acccgtttgg	tcactgcagg	900
40	tcagtccagt	ccagcccggc	ccaccccacc	ggtgcgtgtc	tgctgcacgt	ggcagacgcc	960
	atactctctg	ttcttgttta	aagcccagga	tctactgggc	cctggaggca	agaggatga	1020
	gcagcggaat	ccacgctgag	ctgcccggga	acggagcttc	caaccccaga	aggaggactc	1080
	tgtgctccta	caccttaacc	cttttttagcc	cgaaacttct	ccaacttctt	tggctttggt	1140
	tagagctcga	cagcgcggcc	ccctggcgct	cgttgtgagg	acagtagagg	agagaggcaa	1200
	gggtgttttt	aaacagtttg	cctctcacca	ttatgggggc	gacccgaggg	ggagaccac	1260
45	tcttccgcat	tcccggtaag	tgaaccaccg	gaagaggtcg	aaagtgcagg	attccatgt	1320
	cctctccag	cccccccccc	accctgcccc	tccacaggac	ggtggctctt	cagtgccctt	1380
	tgccgagca	gtggcgtttc	tatgcacgtg	ggtatcaatt	cggactctgg	acgaaatgga	1440
	aacctcctta	gccgacccgg	gtgggatcag	ctgggatcct	gcgcgctccc	ctggggggtt	1500
	gccagccact	ctgttggggg	gcaagaagca	ccatccttcg	gaagctgggc	cgaactggc	1560
	caggctgact	cgtctcccag	cgcccccccc	tccccggcgc	cgcagcaatt	cactggccac	1620
	gcctctgag	ccgggtccgg	acttcggcgc	ctccagagtg	tccccgcgac	ttccccacc	1680
50	gatgagatgg	ggtctggcgt	tggccagtgc	gtgtccaggg	actcgcgggt	ccctggccag	1740
	ccatggggca	gagggcgctg	gtgttaggcc	agtcttcccc	accctgcccc	gtcaccaccag	1800
	ccacacccac	tgtcctgtga	ggccaagcgc	gctccgctgg	tttcttgagc	caggcacctt	1860
	ggccgaggac	aggatccagc	tgtctctcct	tgcgatcctg	tcttcgggga	agtccacgtc	1920
	ctaggcaggt	cctcccaaag	tgcccttggg	gccgatcacc	cctcccagcg	ccttgacaggt	1980
	cctgtgcacc	acctccccca	ctccccattc	aaagccctct	tctctgaagt	ctccggttcc	2040
55	cagagctctt	gcaatccagg	ctttccttgg	aagtggctgt	aacatgtatg	aaaagaaaga	2100
	aaggaggacc	aagagatgaa	agagggctgc	acgcgtgggg	gccccagtg	tggcggggga	2160

5 cagtcgtctt gttacagggg tgctggcctt ccctggcgcc tgccccctgtc ggccccgccc 2220  
 gagaacctcc ctgcccagg gcagggttta ctcatcccgg cgaggtgatc ccatgcccga 2280  
 gggcggggcg aagggcggcc agagaaccca gcaatccgag tatgcccgat cagcccttcc 2340  
 caccaggcac ttcttctctt ttcccgaacg tccaggaggagg gagggccggg cactataaaa 2400  
 ctgagccctt ggccgatccg catgtcagag gctgcctcgc aggggctgcg cgcagcggca 2460  
 agaagtgtct gggctgggac ggacaggaga ggctgtcgc atcggcgtcc tgtgcccctc 2520  
 tgctccggca cggccctgtc gcagtcccc cgctttcccc ggccctgca cgcggcgcgc 2580  
 ctgggtaaca tgcttggggt cctggtcctt ggccgctgg ccctggccgg cctggggttc 2640  
 cccgcacccg cagagccgca gccgggtggc agccagtgc tcgagcacga ctgtctcgcg 2700  
 ctctacccgg gccccgcgac cttcctcaat gccagtgcga tctgcgacgg actgcccggc 2760  
 cacctaata gaagtgcctc ctccggtggct gccgatgtca tttccttgc actgaacggc 2820  
 10 gacggcggcg ttggccggcg gcgcctctgg atcggcctgc agctgccacc cggctgcccg 2880  
 gacccaagc gcctcggggc cctgcccggc ttccagtggg ttacgggaga caacaacacc 2940  
 agctatagca ggtgggcacg gctcgcctc aatgggctc ccctctgcyg ccgttctgc 3000  
 gtcgctgtct ccgctgctga ggccactgtg cccagcagc cgatctggga ggagcagcag 3060  
 tgcaagtga agccgatgg cttcctctgc gagttccact tcccagccac ctgcaggcca 3120  
 ctggctgtgg agcccggcgc cgcggctgcc gccgtctcga tcacctacgg caccctgtc 3180  
 15 gggcccgcg gagcggactt ccaggcgtg ccgggtggca gctccgcccg ggtggctccc 3240  
 ctccgcttac cctaatgtg caccgcgcg cccggagcgg tccaggggca ctgggcccagg 3300  
 gaggcggcg gccttggga ctgcagcgtg gagaacggcg gctgcgagca cgcgtgcaat 3360  
 gcatccctg gggctccccg ctgccagtgc ccagccggcg ccgcccgtca ggcagacggg 3420  
 cgctcctgca ccgcatccgc gacgcagtc tgcaacgacc tctgcgagca cttctgcyt 3480  
 cccaacccc accagccggg ctctactcgc tgcagtgtc agaccggcta ccgctgcyg 3540  
 20 gccgaccaac accggtgca ggcgtggat gactgcatac tggagcccag tccgtgtccg 3600  
 cagcgtgtg tcaacacaca ggggtgctt gagtgccact gctaccctaa ctacgacctg 3660  
 gtggacggcg agtgtgtgga gcccggtggac ccgtgcttca gagccaactg cgagtaccag 3720  
 tgccagccc tgaaccaaac tagctacctc tgcgtctgc ccgagggctt cgcgccatt 3780  
 cccccagc cgcacaggtg ccagatgtt tgaaccaga ctgcctgtcc agccgactgc 3840  
 gacccaaca cccaggctag ctgtgagtgc cctgaaggc acatcctgga cgacggttt 3900  
 25 atctgcacgg acatcgacga gtgcgaaaac ggcggcttct gctccggggt gtgccacaac 3960  
 ctcccggta cttcagagtg catctgcggg cccgactcgg cccttgcccg ccacattggc 4020  
 accgactgtg actccggcaa ggtggacggt ggcgacagc gctctggcga gccccgccc 4080  
 agcccagc cccagctcc tctgactct cggccgtgg ggctcgtgca ttggtcttg 4140  
 ctcataggca tctccatcgc gagcctgtgc ctgggtgtg cgttttggc gtcctctgc 4200  
 30 cacctgcgca agaagcagg cgccgccagg gccaaagtgg agtacaagt cgcggcccct 4260  
 tccaaggagg tagtgctgca gcacgtgcgg accgagcgg gagcctgtgc ctctcacc 4320  
 gctccgtcc aggagcctgg cttcgtccag ggagaagacc ctcccgcac ccagctttg 4380  
 tacciaagca cttagctgg ctttagcga taactggca gggggtgatt agagggagga gaatgagcct 4440  
 gtttcttct cgtgacgtca ctggaccact gggcaatgat ggcaatttg taacgaagac 4500  
 cgccctctt acagactcg atttgtcca ggtcctcact accgggcgca ggagggtag cgttattggt 4560  
 35 cggcagcct ctgggcagac cttgacctc tgggctagg atgactaaaa tatttatttt 4620  
 ttttaagta ttaggtttt gttgtttcc tttgtctta cctgtatgtc tctatttcc 4680  
 actttgcaca gctctccgg gctctctct ctacaaact ccacttgtca tgtgacaggt 4740  
 aaactatctt ggtgaatttt ttttctctag cctctcaca tttatgaag aagcccact 4800  
 tattcccat tcttcttag tttctctcc caggaactgg gccaactcac ctgagtcacc 4860  
 ctacctgtc ctgaccctac ttttttgtt cttagctgtc tgctcagaca gaaccctac 4920  
 40 atgaaacaga aaCaAAAaAa ctAAAaataa aatggccat ttgctttttc accagatttg 4980  
 ctaatttatc ctgaaatttc agattcccag agcaaaataa ttttaacaa aggttgagat 5040  
 gtaaaaggta ttaaattgat gttgctggac tgtcatagaa attacacca aagaggtatt 5100  
 tatcttact ttaaacagt gagcctgaat tttgttctg ttttgattg tactgaaaaa 5160  
 tggaattgt tgctaattt cttagtgaat ttctttttt gttattatta cttattttg 5220  
 acagtgtga aaatgttcag aagggtgctc tagattgaga gaagagacaa acactccca 5280  
 45 ggagacagtt caagaaagct tcaactgca tgattcatgc caattagcaa ttgactgtca 5340  
 ctgttcctg tcaactgtag accaaaataa aaccagctc actggtctt tggaaatggg 5400  
 agcttgggaa tggatcctgg aggatgccc attagggcct agccttaac aggtcctcag 5460  
 agaatttcta ccattcaga gaggccttt ggaatgtgg gcaatgagc cctgaacaa gaattggaag 5520  
 ctgccctgcc catgggagct ggttagaaat gcagaatcct aggctccacc gaattggaag 5580  
 catgagaatc tatatttaac aagatctgca gggggtgtgt ctgctcagta ccatccagtt 5640  
 aaccattcca gactgcttcc aattttctg aatacatgaa atagatgca atttgaggac 5700  
 50 gcaggccaag tcaggccctt attttcaaga aactgaggaa ttttcttgt gtatgaaat 5760  
 tctttgttag aaaaggctag gtacacagct ctgactcag ccacacagg tctgcaagg 5820  
 ctttggttca gctaaagct gaatgaaatc ctgcttcagt gtatggaaat aatgtatca 5880  
 tagaaatgta actttttaa gacaaagggt ttctcttct attttgtaaa ctcaaatat 5940  
 ttgtacatag ttatttatt attggagata atctagaaca caggcaaaat ccttgcttat 6000  
 55 gacatcactt gtacaaaata aacaataac aatgtg 6060

<210> 10  
 <211> 2500

EP 2 305 806 A1

<212> DNA  
<213> Homo sapiens

<400> 10

5	accacattct	gtgtgtggat	agtatcctgc	aggagagatg	ttgtctgcag	tgtgagctgg	60
	gcccaccgga	gtgtgtgaat	aggatcctgc	aggagaaatg	gaatccggag	tgtgagctgc	120
	atccgctgta	gaggggtggat	aaaatcctgc	aggaaagatg	gcatctggaa	tgtcagcggg	180
	agccaccgac	ctctgaggat	gcaccccgcg	gggtgtgatgc	ggggccagtt	ccaaggctgg	240
	gttagggttt	accctggctt	ctgtgttgta	ctctcattct	cttcctcttt	cttctaatac	300
	ctgctctggg	aggcatcagg	ccatgtccag	tgtgcaggcc	atggagacc	acacggcaag	360
10	gaactggaac	cccctgccag	cagcctcggg	ggctccagtc	ttagatggtg	ccctgtggtc	420
	agcaatgcac	ctgtgacctc	cgggctatgt	ctcgtggtag	ttgcttttgt	gttttaacat	480
	agcaacagga	aactagccta	ttaccacca	atcccattcc	aggctgcttt	caaacgcagc	540
	tcaggctaga	acaccagcac	ggggacacag	ctgagacttg	gggtttgcga	cgggaacacg	600
	cccctgctgt	gcctctgaat	ctggcaccgt	caccctgtgg	cctgggttca	gcaacttggc	660
	ctcaccttcc	ttgtctgtga	aatcagact	gggtccttgt	gagatgattg	gagagaatgt	720
15	atgaactatg	tgagaacgcc	acctttgtgc	gtatctcacg	cagtgtcttc	cctcctttcc	780
	aaagtcttct	gctgtctcta	gacacacccg	acgtgggggg	gggggggtcc	ctgggtctcc	840
	tcctaggtct	gtcccaggag	ggcacgcact	gaaggccgcg	agaatcccgg	ggctgtcatt	900
	gcgccgcgcc	aaggactcca	cacaggacct	ttcattttcc	caactgtgct	gagccaggcg	960
	gccggcagag	agcaggtggc	tgacaggccc	cggggagccg	gaccgcctgg	gtctaactct	1020
	cccgcagact	ccctgtctgt	gcgctttggg	gcttgggcct	cagtttcttc	aaaaggaatg	1080
20	aggggctttt	ttggaacggt	aaataatttc	ctacgtggtt	gcgggtaggg	agaaggagaa	1140
	agagaggagc	gcgctgcgc	gctgggaatc	gtgcccggat	cagagcaagc	gctctaanaag	1200
	tgttacaac	attaaggcgc	caactaaaa	accgtagtg	agcgcaggca	gaaaccacgg	1260
	gtaagagaag	tggagaagct	tcgctgtagg	cccagggtcc	cgagccccga	gtctcgagcg	1320
	cagaatcagg	ggtgccaatg	ctctcctccg	cgcccccgag	cgctcgcctt	ggccatgcgg	1380
	gcccgccccc	cgggatgagg	gcgctcaggc	cggacgctgg	ggccccgggt	tctcgccccg	1440
25	ccccgccttc	ggggattcag	agggggccgg	aggagcctcg	cgcattgtga	cagctggcgc	1500
	ccccgccttc	ccgcgcacag	ctgggacgtg	ggccgcggcc	gggcgggcgc	agtcgggagc	1560
	cggccgtggt	ggctccgtgc	gtccgagcgt	ccgtccgcgc	cgctcgccat	ggccaagcgc	1620
	tccaggggct	ccgggcgccc	ctgcctgttg	gcgctcgtgc	tgttctgcgc	ctgggggacg	1680
	ctggccgtgg	tggcccagaa	gccggggcga	gggtgtccga	gcccgtgcct	gtcttcccgc	1740
	accaccgtgc	gctgcatgca	tctgctgtcg	gaggccgtgc	ccgccgtggc	gccgcagacc	1800
	tccatcctgt	gagtgccgcg	ggggacgccc	ggggcgccgg	gtccggggct	tcgtggagat	1860
30	ccgggagcgc	aggggtgatc	ggaggtgggg	ggcgcgagg	gtggaggggg	catcgggagc	1920
	gcgggggggc	tggggacttg	ggacgcagaa	gggaacctcc	gaagggggac	gtggggggac	1980
	ctgggcgccc	ggaccgctg	ggcctttggt	cgccctgcgg	gagacgccga	ggggcggaac	2040
	agagcgtgtg	gcgcgcggcc	ttcgtagccg	cctttgttcg	gaactcggaa	tccccgcagg	2100
	actgggaagt	tgttggagcc	tccggggctc	ccccgcctcg	cctcccgcgg	ccccctctca	2160
	tgctccgccc	gcctcccgtc	tccccctggt	tcggggcccc	tcttccgctc	acctttcccc	2220
35	cgctcaggac	ccctcggctc	ccctccgctc	cccgagcgcg	gcgcagcccc	gcctcctctc	2280
	ccagccccct	ccgccccggt	cctcgtctcg	ttcgtctccc	tcttccgctc	ctctcctctc	2340
	tcccccttct	ctctctctct	cccttctctc	tcctctctcc	cttctctctc	ctctcctctc	2400
	ccccctctcc	tccccctctt	ccttctctct	ccccagcctc	cgccctctcc	ccctcccccg	2460
	ccccctggag	cgcagtgccc	accccatccc	cccgcgcccg			2500

<210> 11  
<211> 2200  
<212> DNA  
<213> Homo sapiens

<400> 11

45	cctcgccttc	tccagccggc	ccccggggcc	cctcctctcg	gcgcccggac	cttggccctc	60
	cctctccttt	cccacttctc	tctttgccct	aacttcgccc	ccatcccccg	ctcatttctc	120
	ctcgcaccgc	ggctcgccaa	tccctctttc	caagtccctc	ttccagcccc	gccttctctc	180
	cgggttcgcc	ccccctctcc	ccaatctccg	tcctctccc	tcccttcgcc	ctccccctct	240
	tccttctctc	tccccctacc	caaccctggt	tccccctggt	cctcagctcc	gatctctccc	300
	ttactctgtc	cccgccact	ctcgcggcgc	ctctcagctc	gggttgagcc	ccagctgtgg	360
	acggccgcgc	ccccactgac	agccgcccgc	cgccggcccc	ccccgcgcc	cgccgggctc	420
50	ctaaaacccc	cgccgcccgc	cctccaccgc	cgcacttctc	ccagcgcaca	gctccccgct	480
	ctctctcttg	ctggccgcac	gccccggccc	cgccagcctc	cgcccgctc	cgagcggcct	540
	acccgcgctt	cgttgccctg	tgggactccg	agcagagccc	gagggaaacc	tcctctctct	600
	ctgggggcca	ctttgtttg	cttgcctggt	tctttctggt	gacttttgca	gctttccaat	660
	atccgtcttc	ggagcgcacg	ggaatccgcc	gagctctgcg	tgcaggccct	ttttctttt	720
	gaggttcaca	tttttgaaa	ttttacgcca	ggcctttgtg	aatttctctc	ccccccgctc	780
55	gacggctctg	gagtcgctcg	ggcctttagg	ccggttatgc	aacgtgtacc	gctcggggct	840
	gccggctgca	cctccgcccg	gcctcggccc	tcactgcgct	agaccggcgc	ccccgcgctc	900
	cgcttcgccc	gcagtcaggg	ggccggcgct	ctgtcagaggt	ctccagctag	agcagggagc	960

EP 2 305 806 A1

5  
10  
15

ccgagccccg	gggagtcccc	ggagccgacg	aagggcttat	tagaccctga	ctcttttctg	1020
aggcgcgag	atttgtctt	tgatcactcc	ctctccgagg	gtctacggcc	gcgagctttc	1080
ggcgccggcg	atggggagaa	gacggaggct	gtgtctccag	ctctacttcc	tgtggctggg	1140
ctgtgtggtg	ctctgggagc	agggcacggc	cggccagcct	cagcctcctc	cgcccaagcc	1200
gccccggccc	cagccgcccg	cgcaacaggt	tcggtccgct	acagcaggct	ctgaaggcgg	1260
gtttctagcg	cccagatc	gagggagggg	tgccgcagtg	gccagccgag	tccgcccggc	1320
aggacagcag	gacgtgctcc	gagggtaagt	gggcaagcgg	ctccgcacct	agggctccgg	1380
cttggggggag	gggggaatcc	tcagtttggc	ggctttctgg	cccactccgt	cccagaccct	1440
ttagctggag	cctagagctg	cagccccctt	cagccaata	tccaaagacc	cccaggagcg	1500
cgccccctt	ttccttccca	acccccgagc	tcagcggggc	gaaagcctc	tctccggggg	1560
ttgggcccgg	ggtggttagg	gggtccaggg	gtgccgatcg	cagagcgtgt	gcagagctcg	1620
cgctgcggga	acaggttctg	aatgtccggc	ggcaggcggg	cctgggtccg	cctgctgcag	1680
gggcccagaga	agcctgcttg	ctccccacgt	cggggccgccc	gctcgtgagc	cttttgtttg	1740
aggacgtgtg	caggtttcac	agctcacctt	ctcatcgtca	acccgagcgc	tccaccttgc	1800
gacgcgcttt	ccttgacacg	tcggggccaa	agtaacagtt	gaccaaggag	gaatggattt	1860
gggaaggagg	gcaaggattc	tttggaacgg	aatggctcct	ttgttctctg	catctggaag	1920
ctagaatagt	agcaaattat	atgtttccat	gcctcttttc	gccctttaa	aaggcaggca	1980
agggacgaca	gatgaaaggc	agtgtttaga	cattcttgac	cctcctgcat	tccagcatct	2040
agctcttttg	cttccacgtc	tgcttcccga	tctccaata	tttgaagtgt	aattttgatt	2100
tgtttgttgt	cctgaaatct	actcgctcgg	ggcattgctt	acgaagaccg	tttataatgtt	2160
gctgcatccc	tctacctatc	tgttacgtga	ccgcgcttgt			2200

20  
<210> 12  
<211> 2000  
<212> DNA  
<213> Homo sapiens

25  
30  
35  
40  
45  
50

<400> 12						
ttggaagaaa	aggatctccg	aggaaggggg	tgagagaagg	gcaggggtgaa	ctggactaaa	60
ggccagagta	ggaaggagaa	gaggggcca	aaaagaagg	gatgaaatta	agcacagaag	120
atgggtaaa	aaaaaagtat	caggggaaagg	gcaaaataag	agaaagcctt	gaggataaga	180
gggtagaagg	ctaaagaaca	aggggaccac	tgggtcgggg	aagcgtgccc	tgaacggcgg	240
gacagtgaca	aagaaagggc	gctggcgata	ttcgaccaa	gggtgcaaaa	cgcaatcggg	300
aggtgagaaa	tggaaagaag	gcgaatgccc	ggctacaagt	agcctgggac	tgaaagggga	360
cctggggggag	gggctgggccc	cagggcagaa	aagtccaggt	tcccatgccc	cctgggcca	420
cgtggagcgg	gcgctgaatc	accggtcagc	cgccccctc	ccctcctccc	cgaccggtgc	480
ccgcagtccc	gcctcctcgc	gccgcccctc	ccacggggcg	gggcccctggc	ccgggaccag	540
cgccgaggct	ataaatgggc	tgccggcgagg	ccggcagaac	gctgtgacag	ccacacgccc	600
caaggcctcc	aagatgagct	acacgttggg	ctcgtgagg	aaccggtccc	cctaccggcg	660
ggtaaccgag	acccgctcga	gcttcagccc	cgtcagcggc	tccccgtcca	gtggcttccg	720
ctcgcagctc	tggtcccgcg	gctcggccc	caccgtgtcc	tctcctata	agcgcagcat	780
gctcggcccc	cgctcgcctt	acagctcggc	catgctcagc	tccgccgaga	gcagccttga	840
cttcagccag	tcctcgtccc	tgctcaacgg	cggctccgga	cccggcggcg	actacaagct	900
gtcccgtctc	aacgagaagg	agcagctgca	ggggctgaac	gaccgctttg	ccggctacat	960
agagaagggtg	cactacctgg	agcagcagaa	taaggagatt	gaggcggaga	tccaggcgtc	1020
gcggcagaag	caggcctcgc	acgcccagct	gggcgacgag	tacgaccagg	agatccgcga	1080
gctgcgccc	accctggaga	tggtgaacca	cgagaaggct	caggtgcagc	tggactcggg	1140
ccacctggag	gaagacatcc	accggctcaa	ggagcgtttt	gaggaggagg	cgcggttgcg	1200
cgacgacact	gaggcggcca	tccgcgcgct	gcgcaaagac	atcgaggagg	cgctcgtggt	1260
caaggtggag	ctggacaaga	aggtgcagtc	gctgcaggat	gaggtggcct	tcctgcggag	1320
caaccacgag	gaggaggtgg	ccgaccttct	ggcccagatc	caggcatcgc	acatcacggt	1380
ggagcgcgaaa	gactacctga	agacagacat	ctcgcagcgg	ctgaaggaaa	tccgctcca	1440
gctcgaaagc	cactcagacc	agaatatgca	ccaggccgaa	gagtggttca	aatgccgcta	1500
cgccaagctc	accgaggcgg	ccgagcagaa	caaggaggcc	atccgctccg	ccaaggaga	1560
gatcgccgag	taccggcgcc	agctgcagtc	caagagcatc	gagctagagt	cgtgctcggg	1620
caccaaggag	tccctggagc	ggcagctcag	cgacatcgag	gagcgcaca	accacgacct	1680
cagcagctac	caggtaggaa	ccgcggctgc	cgccagcggc	tgccgagcgc	ccagcggcgc	1740
gccccccgga	cacttgggct	cgctgcccagg	cgccctctcc	gccgcgctcc	ctggtggccg	1800
ctcgctagag	cacgcgcgccc	gcagacctag	ggtatattg	gatcagcgtc	ctcgcctatc	1860
tcctcctcca	cactccgccc	ccaccacct	gccccagctg	ctaagggtct	tgacctttt	1920
cagaaacgtg	catcttttcc	agttctaatt	ttgcacgctt	gcacgtttaa	agcaggaggg	1980
atgaattcgg	tagtggataa					2000

55  
<210> 13  
<211> 2300  
<212> DNA  
<213> Homo sapiens

<400> 13

EP 2 305 806 A1

tcagattgtc attgggaggg tgaataaatg aatgcttgca ttatgagagt ttgggggagc 60  
 aaatagcca cagactctta tctgaagcca tcagatttag tggctgcgaa cccaccgaag 120  
 tcagggattt acatttttta cagcaacgag agaaaacttc ccctttcttc tgcagaagtc 180  
 5 aggactggat ctcaaaaata gaaatgtgtc ctctaaatg tgtgccatc cccgtggttg 240  
 acaaacacg gatttcccaa gatagctgcc acacacttgg tttctaactc ctgtattgct 300  
 tccccgccag aatgtcgaag tcttcccgga atatgccag tcatactttc tgaacttttg 360  
 agcaaacacc gtccggcttc ttgtgcttcc ctcaaagacc ccaggcaccc gcagggagga 420  
 cacaggccgg ggcagagcgc ccctgcgcgg gggattcctg ccaactccgc ccagcctgcg 480  
 gcgcaaacgc tcttctcagc cgcagtccca cccgtgctg gcaatctgaa tgaggagccg 540  
 cgctattttt acctccccgg ctgcaatcct ttatatattac atgcaggaag caaatatata 600  
 10 agggattaag aaggagatgc gtggccttag tttatccaga gcaggaagag gttggaatag 660  
 gagagggtat gtgaagtctg ggggtggtgga aaaggcaggt ggacttcggc tgggtgtttt 720  
 ctccccatca tccctgtctc tggcctggaa acccccgtac tctctttctt ctggcttacc 780  
 cgtgactgca ggctccccct ccaccgccc catcttttga ggtaccacc ccacctccg 840  
 atgctgcttg ggctgctgca tcaactgtct gctttaccct cttccccgcc cccaacaaa 900  
 gcatgctcag tgcgttccgg gccaggcaac agcagcagca cagcatccag caacagcatc 960  
 15 agcaccgcaa gccccgctcg ggcgcgctct cggggggcgg ggcgcacgcc cgctccgcgc 1020  
 gtccccgcgc cgctcgctcc cgcgcgctcc cgcgcgctc gctccccgcg gccgcctcag 1080  
 catcctcagg cccggcgcca ccccccgcag tcgctgaagc ggccgcgcc gccgggggag 1140  
 ggagtagccg ctggggaggc tccaagtgg cggagcggcg aggaccctg gactcctctg 1200  
 cgtccccccc cgggagtggc tgcgaggcta ggcgagccgg gaaaggggg gccgcccagc 1260  
 cccgagcccc gcgccccgtg ccccgagccc ggagccccct gcccgcgcg gcaccatgcg 1320  
 cgccgagccg cgtgaccgc ctccgcccgc ggccgcccc cagctagccc ggcgctctcg 1380  
 20 ccggccacac ggagcggcgc cggggagcta tgagccatga agccgcccgg cagcagctcg 1440  
 cggcagccgc ccctggcggg ctgcaacctt gccggcgctt cctgcccgcc ccaacgcggc 1500  
 cccgcccggc cggtgcctgc cagcgcctcc gccgcacgc cgccctgccc cctgcttctc 1560  
 gtccttctcc tgcctcctcc gctcgcgcgc tcgtcccggc cccgcgcctg gggggctgct 1620  
 gcgcccagcg tggggtatgg ccccgtccc tttgcgttgg ctttcccgcg gggcctgca 1680  
 25 gagaaaagcg aagggcgcgc ggggtccgtgt gctccgggct tgtccccggc tcggcctttc 1740  
 cttccctccc tgctgtctt tccacccttc tcgttcccaa accccattc atcccagttc 1800  
 acttttggaa gtccatttct gttgcattcg cgaaaaacc attccaattc ttgttggttc 1860  
 cactgggagg tgttttagtgg atcctgggtc cctcagcag ctctgtgcaa cttgaggagg 1920  
 ggcaaccagt ggatgggaaa tacagcgagg gacgaagtg ctacttgcgt ggtggaactc 1980  
 taatgtgaat gcggggagga tgtagtgata atagtggtaa tgggctgttt cctcaaatc 2040  
 cgatccggc gcattcagtg cggttggaat taaggtgggg gaggcacact tcggggacca 2100  
 30 aagaattaag gtgctgaaga catacttcat gcacgacct tggttctgat ttctcaaagt 2160  
 gcttgtcatt ataataaaca ataatataa taccatcttc tatatatga tgattggaag 2220  
 tcactgaag cagaaagctg gctttgtcag gaaaataaaa agaaattggg aagctgcccag 2280  
 catctgata cctacatggc

<210> 14  
 <211> 3000  
 35 <212> DNA  
 <213> Homo sapiens

<400> 14  
 tactgccgac tttaggtctc tctggatctc aggccccctt ctctaagatg catcctagag 60  
 40 gacaaaaaat acactttatt tgggcttcgc ctgcttttgt ggaagggtag ttactagag 120  
 gatataatct cgtgttttaa tttgctctct ctctaaagg aaatgtggag aaaaaaaaaa 180  
 agcagaaatt ggaataaacc aatatttagt ttatttcatt cgattcctag gggaaactggt 240  
 gaggagccta agatgatttt cccttctag agaaagaatc caaagtccag ggaaatagcg 300  
 acaggggagt tcaagactgc cctgctagg ccttcttgg ctactctccg ctgcgatcgc 360  
 45 aggatagctc tcaatagcag gagaatcggg caagtgtgtg gataagtaga gagtgtgttg 420  
 aacaacttgt aacgttttat gaaatacgc tttgtcatggt tccctaaaag gctttgcgga 480  
 agccgtttgt cttactaat caagtcttta cttacacaaa agtagaagta gaagtagttt 540  
 tagaaaacat actaacaatc ttctatcccc ttgaagacca gtagtagcaga aaacaggtag 600  
 tttgcattat aaaattgcac tcaacttttc ctctttcag atttcacatt acattagccc 660  
 atttgtgtta cgggtgtataa aaaatggaac agggcctctc actgcattgt tctccttaa 720  
 50 aaatagatca cttacaccct aactttgttt tccttaaatt cgattcttaa caggagagct 780  
 ttctattatt tcagatggag tgaggttgca cgactgggat ggaagaaagg aatcccttaa 840  
 atttggggga atttctgttc tctgttccaa gacctttta cttgggggtg gggggtgggc 900  
 gcggcggtca gggcagtggc acgcagtcgc ggctgcgcca tccctgcact tccaggcgcg 960  
 cgggagggac gggcggggac gcgagctgcg gactctggcg aactcggggg aggcagacag 1020  
 ggggagggcg acaccagcc ggcaggcgtc tcagcctccc cgcagccggc gggcttttct 1080  
 cctgacagct ccaggaaagg cagaccctt cccagccag ccaggtaagg taagactgc 1140  
 55 tgttgagctt gctgttactg agggcgcaca gaccctgggg agaccgaagc ttgcccactgc 1200  
 gggattctgt ggggtaacct ggggtctacgg aagtttcttg aaaggggga gaagggttg 1260  
 catttttctt atggaggatt cttctctctc tagcatttctg tttgatgtat tcaactggtg 1320  
 gaagtgagat ttcaacaggt agcagagagc gctcacgtgg aggaggttg gggcgccgcg 1380

EP 2 305 806 A1

	gcgccacccc	caccctcct	cgggaccgcg	cctatttcta	aagttacacg	tcgacgaact	1440
	aacctatgct	ttaaattcct	ctttccagcc	ccgtgagtcc	gcggcgacat	tgggccgtgg	1500
	ggtggctggg	aacgggtccc	tcctccggaa	aaaccagaga	acggcttggg	gagctgaaac	1560
	gagcgtcccg	gagcaggtcc	gtgcagaacc	gggcttcagg	accgctgagc	tcctgagggc	1620
5	gtccttgggg	gacgccaagg	cgccggctcc	tctgccctcg	ttgagatgga	caacgcctcg	1680
	ttctcggagc	cctggccccg	caacgcacat	ggccccgacc	cggcgctgag	ctgctccaac	1740
	gcgctgactc	tggcgccgct	gccggcgccg	ctggcggtgg	ctgtaccagt	tgtctacgcg	1800
	gtgatctgcg	ccgtgggtct	ggcgggcaac	tccgccgtgc	tgtacgtgtt	gctgcgggcg	1860
	ccccgcatga	agaccgtcac	caacctgttc	atcctcaacc	tggccatcgc	cgacgagctc	1920
	ttcacgctgg	tgctgcccac	caacatcgcc	gacttcctgc	tgcggcagtg	gcccttcggg	1980
10	gagctcatgt	gcaagctcat	cgtaggtatc	gaccagtaca	acaccttctc	cagcctctac	2040
	ttcctcaccg	tcatgagcgc	cgaccgctac	ctggtgggtg	tggccactgc	ggagctcgcg	2100
	cgggtggccg	gccgcaccta	cagcgccgcg	cgcgcgggtg	gcctggccgt	gtgggggatc	2160
	gtcacactcg	tcgtgctgcc	cttcgcagtc	ttcgcccgcc	tagacgacga	gcagggccgg	2220
	cgccagtgcg	tgctagtctt	tcgcgagccc	gaggccttct	ggtggcgcgc	gagccgcctc	2280
	tacacgctcg	tgctgggctt	cgccatcccc	gtgtccacca	tctgtgtcct	ctataccacc	2340
15	ctgctgtgcc	ggctgcatgc	catgcggtcg	gacagccacg	ccaaggccct	ggagcgcgcc	2400
	aagaagcggg	tgaccttctt	ggtgggtggc	atcctggcgg	tgtgectcct	ctgtggacg	2460
	ccctaccacc	tgagcaccgt	ggtggcgctc	accaccgacc	tcccgcagac	cccgtgggtc	2520
	atcgctatct	cctacttcat	caccagcctg	agctacgcca	acagctgcct	caacccttct	2580
	ctctacgcct	tcctggacgc	cagcttccgc	aggaacctcc	gccagctgat	aacttgccgc	2640
	gcggcagcct	gactccccca	gcgtccggct	ccgcaactgc	ccgccactcc	tgccagcgga	2700
20	gggaggagcc	ggcgccagag	tgcgggacca	gacagggcgc	ctaggcctcc	tggggaaacc	2760
	gactcgcgcc	ccatacccga	cctagcagat	cggaaagcgt	gcgactgtgc	ccgagggttg	2820
	accttgccaa	gccctccagg	tgatgcgcgg	ccatgccggg	tgaggagaac	tgaggctgag	2880
	atcgccacac	tgagggctcc	ctaaagccga	ggtggaggaa	gaggagggtg	gaggaggagg	2940
	gcggtattgc	tggaaccgcg	cccctccctg	ccctgctccc	tgctgcccc	cccgagccct	3000
25	<210>	15					
	<211>	3000					
	<212>	DNA					
	<213>	Homo sapiens					
30	<400>	15					
	gaatacatta	aagtaggggc	aacccttgag	cccagacttc	tgccatgtga	agaccctttg	60
	aaaatcctga	caaacacagg	tactgcgtaa	gtggtcagct	aattaaagag	gggaggtgga	120
	gctgtccttt	gtgatccaa	taagtaccca	ttatctcatt	tgagcatgaa	aagaggccac	180
	tgttattact	ttcaagaagg	aaagtaagca	ggatagctca	tattttttaga	accattcctc	240
	accaaattgga	ataattccgg	tgaaaagtgg	gagtgaggaa	gaaagaaaaa	aaaaacttct	300
	aatcataatg	tttgggaata	agaaaggaag	aagaaactca	cgtaaaagcc	gacttttctc	360
	tgcagctgta	aaataaactc	ttaagacctt	tcctgtgtaa	actctggaga	ggaaaactgg	420
35	agtggcgggt	ggcctttgcc	tgacgtcaa	ctctccctcg	cggcgcgggc	gcggctgggt	480
	tcagcacctc	ggaaaagcgc	cctcgcgggc	ccccgggatt	acgcatgtct	cttggggccc	540
	gccgccttgg	ccgtgcaagt	gccaccgtaa	ctggtgagag	ccgctggcaa	cccaccgga	600
	gttgacaacc	gcggagagac	gcagacaccc	actgacctcc	aggaagctga	gcgtgggtgga	660
	tggaactcta	cgatctcttt	ctctccaagg	acggaaacct	catccaagca	gtcccagagg	720
	aaacggataa	aggtatttga	aagggagcga	gcggcccca	atcgcaaat	tgaggcgctg	780
40	ggggagttat	gcgccagtgc	cccagtgacc	cggggacacg	gagaggggaa	gtctgctgtg	840
	tacataagga	cctagggact	ccgagcttgg	cctgagaacc	cttgacgcc	gagtgcttgc	900
	cttacgggct	gcactcctca	actctgctcc	aaagcagccg	ctgagctcaa	ctcctgcgct	960
	cagggcgctt	gctgcgcgcc	aggacgcgct	tagtaccag	ttcctgggct	ctctcttcag	1020
45	tagctgcttt	gaaagctccc	acgcacgtcc	cgcaggctag	cctggcaaca	aaactggggg	1080
	aaaccgtggt	atcttaggtc	ttgtcccca	gaacatgacc	tagaggtacc	tgcgcatgca	1140
	gatggccgat	gcagccacga	tagccaccat	gaataaggca	gcaggcggg	acaagctagc	1200
	agaactcttc	agtctggtcc	cggaccttct	ggaggcggcc	aacacgagtg	gtaacgcgct	1260
	gctgcagctt	ccggacttgt	ggtgggagct	ggggctggag	ttgccggacg	gcgcgccgcc	1320
	aggacatccc	cggggcagcg	gcggggcaga	gagcgcggac	acagaggccc	gggtgcggat	1380
	tctcatcagc	gtggtgtact	gggtggtgtg	cgccctgggg	ttggcgggca	acctgctggt	1440
	tctctacctg	atgaagagca	tgcaaggctg	gcgcaagtcc	tctatcaacc	tcttctgcac	1500
	caacctggcg	ctgacggact	ttcagtttgt	gctcaccctg	cccttctggg	cggtggagaa	1560
50	cgctcttgac	ttcaaatggc	ccttcggcaa	ggccatgtgt	aagatcgtgt	ccatggtgac	1620
	gtccatgaac	atgtacgcca	cgctgttctt	cctcactgcc	atgagtgtga	cgcgctacca	1680
	ttcgggtggc	tcggctctga	agagccaccg	gaccgagga	cacggccggg	gcgactgctg	1740
	cggccggagc	ctgggggaca	gctgctgctt	ctcggccaag	gcgctgtgtg	tgtggatctg	1800
	ggctttggcc	gcgctggcct	cgctgcccac	tgcaattttc	tccaccacgg	tcaaggtgat	1860
	gggcgaggag	ctgtgctgg	tgcaaatgtg	ggcaagtgtg	ctgggccgcg	ctgggaggtt	1920
	ctggctgggc	ctctaccact	cgcagaaggt	gctgctgggc	ttcgtgctgc	cgctgggcat	1980
55	cattatcttg	tgctacctgc	tgctggtgcg	cttcatcgcc	gaccgcccgc	cggcggggac	2040
	caaaggaggg	gccgcggtag	ccggaggacg	cccagccgga	gccagcggcc	ggagactgtc	2100

EP 2 305 806 A1

5  
10  
15  
20  
25  
30  
35  
40  
45

gaaggtcacc	aaatcagtga	ccatcgttgt	cctgtccttc	ttcctgtggt	ggctgcccaa	2160
ccaggcgctc	accacctgga	gcacccctcat	caagttcaac	gcggtgccct	tcagccagga	2220
gtatttcctg	tgccagggtat	acgcggtccc	tgtgagcgtg	tgcctagcgc	actccaacag	2280
ctgcctcaac	cccgcctctc	actgcctcgt	gcgcgcgag	ttccgcaagg	cgctcaagag	2340
cctgctgtgg	cgcatcgcgt	ctccttcgat	caccagcatg	cgccccttca	ccgcccactac	2400
caagccggag	cacgaggatc	aggggctgca	ggccccggcg	ccgccccacg	cggccgcgga	2460
gccggacctg	ctctactacc	cacctggcgt	cgtggtctac	agcggggggc	gctacgacct	2520
gctgcccagc	agctctgcct	actgacgcag	gcctcaggcc	cagggcgcg	cgctcggggca	2580
agttggcctt	ccccgggcgg	taaagaggtg	aaagtagtaa	ggagggctgg	ggggggcccc	2640
atttaagaag	taggtggggag	gaggatgggc	agagcatgga	ggagggacct	gtggataggc	2700
cgaggacctt	ctctggagag	gagatgcttc	gaaatcaggt	ggagagagga	aattggcaaa	2760
gggatagaga	cgagccccac	gggcccagaca	gccaacctcc	gctccgcacc	ccacagcctc	2820
tccttactct	tcccacgcgtg	agtagtgtgg	gggcccag	aagcgaagac	aagcagcaaa	2880
aatgttagta	aattggcacg	gggagcgggg	cttagccaaa	tgatgcacag	acaattgtgc	2940
acgtttattc	cagcgacttc	tgccggagagg	gcagccgtcg	gcacaaacac	tcctttgctg	3000

<210> 16  
<211> 2200  
<212> DNA  
<213> Homo sapiens

20  
25  
30  
35  
40  
45  
50  
55

<400> 16	gtccccgat	tcctcacc	atcatataac	gtgtgtattt	attatgtttc	ccgtttcctc	60
	tgtctccgcc	agcagaatgt	aaactccatg	aggctcaggaa	tctccgagtt	atgtttgcgc	120
	agtgtaatcc	aagagcccgg	aacagtgctt	ggcacacagc	gggcatatgg	agaacaaat	180
	gtgtgaaggt	gtgaatgaat	gaataattga	aagaataaat	agtagttctc	agcctcacag	240
	aacacgggtc	acaacctcaa	atgacctgct	accctgccca	taaataacag	agatgcagga	300
	gtaagtgtct	ggctgtgacc	tgtcaacatg	ctaagccgct	caaacaaaac	tgcccacacg	360
	cccgtggccc	gcctatttgc	agcactgggc	cctgagccgc	acattcccat	ttcgttgata	420
	aagaaactga	ccagatagtt	taagtggcct	gctgcggaag	acagagctgg	tgctgcaccg	480
	gtcgctgctt	ccccagtcct	tttttggcct	cctttctgac	gcgacgcaga	ccccagttct	540
	ggagagtctg	tactcgcctc	cccgtgggtg	gagatcagag	gcctggtgtc	cttgggagcg	600
	gcgagcggtg	ctcggcgag	gatagaaagg	gagtgccgc	ccgagtcccc	cagatccctg	660
	ggaaccgcg	ccacctccc	gcccctgccc	atccccggcc	gcgctgtcag	tctccattag	720
	cgtaacagg	ctccagacgg	agcgggccc	gcgctgggtt	aatgcaatcg	gcgctgtacc	780
	tggggcgag	gctacattac	cagcccggcc	cccgccaggc	acggccagaa	ccagtcagcc	840
	gcgcccctgc	cgcccggccc	gcgcccag	ctcttcccc	gccccggcc	aacgccacac	900
	ggcggagccc	agccccagcc	cgcccctag	agcttcccaa	ggcgcgcgc	gtcggggggc	960
	ggcagggcgc	aaggcaccag	ggatcccctc	gcccgggac	acgtgagtgc	gccctgagcg	1020
	cgggacagg	ctaggtctgc	ctgggagggc	cgggcccaga	cgccagca	gagggctagc	1080
	gagttttag	tgagtgacg	ttaagtgtcc	gagaaaggct	ctgtggctgt	tgaagtgtcg	1140
	cggacctgag	ctggggaggg	ggtcggcag	ctgccctcag	cctcggtgag	ttcaatccca	1200
	gccatttggg	gcaggcgaga	gtgggtgaac	gaggaaaagt	gctgcaggg	cttcagccgc	1260
	ccccagagg	ctgtcagaag	tctccaactc	ttgagttccg	gcgtgcccc	acctctgttt	1320
	ccaaattttt	ccagcggacg	cgcgctcttt	tctgggaacc	ctgcgtccgc	tcagcgcgcg	1380
	ctcatcccag	tgtctaaggc	gctcccgggt	ggtcttggga	gttgcaagta	gggaggaacg	1440
	gcccggtaac	cacctctttt	ccctttatcc	aagcagagcc	tcggcgtgcc	cccaggaccg	1500
	gtaaagttcc	tctcgccagc	cgcatccatg	cttctggcgc	ggatgaacc	gcaggtgcag	1560
	cccgagaaca	acggggcgga	cacgggtcca	gagcagcccc	ttcgggcgcg	caaaactgcg	1620
	gagctgctgg	tggtgaagga	gcgcaacggc	gtccagtgcc	tgctggcgcc	ccgcgacggc	1680
	gacgcgcagc	ccccgggagc	ctggggcaag	aagatcgact	tcctgctgtc	cgtagtcggc	1740
	ttcgcagtgg	acctggccaa	cggtgggcgc	ttcccctacc	tctgctacaa	gaacggcggc	1800
	ggtgagcgtg	gggtcgggct	gggaatttga	atctgggagg	tccactgtct	gcagcgtgg	1860
	ctgggacagg	agctggaata	cacacggaag	ggaggcgagg	agacaggggc	aaatctgggg	1920
	cgcagaaaga	actggacagg	gctaaccggga	aaaaaaaaag	attggagtcc	tctggaaggt	1980
	cattttccca	ggctctttgc	agagtacctc	gagctcattc	cagcggaggt	gtcaggattg	2040
	ggcaccctgg	aagcaaaaCa	gcagaagagt	gaaatcgagt	catgacccta	aagtcattgt	2100
	aggggtatgg	atggaaagga	cagaatctgg	ggtgccaggt	tgggtggggg	agcctgacct	2160
	tttgatggtc	tgctggaagg	gaggtggaga	ttccaagagc			2200

<210> 17  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Designed oligonucleotide

<400> 17

ctcagcacc c aggcggcc 18

<210> 18  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

<400> 18 20  
 ctggccaaac tggagatcgc

<210> 19  
 <211> 386  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

<400> 19	ctcagcacc	aggcggccgc	gatcatgagg	cgcgagcggc	gcgcgggctg	ttgcagagtc	60
	ttgagcgggt	ggcaCaccgc	gatgtagcgg	tcggctgtca	tgactaccag	catgtaggcc	120
	gacgaaaca	tgccgaacac	ctgcaggtgc	ttcaccacgc	ggcacagcca	gtcggggccg	180
	cggaagcgg	aggtgatgtc	ccagcacatt	tgcggcagca	cctggaagaa	tgccacggcc	240
	aggtcggcca	ggctgaggtg	tcggatgaag	aggtgcatgc	gggacgtctt	gcgcggcgtc	300
	cggtgcagag	ccagcagtac	gctgctgttg	cccagcacgg	ccaccgcgaa	agtcaccgcc	360
	agcacggcga	tctccagttt	ggccag				386

<210> 20  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

<400> 20 17  
 ctggccaaac tggagat

<210> 21  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

<400> 21 17  
 atctccagtt tggccag

<210> 22  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

<400> 22 19  
 tgagctccgt agggcgtcc

<210> 23  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Designed oligonucleotide

<400> 23  
gcgccgggtc cgggcc 17

5  
<210> 24  
<211> 121  
<212> DNA  
<213> Artificial Sequence

10  
<220>  
<223> Designed oligonucleotide

<400> 24  
gcgccgggtc cgggccgat gcgttggcgg gccagggctc cgagaacgag gcgttgtcca 60  
tctcaacgag ggcagaggag ccggcgacct ggcgtcccc aaggacgcc tacggagctc 120  
a 121

15  
<210> 25  
<211> 19  
<212> DNA  
<213> Artificial Sequence

20  
<220>  
<223> Designed oligonucleotide

<400> 25  
gacaacgcct cgttctcgg 19

25  
<210> 26  
<211> 20  
<212> DNA  
<213> Artificial Sequence

30  
<220>  
<223> Designed oligonucleotide

<400> 26  
ccgagaacga ggcgttgtct 20

35  
<210> 27  
<211> 386  
<212> DNA  
<213> Artificial Sequence

40  
<220>  
<223> Designed oligonucleotide

<400> 27  
ctcagcacc aggcggccg gatcatgagg cgcgagcggc gcgcgggctg ttgcagagtc 60  
ttgagcgggt ggcacaccgc gatgtagcgg tcggctgtca tgactaccag catgtaggcc 120  
gacgcaaaca tgccgaacac ctgcaggtgc ttcaccacgc ggcacagcca gtcggggccg 180  
cggaagcgg aggtgatgac ccagcacatt tgccggcagca cctggaagaa tgccacggcc 240  
aggtcggcca ggctgaggtg tcggatgaag aggtgcatgc gggacgtctt gcgcgccgctc 300  
cggtgcagag ccagcagtac gctgctgttg cccagcacgg ccaccgcgaa agtcaccgcc 360  
agcacggcga tctccagttt ggccag 386

45  
<210> 28  
<211> 271  
<212> DNA  
<213> Artificial Sequence

50  
<220>  
<223> Designed oligonucleotide

<400> 28  
tagggagtgc cagacagtgg gcgagggcca gtgtgtgtgc gcaccgtgcg cgagccgaag 60  
cagggcgagg cattgcctca cctggaagc gcaaggggtc agggagtcc ctttctgagt 120  
caaagaaagg ggtgacggtc gcacctgga aatcgggtca ctcccaccg aatattgcgc 180

55

EP 2 305 806 A1

	ttttcagacc ggcttaagaa acggcgcacc acgagactat atccccacacc tggctcggag	240
	ggtcctacgc ccacggaatc tcgctgattg c	271
5	<210> 29 <211> 20 <212> DNA <213> Artificial Sequence	
	<220> <223> Designed oligonucleotide	
10	<400> 29 atagtctcgt ggtgcgccgt	20
15	<210> 30 <211> 20 <212> DNA <213> Artificial Sequence	
	<220> <223> Designed oligonucleotide	
20	<400> 30 acggcgcacc acgagactat	20
25	<210> 31 <211> 30 <212> DNA <213> Artificial Sequence	
	<220> <223> Designed oligonucleotide	
30	<400> 31 cagtgtgtgt gcgaccgtg cgcgagccga	30
35	<210> 32 <211> 30 <212> DNA <213> Artificial Sequence	
	<220> <223> Designed oligonucleotide	
40	<400> 32 ggcggagcat tgcctcacct gggaagcgca	30
45	<210> 33 <211> 30 <212> DNA <213> Artificial Sequence	
	<220> <223> Designed oligonucleotide	
50	<400> 33 ggtgacggtc gcacctggaa aatcgggtca	30
55	<210> 34 <211> 30 <212> DNA <213> Artificial Sequence	
	<220> <223> Designed oligonucleotide	
	<400> 34 acccgaatat tgcgcttttc agaccggctt	30

<210> 35  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 5  
 <220>  
 <223> Designed oligonucleotide  
 <400> 35  
 tcggagggtc ctacgcccac ggaatctcgc 30  
 10  
 <210> 36  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 <400> 36  
 aggtgagcta cgtgtgtttg g 21  
 15  
 <210> 37  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 <400> 37  
 agacatgtgc tcacgtacgg t 21  
 20  
 <210> 38  
 <211> 331  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 <400> 38  
 aggtgagcta cgtgtgtttg ggcgtcgtgc actggctcac ttgtacgcgc agaaatggca 60  
 gcttgtacga ttggtgaccc gccttttcga cactggaccg ctatggacgt ggcggcggtg 120  
 tggcggcggc tcaatgacct gtggcgcccg tttgtggcgt gcatagtcg agccgcctgt 180  
 cacgtgcgcg gccgccctgc tccgtttgac gcatgcata gcatgcgacc acccagtaat 240  
 catactgctg acgctattgg tcacgtggtt atggcagctg ctgttgactg cggtggcgtc 300  
 ccgtttcac accgtacgtg agcacatgct t 331  
 35  
 <210> 39  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 <400> 39  
 agacatgtgc tcacgtacgg t 21  
 40  
 <210> 40  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotidet  
 <400> 40  
 55

accgtacgtg agcacaatgtc t 21

5 <210> 41  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

10 <400> 41  
 ggacctgtgt ttgacgggta t 21

15 <210> 42  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

20 <400> 42  
 agtacagatc tggcgttctc g 21

25 <210> 43  
 <211> 117  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

30 <400> 43  
 ggacctgtgt ttgacgggta taacactaag ttgcgcaatt tgctgtattg cgaaatccgc 60  
 ccggacgata tcaactctga gcgcatgtgc cgtttccgag aacgccagat ctgtact 117

35 <210> 44  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

40 <400> 44  
 agtacagatc tggcgttctc g 21

45 <210> 45  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

50 <400> 45  
 cgagaacgcc agatctgtac t 21

55 <210> 46  
 <211> 349  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

<400> 46  
 taggtgagct acgtgtgttt gggcgtcgtg cactggctca cttgtacgcg cagaaatggc 60

EP 2 305 806 A1

agcttgtagc attggtgacc cgccttttcg aactggacc gctatggacg tggcggcgg 120  
 gtggcggcgg ctcaatgacc tgtggcgccc gtttggcg tgcgatagtc gagccgcctg 180  
 tcacgtgagc ggccgcccctg ctccgtttga cgcgatgcat agcatgagc caccagtaa 240  
 tcatactgct gacgctattg gtcacgtggt tatggcagct gctgttgact gcggtggcgt 300  
 cccgtttcca caccgtacgt gagcacatgt ctggattgc 349

5  
 <210> 47  
 <211> 244  
 <212> DNA  
 <213> Artificial Sequence

10  
 <220>  
 <223> Designed oligonucleotide

15  
 <400> 47  
 taggaaatac attccgaggg cgcccgcaca aggcctatta ttagagggac ctgtgtttga 60  
 cgggtataac actaagttgc gcaatttctg gtattgcaa atccgcccgg acgatatac 120  
 tcttgagcgc atgtgccgtt tccgagaacg ccagatctgt actgagatcg cacacgagga 180  
 gacacagcgt cacgtgtttt gccattttgt acgacaaatg aaccgcctgg ccacgcctct 240  
 aatc 244

20  
 <210> 48  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

25  
 <220>  
 <223> Designed oligonucleotide

30  
 <400> 48  
 gcgtcgtgca ctggctcact tgtacgcgca 30

35  
 <210> 49  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

40  
 <220>  
 <223> Designed oligonucleotide

45  
 <400> 49  
 cttgtacgat tggtagccg ctttttcgac 30

50  
 <210> 50  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

55  
 <220>  
 <223> Designed oligonucleotide

<400> 50  
 actggaccgc tatggacgtg gcggcgggtg 30

<210> 51  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide

<400> 51  
 ggcggcggct caatgacctg tggcggccgt 30

<210> 52  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Designed oligonucleotide  
 5 <400> 52  
 ttgtggcgtg cgatagtcga gccgcctgtc 30  
 <210> 53  
 <211> 25  
 <212> DNA  
 10 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 <400> 53  
 15 acgtgcgcgg ccgccctgct ccgtt 25  
 <210> 54  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 20 <220>  
 <223> Designed oligonucleotide  
 <400> 54  
 tgacgcatg catagcatgc gaccaccag 30  
 25 <210> 55  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 30 <220>  
 <223> Designed oligonucleotide  
 <400> 55  
 actgctgacg ctatttgtca cgtggttatg 30  
 35 <210> 56  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 40 <400> 56  
 ctgctgttga ctgcggtggc gtcccgtttc 30  
 <210> 57  
 <211> 21  
 <212> DNA  
 45 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 <400> 57  
 50 ggacctgtgt ttgacgggta t 21  
 <210> 58  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
 55 <220>  
 <223> Designed oligonucleotide

<400> 58  
 aacctaaagt tgcgcaattt gctgt 25  
 5  
 <210> 59  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 10  
 <400> 59  
 attgcgaaat ccgcccggac gatat 25  
 15  
 <210> 60  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 20  
 <400> 60  
 cactcttgag cgcattgtgcc gtttc 25  
 25  
 <210> 61  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 30  
 <400> 61  
 aggtgagcta cgtgtgtttg g 21  
 35  
 <210> 62  
 <211> 332  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 40  
 <400> 62  
 tagaatatcc aatacagaga agtgcttaaa ggagctgatg gagctgaaaa ccaaggctcg 60  
 agaactacgt gaagaatgca gaagcctcag gagccgatgc gatcaactgg aagaaagggt 120  
 atcagcaatg gaagatgaaa tgaatgaaat gaagcgagaa gggaagttaa gagaaaaaag 180  
 aataaaaaga aatgagcaaa gcctccaaga aatatgggac tatgtgaaaa gaccaaactc 240  
 acgtctgatt ggtgtacctg aaagtgatgt ggagaatgga accaagtttg aaaacactct 300  
 gcaggatatt atccaggaga acttcccaaa tc 332  
 45  
 <210> 63  
 <211> 267  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Designed oligonucleotide  
 50  
 <400> 63  
 tagaactcag gattaagaat ctcaactcaaa gccgctcaac tacatggaaa ctgaacaacc 60  
 tgctcctgaa tgactactgg gtacataacg aaatgaaggc agaaataaag atgttctttg 120  
 aaaccaacga gaacaaagac accacatacc agaactctctg ggacgcattc aaagcagttg 180  
 gtagagggaa atttatagca ctaaatgcct acaagagaaa gcaggaaaga tccaaaattg 240  
 acaccctaac atcacaatta aaagaac 267  
 55  
 <210> 64

EP 2 305 806 A1

<211> 85  
 <212> DNA  
 <213> Artificial Sequence  
 5 <220>  
 <223> Designed oligonucleotide  
 <400> 64  
 cgggcgcggt ggctcacgcc tgtaatccca gcactttggg aggccgaggt gggcggatca 60  
 cgaggtcagg agatcgagac catcc 85  
 10 <210> 65  
 <211> 117  
 <212> DNA  
 <213> Artificial Sequence  
 15 <220>  
 <223> Designed oligonucleotide  
 <400> 65  
 ggacctgtgt ttgacgggta taacactaag ttgcgcaatt tgctgtattg cgaaatccgc 60  
 ccggacgata tcaactttga gcgcatgtgc cgtttccgag aacgccagat ctgtact 117  
 20 <210> 66  
 <211> 85  
 <212> DNA  
 <213> Artificial Sequence  
 25 <220>  
 <223> Designed oligonucleotide  
 <400> 66  
 cgggcgcggt ggctcacgcc tgtaatccca gcactttggg aggccgaggt gggcggatca 60  
 cgaggtcagg agatcgagac catcc 85  
 30 <210> 67  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 35 <220>  
 <223> Designed oligonucleotide  
 <400> 67  
 ggatggtctc gatctcctga c 21  
 40 <210> 68  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence  
 45 <220>  
 <223> Designed oligonucleotide  
 <400> 68  
 gtcaggagat cgagaccatc c 21  
 50 <210> 69  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 55 <220>  
 <223> Designed oligonucleotide  
 <400> 69  
 ggtggctcac gcctgtaatc 20  
 <210> 70

<211> 21  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Designed oligonucleotide

<400> 70  
 ggatggcttc gatctcctga c

21

### Claims

1. A method for quantifying or detecting DNA comprising a target DNA region contained in a specimen comprising:

- (1) First step of preparing from a specimen DNA for which the target DNA region is to be detected;
- (2) Second step of treating the DNA prepared in First step with a DNA methylation enzyme,
- (3) Third step of preparing single-stranded methylated DNA from the DNA treated in Second step,
- (4) Fourth step of forming a complex of a single-stranded methylated DNA comprising a methylated target DNA region, a methylated DNA antibody, and a specific oligonucleotide by mixing the single-stranded methylated DNA prepared in Third step, the methylated DNA antibody, and the specific oligonucleotide comprising a nucleotide sequence that does not inhibit binding between one or more methylated bases in the target DNA region in the single-stranded methylated DNA and the methylated DNA antibody, and that is capable of binding with the single-stranded DNA comprising the target DNA region by complementation, and
- (5) Fifth step of quantifying or detecting the DNA comprising the target DNA region in the single-stranded methylated DNA by quantifying or detecting the methylated DNA antibody contained in the complex formed in Fourth step by its identification function.

2. The method according to claim 1, wherein the complex is formed in a reaction system containing a divalent cation in Fourth step.

3. The method according to claim 2, wherein the divalent cation is a magnesium ion.

4. The method according to any one of claims 1 to 3, wherein the antibody contained in the complex formed in Fourth step has been bound to a support before starting of Fifth step.

5. The method according to any one of claims 1 to 3, wherein the specific oligonucleotide contained in the complex formed in Fourth step has been bound to a support before starting of Fifth step.

6. The method according to any one of claims 1 to 5, wherein the DNA methylation enzyme is a cytosine methylation enzyme.

7. The method according to any one of claims 1 to 6, wherein the DNA methylation enzyme is SssI methylase.

8. The method according to any one of claims 1 to 7, wherein the methylated DNA antibody is a methylcytosine antibody.

9. The method according to any one of claims 1 to 8, wherein the specimen is any of the following specimen:

- (a) mammalian blood, body fluid, excreta, body secretion, cell lysate, or tissue lysate,
- (b) DNA extracted from one selected from the group consisting of mammalian blood, body fluid, excreta, body secretion, cell lysate, and tissue lysate,
- (c) DNA prepared by using as a template RNA extracted from one selected from the group consisting of mammalian tissue, cell, tissue lysate and cell lysate,
- (e) DNA extracted from cell, fungus or virus, or
- (f) DNA prepared by using as a template RNA extracted from cell, fungus or virus.

10. The method according to any one of claims 1 to 9, wherein DNA for which the target DNA region is to be detected

is any of the following DNAs (a) to (e):

- (a) DNA digested in advance with a restriction enzyme recognition cleavage site for which is not present in the target DNA region,
- (b) DNA purified in advance,
- (c) free DNA in blood,
- (d) DNA derived from microbial genome, or
- (e) DNA generated from RNA by a reverse transcriptase.

**11.** The method according to any one of claims 1 to 10, wherein a counter oligonucleotide is added in forming the complex in Fourth step.

**12.** The method according to any one of claims 1 to 11, wherein concentration of a sodium salt in a solution used in a DNA extracting operation for preparing DNA from a specimen in First step is 100 mM or more and 1000 mM or less.

**13.** The method according to any one of claims 1 to 11, wherein concentration of a sodium salt in a solution used in a DNA extracting operation for preparing DNA from a specimen in First step is 100 mM or more and 200 mM or less.

**14.** A method for selecting a specimen from a cancer patient comprising the step of evaluating that a specimen from a test subject is a specimen from a cancer patient when there is significant difference between a quantification result or a detection result of DNA quantified or detected by using the specimen from the test subject according to the method of any one of Inventions 1 to 13 and a quantification result or a detection result of DNA quantified or detected by using a specimen from a healthy subject according to the same method, and identifying a specimen from a cancer patient based on a result of the evaluation.

**15.** The method according to claim 14, wherein the specimen is mammalian serum.

**16.** The method according to claim 14 or 15, wherein DNA comprising a target DNA region is free DNA comprising the target DNA region in a mammalian serum.

Fig.1




Fig.2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig.11




Fig.12




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig.19




Fig.20




Fig. 21




Fig. 22




Fig. 23




Fig. 24




Fig. 25




Fig. 26




Fig. 27




Fig. 28




Fig.29




Fig.30




Fig. 31




Fig. 32





Fig. 33



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2009/061067

A. CLASSIFICATION OF SUBJECT MATTER C12N15/09 (2006.01) i, C12Q1/25 (2006.01) i, C12Q1/68 (2006.01) i, G01N33/53 (2006.01) i  According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED  Minimum documentation searched (classification system followed by classification symbols) C12N15/09, C12Q1/25, C12Q1/68, G01N33/53  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2009 Kokai Jitsuyo Shinan Koho 1971-2009 Toroku Jitsuyo Shinan Koho 1994-2009  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA/BIOSIS/MEDLINE/WPIDS (STN), JSTPlus/JMEDPlus/JST7580 (JDreamII)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BAEK, T.J., et al., Development of a photodiode array biochip using a bipolar semiconductor and its application to detection of human papilloma virus. Anal. Bioanal. Chem., Mar 2008, Vol.390, No.5, p.1373-1378	1-16
A	JP 2004-536596 A (U.S. Genomics, Inc.), 09 December, 2004 (09.12.04), & US 2002/0197639 A1 & EP 1402071 A & WO 2002/101353 A2	1-16
A	JP 2004-347508 A (Japan Science and Technology Agency), 09 December, 2004 (09.12.04), & WO 2004/104582 A1	1-16
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
Date of the actual completion of the international search 19 August, 2009 (19.08.09)	Date of mailing of the international search report 01 September, 2009 (01.09.09)	
Name and mailing address of the ISA/ Japanese Patent Office	Authorized officer	
Facsimile No.	Telephone No.	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2009/061067

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2005/080565 A1 (Japan Science and Technology Agency), 01 September, 2005 (01.09.05), & US 2008/0227652 A1 & EP 1717312 A1	1-16
A	GAO, L., et al., DNA microarray: a high throughput approach for methylation detection. Colloids Surf. B: Biointerfaces., 2005, Vol.40, No.3-4, p.127-131	1-16

Form PCT/ISA/210 (continuation of second sheet) (April 2007)

**REFERENCES CITED IN THE DESCRIPTION**

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

**Non-patent literature cited in the description**

- *J. Cataract. Refract. Surg.*, 2007, vol. 33 (4), 635-641 [0002]
- *Environ. Mol. Mutagen.*, 1991, vol. 18 (4), 259-262 [0002]
- *Methods in Yeast Genetics*. Cold Spring Harbor Laboratory Press [0071]
- *Molecular Cloning-A Laboratory Manual*. Cold Spring Harbor Laboratory Press [0071]
- *Methods in Yeast Genetics*. Cold Spring Harbor Laboratory [0304] [0325] [0346] [0365] [0382] [0399] [0417] [0457] [0476] [0495] [0516]

专利名称(译)	检测或定量DNA的方法		
公开(公告)号	<a href="#">EP2305806A4</a>	公开(公告)日	2011-11-02
申请号	EP2009762575	申请日	2009-06-11
[标]申请(专利权)人(译)	住友化学有限公司		
申请(专利权)人(译)	住友化学公司		
当前申请(专利权)人(译)	住友化学公司		
[标]发明人	TOMIGAHARA YOSHITAKA SATOH HIDEO TARUI HIROKAZU		
发明人	TOMIGAHARA, YOSHITAKA SATOH, HIDEO TARUI, HIROKAZU		
IPC分类号	C12N15/09 C12Q1/25 C12Q1/68 G01N33/53		
CPC分类号	G01N33/57484 C12Q1/6816 C12Q1/6827 C12Q1/6886 G01N33/5308		
优先权	2008152617 2008-06-11 JP		
其他公开文献	EP2305806A1		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

本发明涉及定量或检测具有靶DNA区域的DNA的方法，等等。